{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "d3084a4a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'/home/user/Desktop/medical_bot/Eye_Disease_Chatbot/research'"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "%pwd\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e9572026",
   "metadata": {},
   "source": [
    "For geting back to root directory to load pdfs\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "id": "316d4126",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[Errno 2] No such file or directory: 'medical_bot/Eye_Disease_Chatbot'\n",
      "/home/user/Desktop/medical_bot/Eye_Disease_Chatbot/research\n"
     ]
    }
   ],
   "source": [
    "cd medical_bot/Eye_Disease_Chatbot"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "id": "c000242e",
   "metadata": {},
   "outputs": [],
   "source": [
    "# import os\n",
    "# os.chdir(\"../\")\n",
    "\n",
    "# %pwd"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "901b587a",
   "metadata": {},
   "source": [
    "Load Pdfs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "id": "387d824e",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_community.document_loaders import PyPDFLoader, DirectoryLoader\n",
    "from langchain_text_splitters import RecursiveCharacterTextSplitter"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "id": "5a64c4a1",
   "metadata": {},
   "outputs": [],
   "source": [
    "#extracting text from pdf files\n",
    "def load_pdfs(data):\n",
    "    loader = DirectoryLoader(\n",
    "        data,\n",
    "        glob=\"*.pdf\",\n",
    "        loader_cls=PyPDFLoader\n",
    "    )\n",
    "    documents = loader.load()\n",
    "    return documents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "id": "22fac495",
   "metadata": {},
   "outputs": [
    {
     "ename": "FileNotFoundError",
     "evalue": "Directory not found: 'Data'",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mFileNotFoundError\u001b[39m                         Traceback (most recent call last)",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[74]\u001b[39m\u001b[32m, line 1\u001b[39m\n\u001b[32m----> \u001b[39m\u001b[32m1\u001b[39m extract_pdfs = \u001b[43mload_pdfs\u001b[49m\u001b[43m(\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mData\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[73]\u001b[39m\u001b[32m, line 8\u001b[39m, in \u001b[36mload_pdfs\u001b[39m\u001b[34m(data)\u001b[39m\n\u001b[32m      2\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mload_pdfs\u001b[39m(data):\n\u001b[32m      3\u001b[39m     loader = DirectoryLoader(\n\u001b[32m      4\u001b[39m         data,\n\u001b[32m      5\u001b[39m         glob=\u001b[33m\"\u001b[39m\u001b[33m*.pdf\u001b[39m\u001b[33m\"\u001b[39m,\n\u001b[32m      6\u001b[39m         loader_cls=PyPDFLoader\n\u001b[32m      7\u001b[39m     )\n\u001b[32m----> \u001b[39m\u001b[32m8\u001b[39m     documents = \u001b[43mloader\u001b[49m\u001b[43m.\u001b[49m\u001b[43mload\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m      9\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m documents\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages/langchain_community/document_loaders/directory.py:117\u001b[39m, in \u001b[36mDirectoryLoader.load\u001b[39m\u001b[34m(self)\u001b[39m\n\u001b[32m    115\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mload\u001b[39m(\u001b[38;5;28mself\u001b[39m) -> List[Document]:\n\u001b[32m    116\u001b[39m \u001b[38;5;250m    \u001b[39m\u001b[33;03m\"\"\"Load documents.\"\"\"\u001b[39;00m\n\u001b[32m--> \u001b[39m\u001b[32m117\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mlist\u001b[39;49m\u001b[43m(\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mlazy_load\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages/langchain_community/document_loaders/directory.py:123\u001b[39m, in \u001b[36mDirectoryLoader.lazy_load\u001b[39m\u001b[34m(self)\u001b[39m\n\u001b[32m    121\u001b[39m p = Path(\u001b[38;5;28mself\u001b[39m.path)\n\u001b[32m    122\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m p.exists():\n\u001b[32m--> \u001b[39m\u001b[32m123\u001b[39m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mFileNotFoundError\u001b[39;00m(\u001b[33mf\u001b[39m\u001b[33m\"\u001b[39m\u001b[33mDirectory not found: \u001b[39m\u001b[33m'\u001b[39m\u001b[38;5;132;01m{\u001b[39;00m\u001b[38;5;28mself\u001b[39m.path\u001b[38;5;132;01m}\u001b[39;00m\u001b[33m'\u001b[39m\u001b[33m\"\u001b[39m)\n\u001b[32m    124\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m p.is_dir():\n\u001b[32m    125\u001b[39m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mValueError\u001b[39;00m(\u001b[33mf\u001b[39m\u001b[33m\"\u001b[39m\u001b[33mExpected directory, got file: \u001b[39m\u001b[33m'\u001b[39m\u001b[38;5;132;01m{\u001b[39;00m\u001b[38;5;28mself\u001b[39m.path\u001b[38;5;132;01m}\u001b[39;00m\u001b[33m'\u001b[39m\u001b[33m\"\u001b[39m)\n",
      "\u001b[31mFileNotFoundError\u001b[39m: Directory not found: 'Data'"
     ]
    }
   ],
   "source": [
    "extract_pdfs = load_pdfs(\"Data\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d00e3f94",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'producer': 'ReportLab PDF Library - www.reportlab.com', 'creator': '(unspecified)', 'creationdate': '2025-12-10T12:56:23+00:00', 'author': '(anonymous)', 'keywords': '', 'moddate': '2025-12-10T12:56:23+00:00', 'subject': '(unspecified)', 'title': '(anonymous)', 'trapped': '/False', 'source': 'Data/NORMAL_KB_Document.pdf', 'total_pages': 3, 'page': 0, 'page_label': '1'}, page_content='Normal Retina — Comprehensive KB Entry\\n1 — Short Definition\\nA normal retina is a multilayered neural tissue lining the back of the eye, responsible for converting light\\ninto visual signals. On OCT imaging, the normal macula shows a clean foveal depression, well-defined\\nretinal layers, and absence of any fluid, cysts, or abnormal elevations.\\n2 — Basic Anatomy of the Retina (Layer by Layer)\\nFrom inner (vitreous side) to outer (RPE/choroid side), the key layers are:\\n- Internal Limiting Membrane (ILM)\\n- Nerve Fiber Layer (NFL)\\n- Ganglion Cell Layer (GCL)\\n- Inner Plexiform Layer (IPL)\\n- Inner Nuclear Layer (INL)\\n- Outer Plexiform Layer (OPL)\\n- Outer Nuclear Layer (ONL)\\n- External Limiting Membrane (ELM)\\n- Photoreceptor Inner Segments and Outer Segments\\n- Ellipsoid Zone (EZ)\\n- Retinal Pigment Epithelium (RPE)\\n- Bruch’s Membrane and Choroid beneath\\n3 — OCT Characteristics of a Healthy Macula\\n- **Foveal Depression:** Smooth, symmetric curvature with thinnest point at the fovea.\\n- **Layer Clarity:** All retinal layers appear sharply demarcated.\\n- **No Fluid:** No intraretinal cysts (IRF) and no subretinal fluid (SRF).\\n- **Intact Ellipsoid Zone:** Strong hyperreflective band indicating healthy photoreceptors.\\n- **Normal RPE Line:** Continuous, smooth hyperreflective line with no elevation.\\n- **Stable Thickness:** Normal macular thickness without thickening or thinning.\\n4 — What Is NOT Present in a Normal Retina (Important for Classification)\\n- No cystoid spaces.\\n- No drusen or sub-RPE deposits.\\n- No pigment epithelial detachment (PED).\\n- No choroidal neovascularization or subretinal hyperreflective material.\\n- No edema, exudates, or hemorrhage.\\n- No tractional changes or disruption of the photoreceptor bands.\\n5 — Physiological Variations (Still Considered Normal)'),\n",
       " Document(metadata={'producer': 'ReportLab PDF Library - www.reportlab.com', 'creator': '(unspecified)', 'creationdate': '2025-12-10T12:56:23+00:00', 'author': '(anonymous)', 'keywords': '', 'moddate': '2025-12-10T12:56:23+00:00', 'subject': '(unspecified)', 'title': '(anonymous)', 'trapped': '/False', 'source': 'Data/NORMAL_KB_Document.pdf', 'total_pages': 3, 'page': 1, 'page_label': '2'}, page_content='- Mild inter-individual variation in foveal pit shape.\\n- Slight differences in reflectivity due to age.\\n- Occasional benign vitreomacular adhesion (VMA) without traction.\\n6 — Importance in Machine Learning / Classification\\nA “normal” OCT class acts as:\\n- The baseline template for retinal architecture.\\n- The reference to detect abnormalities such as fluid, drusen, or neovascular membranes.\\n- A stabilizing anchor in the model for contrast between pathological and healthy states.\\n7 — Clinical Significance of Normal Findings\\n- Normal OCT suggests no active retinal disease.\\n- Clear layers and intact EZ correspond to good visual potential.\\n- Important for ruling out diabetic macular edema, drusen, and CNV.\\n8 — Patient Education (Chatbot-Friendly Snippets)\\n- “A normal retina has smooth, well-organized layers with no swelling or abnormal fluid.”\\n- “Your OCT scan shows no signs of leakage, deposits, or damage.”\\n- “An intact photoreceptor layer means healthy visual function.”\\n9 — When Normal OCT Occurs Despite Symptoms\\nA patient may feel symptoms but still have a normal OCT due to:\\n- Dry eye symptoms (not retinal).\\n- Migraine aura.\\n- Functional visual disturbances.\\n- Early disease not yet visible structurally.\\n10 — Safety & Advice for Patients with Normal OCT\\n- If vision symptoms persist, a clinical exam may still be needed.\\n- Monitor for any new distortion or vision changes.\\n- Maintain regular eye health practices (good lighting, glucose control if diabetic, etc.).\\n11 — Decision Flow (for Chatbot Use)\\n- OCT shows no fluid + intact layers → classify as NORMAL.\\n- If symptoms but OCT normal → recommend clinical evaluation for non-retinal causes.\\n- If minimal benign variations → still NORMAL unless accompanied by structural abnormalities.\\n12 — Snippets for Embedding\\n- “Normal OCT: clear layers, no fluid, intact RPE and photoreceptors.”\\n- “Healthy macula shows a smooth foveal dip with no cysts or swelling.”'),\n",
       " Document(metadata={'producer': 'ReportLab PDF Library - www.reportlab.com', 'creator': '(unspecified)', 'creationdate': '2025-12-10T12:56:23+00:00', 'author': '(anonymous)', 'keywords': '', 'moddate': '2025-12-10T12:56:23+00:00', 'subject': '(unspecified)', 'title': '(anonymous)', 'trapped': '/False', 'source': 'Data/NORMAL_KB_Document.pdf', 'total_pages': 3, 'page': 2, 'page_label': '3'}, page_content='- “No signs of drusen, edema, or abnormal vessels.”\\n13 — Disclaimer\\nThis information is for educational use only and should not replace clinical assessment by an eye care\\nprofessional.'),\n",
       " Document(metadata={'producer': 'Skia/PDF m143', 'creator': 'Mozilla/5.0 (X11; Linux x86_64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/143.0.0.0 Safari/537.36', 'creationdate': '2026-01-05T10:04:19+00:00', 'title': 'Choroidal Neovascularization: OCT Angiography Findings - EyeWiki', 'moddate': '2026-01-05T10:04:19+00:00', 'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf', 'total_pages': 2, 'page': 0, 'page_label': '1'}, page_content='Type 1 CNV. Type 1 neovascular lesion is located\\nbelow the RPE as seen in the B-scan frame. In the\\nOCT-A frame, a neovascular coralliform network is\\nobserved which emanates from the choroidal\\nvasculature and extends to the sub-RPE space.\\nType 2 CNV. In B-scan and OCT-A, a neovascular\\nlesion is identified that extends from the choroidal\\nvessels through the Bruch\\'s membrane and RPE\\nand grows into the subretinal space. The En Face\\nimage shows a change in color in macula secondary\\nto edema and serous detachment of the retina.\\nChoroidal Neovascularization: OCT Angiography Findings\\nAll content on Eyewiki is protected by copyright law and the Terms of Service. This content may not be reproduced, copied, or put into any artificial intelligence\\nprogram, including large language and generative AI models, without permission from the Academy.\\nDisease Entity\\nDisease\\nChoroidal neovascularization (CNV) is part of the spectrum of exudative age-related macular\\ndegeneration (AMD) that consists of an abnormal growth of vessels from the choroidal vasculature to\\nthe neurosensory retina through the Bruch\\'s membrane.  CNV can also develop in a number of other\\nconditions such as myopic degeneration, chronic central serous chorioretinopathy, macular\\ntelangiectasia type 2, various white dot syndromes and other uveitic processes, and some choroidal\\ntumors.  Leakage of retinal edema and hemorrhage from CNV threatens visual acuity.\\nEtiology\\nEtiology of CNV is multifactorial. Alterations in Bruch\\'s membrane, migration of macrophages and\\nproduction of vascular endothelium growth factor (VEGF), play an important role in the development of\\nthis disease.\\nRisk Factors\\nThe incidence and progression of AMD are related to age and genetic factors.  With aging, the\\nlysosomal activity for the degradation of external segments of photoreceptors decreases. This leads to\\nsubsequent accumulation of lipofuscin, which affects the normal function of the RPE. Another important\\nrisk factor for the development of CNV is the presence of large, confluent soft drusen.\\nOxidative stress may play an important role in AMD.  Several modifiable risk factors have been\\nidentified, including quitting smoking, dietary intake of omega-3 fatty acids, consuming vegetables and\\nfruit with antioxidants including lutein and zeaxanthin, exercise, wearing sunglasses, and maintaining a\\nhealthy weight.\\nPathophysiology\\nAlterations in the normal transport of metabolites, ions and water through Bruch\\'s membrane in AMD,\\nalter the nutrition and stability of retinal pigment epithelium (RPE) from choriocapillaris and the\\ntransport of waste out from the neurosensory retina. Hypoxia leads to VEGF being released by the RPE,\\nwhich initiates a cascade of angiogenic responses at the level of the choroidal endothelium. Bruch´s\\nmembrane damage is required to allow the passage of abnormal neovascular vessels from the choroidal\\nvasculature through the breaks in Bruch’s membrane to the retina. This impairment is part of the\\npathological course of AMD.\\nClassification\\nHistologically, neovascular membranes are classified into:\\nType 1 (\"occult\"), when the neovascular membrane is located below the RPE. Type 1 CNV\\ndemonstrates occult leakage on fluorescein angiography. Polypoidal choroidal vasculoplathy (PCV) is\\na subtype of Type 1 CNV that is characterized by the presence of polyp-like aneurysmal dilations of\\nthe branching vascular network.\\nType 2 (\"classic\"), passes through the RPE and is located above the RPE in the subretinal space. This\\nis related to the angiographic classification of a classic CNV.\\nArticle initiated by: Andrea Tamine Hoyos Dumar, MD, Juan.David.Arias\\nAll contributors: Leo A. Kim, MD, PhD,\\xa0Sun Young (Sunny) Lee, MD, PhD,\\xa0Koushik Tripathy, MD (AIIMS),\\xa0Andrea Tamine Hoyos Dumar,\\nMD,\\xa0Diana V. Do, MD,\\xa0Talisa de Carlo, MD,\\xa0Neelakshi Bhagat, MD, FACS,\\xa0Jennifer I Lim MD,\\xa0Aidan Lee, MD\\nAssigned editor: Sun Young (Sunny) Lee, MD, PhD\\nReview: Assigned status Up to Date\\n\\xa0by Sun Young (Sunny) Lee, MD, PhD on September 18, 2025.\\nChoroidal Neovascularization\\nDiseasesDB 32400\\nICD-10 H35.3\\nMeSH D020256\\n[1]\\n[2][3]\\n[4][5][6][7]\\n[8]\\n[9]\\n[10]\\n[11]\\n[12][13]\\nLearn more Accept'),\n",
       " Document(metadata={'producer': 'Skia/PDF m143', 'creator': 'Mozilla/5.0 (X11; Linux x86_64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/143.0.0.0 Safari/537.36', 'creationdate': '2026-01-05T10:04:19+00:00', 'title': 'Choroidal Neovascularization: OCT Angiography Findings - EyeWiki', 'moddate': '2026-01-05T10:04:19+00:00', 'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf', 'total_pages': 2, 'page': 1, 'page_label': '2'}, page_content=\"Type 3 CNV. \\xa0An intraretinal neovascular lesion is\\nobserved. The color photo identifies typical\\npunctate hemorrhages. The OCT B-scan shows\\nretinal edema without disruption of Bruch's\\nmembrane or RPE. OCT-A depicts an anastomosis\\noriginating in the neurosensory retina.\\nType 3 is defined as Retinal Angiomatous Proliferation (RAP), which corresponds to neovascularization that develops within the neurosensory retina an\\nprogresses posteriorly into the subretinal space.\\nDiagnosis\\nClinical findings\\nIn the presence of CNV, the patient experiences an acute decrease in visual acuity, relative scotoma,\\nand/or metamorphopsia. The retinal examination shows a grayish macular lesion associated with\\nsubretinal fluid, macular edema, exudation, and/or hemorrhages.\\nDiagnostic Procedures\\nOCT Angiography\\nEn face OCT angiography (OCTA) is a new technology that has the great ability to show the retinal and\\nchoroidal microcirculation in detail without invasive means.  Instead of intraocular contrast, it uses\\nmotion contrast by comparing the decorrelation signal between repeated B-scans obtained at a given\\nretinal cross-section to detect blood flow. It utilizes the principle that theoretically only the circulating\\nRBCs within the retinal vasculature would be moving between the B-scans. Each en face OCT angiogram\\nis cross-registered with the corresponding OCT B-scans, an OCT thickness map, and a structural en face\\nOCT, which allows for concurrent visualization of structure and blood flow. OCTA is available on both\\nspectral domain and swept source OCT devices.\\nThe conventional CNV evaluation often consists of multimodal imaging with fluorescein angiography\\n(FA) combined with indocyanine green angiography (ICGA) and OCT. These well-established modalities\\ncan guide effective CNV management but have their limitations, especially when characterizing vascular\\nstructures at different depths. For example, FA only allows for evaluation of the superficial capillary\\nplexus within the retina. OCTA, on the other hand, allows for noninvasive three-dimensional analysis of\\nthe retinal and choroidal vasculature and can be segmented to view each of the vascular plexuses\\nindividually.\\nThis ability to visualize vascular structures at different depths/layers of the retina makes OCTA a tool well suited to evaluate CNV. For the purpose of\\nvisualizing changes in eyes with CNV or suspected CNV, a segmentation of the outer retina (extending from the outer plexiform layer to Bruch’s membrane)\\nand a segmentation of the choriocapillaris (approximately 20um thick region just below the RPE) are most useful. CNV can be seen as a seafan or coraliform\\nneovascular complex within the outer retina, which is ordinarily devoid of blood flow in normal eyes. Type 1 CNV is observed in OCTA as a neovascular complex\\nbetween the RPE and Bruch's membrane, originating in the choroid.  The type 2 CNV is visualized as a neovascular network that grows from the choroid\\nvasculature and traverses the RPE-Bruch's membrane complex into the subretinal space.  Type 3 CNV is clinically seen as tiny intra- and subretinal\\nhemorrhages that correlate on OCTA as an intraretinal anastomosis originating in the deep capillary plexus of the retina.\\nThe PCV subtype of CNV can also be seen as a branching neovascular network within the outer retina but with concurrent aneurysmal dilations. After repeat\\npharmacologic intervention the large branches of the CNV become pruned and the smaller capillaries and any polyps may no longer be visualized (whether due\\nto slow or absent flow, or complete regression). The choriocapillaris layer may demonstrate decreased flow or flow voids adjacent to the CNV complex.\\nAdditionally, choriocapillaris hypoperfusion may be seen underlying any areas of RPE atrophy.\\nThe use of OCTA in CNV imagining is not without challenges.  OCTA is susceptible to several imaging artifacts. Some of these, such as motion or signal\\nattenuation, may be mitigated through patient instruction and technician training. Projection artifacts arise when blood flow of su perficial layers of the retina is\\nprojected onto deeper structures below, which can cause false flow signal in deeper anatomical layers. CNV assessment suffers since proper visualization\\nrequires high-quality images of the outer retina, where projection artifacts are especially prominent due to proximity to the highly reflective RPE layer.\\nFurthermore, the eruption of CNV can lead to segmentation artifact via the distortion of the retinal layers. This may require manual adjustment of the\\nsegmentation slabs, which may be time consuming and lower the repeatability of the test. Tools for automatic segmentation through deep learning and\\nmodality of OCTA such as projection-resolved OCTA (PR-OCTA) algorithm have been reported to improve the quality and repeatability of OCTA studies.\\nManagement\\nTreatment\\nTaking into account the numerous recent studies on the treatment of CNV in AMD, it has been shown that antiangiogenic therapy shows the best result both\\nhistologically with the regression of the neovascular lesion and functionally with improvement of the visual acuity. Although the treatment is the same for all\\ntypes of CNV, it is important to differentiate them, since they do not all respond identically and some of them have a higher rate of recurrence.\\nReferences\\n1. Turbert, D. (2020, March 18). What are Choroidal Neovascular\\nmembranes? Reviewed by Ninel Z Gregori, MD. American Academy of\\nOphthalmology. https://www.aao.org/eye-health/diseases/choroidal-\\nneovascular-membranes.\\n2. Cheung C. et al. “Myopic Choroidal Neovascularization: Review,\\nGuidance, and Consensus Statement on Management”. Ophthalmology.\\n2017 Nov;124(11):1690-1711. doi: 10.1016/j.ophtha.2017.04.028\\n3. Agarwal A. et al. “An update on inflammatory choroidal\\nneovascularization: epidemiology, multimodal imaging, and management”.\\nJ Ophthalmic Inflamm Infect. Vol: 8(13). doi: 10.1186/s12348-018-0155-\\n6\\n4. Kennedy CJ, Rakoczy PE, Constable IJ. Lipofuscin of the retinal pigment\\nepithelium: a review. Eye 1995;9:763–71.\\n5. Rakoczy PE, Zhang D, Robertson T, et al. Progressive age-related changes\\nsimilar to age-related macular degeneration in a transgenic mouse model.\\nAm J Pathol 2002;161:1515–24\\n6. Hageman GS, Mullins RF. Molecular composition of drusen as related to\\nsubstructural phenotype. Mol Vis 1999;5:28.\\n7. Spillsbury K. et al. “Overexpression of Vascular Endothelial Growth Factor\\n(VEGF) in the Retinal Pigment Epithelium Leads to the Development of\\nChoroidal Neovascularization”. Am J Pathol. 2000 Jul; 157(1): 135–144.\\ndoi: 10.1016/S0002-9440(10)64525-7\\n8. Klein R, Klein BE, Jensen SC, et al. The five-year incidence and progression\\nof age-related maculopathy: the Beaver Dam Eye Study [see comments].\\nOphthalmology 1997;104:7–21.\\n9. Mullins RF, Russell SR, Anderson DH, et al. Drusen associated with aging\\nand age-related macular degeneration contain proteins common to\\nextracel- lular deposits associated with atherosclerosis, elastosis,\\namyloidosis, and dense deposit disease. FASEB J 2000;14:835–46.\\n10. Sarks JP, Sarks SH, Killingsworth MC. Evolution of soft drusen in age-\\nrelated macular degeneration. Eye 1994;8:269–83.\\n11. The Age-Related Eye Disease Study 2 (AREDS2) Research Group*. Lutein\\n+ Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular\\nDegeneration: The Age-Related Eye Disease Study 2 (AREDS2)\\nRandomized Clinical Trial. JAMA. 2013;309(19):2005–2015.\\ndoi:10.1001/jama.2013.4997\\n12. Abdelsalam A, Del Priore L, Zarbin MA. Drusen in age-related macular\\ndegeneration: pathogenesis, natural course, and laser photocoagulation-\\ninduced regression. Surv Ophthalmol 1999;44:1–29.\\n13. Tombran-Tink J, Shivaram SM, Chader GJ, et al. Expression, secretion, and\\nage-related downregulation of pigment epithelium-derived factor, a\\nserpin with neurotrophic activity. J Neurosci 1995;15:4992–5003.\\n14. de Carlo TE, Bonini Filho MA, Chin AT, et al. Spectral-domain optical\\ncoherence tomography angiography of choroidal neovascularization.\\nOphthalmology. 2015;122(6):1228-38.\\n[14]\\n[15]\\n[16]\\n[17]\\n[18]\\n[19]\\n[20]\\n[21][22]\\nLearn more\"),\n",
       " Document(metadata={'producer': 'Skia/PDF m143', 'creator': 'Mozilla/5.0 (X11; Linux x86_64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/143.0.0.0 Safari/537.36', 'creationdate': '2026-01-05T10:07:54+00:00', 'title': 'Retinal Drusen: Everything You Need to Know', 'moddate': '2026-01-05T10:07:54+00:00', 'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf', 'total_pages': 2, 'page': 0, 'page_label': '1'}, page_content='What Are Retinal Drusen?\\nWritten by WebMD Editorial Contributors Medically Reviewed by Timothy G. Murray,\\xa0MBA,\\xa0MD,\\xa0FACS on August 01, 2025\\n4 min read\\nRetinal drusen are yellow/white-colored spots seen under the retina of your eye that are made up of proteins and a type of fat called lipids.\\nThe retina is the layer of cells lining the inside surface of the back of your eye that sends signals to your brain and enables you to see. \\nSmall drusen may not cause problems for some people, but larger drusen can increase your risk of a medical condition called age-related\\nmacular degeneration (AMD). Drusen can be a sign that you already have age-related macular degeneration.\\xa0\\nIn age-related macular degeneration, the cells of the macula, a part of the retina, start to change because of aging. Dry macular\\ndegeneration comes first. Wet macular degeneration is an advanced form of the condition. A second type of advanced maculardegeneration is called geographic atrophy (GA).\\nTypes of Retinal Drusen\\n There are two types of retinal drusen: hard and soft.\\n Hard drusen are small, dotted, yellow-colored, and abnormal tissue growths. When the drusen is hard, there is a lower risk of losingyour vision in the future.\\nSoft drusen look large and raised, are pale yellow or grayish-white in color, and have a dome shape. There is a higher risk of losing\\nvision in the future if you have many large or medium-sized soft drusen.\\xa0\\nCauses of Retinal Drusen\\n Retinal drusen can occur as a result of aging. It is common to see drusen in people over 60 years of age. 90% of drusen are caused by dry\\nmacular degeneration. The remaining 10% of drusen are caused by wet macular degeneration. \\nIn dry macular degeneration, your central vision becomes blurry or lessens because of the thinning of the part of your retina called the\\nmacula. Dry macular degeneration can cause you to lose vision slowly over time.  \\nIn wet macular degeneration, your vision gets blurred or you may see a blind spot in your field of vision. This condition is caused by\\nabnormal blood vessels that break, bleed, or leak fluid into the macula and may cause sudden and severe loss of vision.\\nSymptoms\\n Sometimes you may have retinal drusen and not experience any symptoms. You may not find out you have them until your doctor seesthem during a routine eye exam. Having a few small drusen doesn’t mean that you have eye disease.\\xa0 \\nWhen you have a lot of larger drusen, it can mean that you have age-related macular degeneration. You could then see the symptoms linked\\nto age-related macular degeneration:\\n Dim or cloudy vision\\n Difficulty seeing when the light changes from bright to dim light\\nA blank or blurry spot in your central vision\\nRisk Factors\\n Retinal drusen can be commonly seen in people over 60 years of age. But other factors can increase your risk of getting this condition:\\n Family history of retinal drusen\\n Smoking tobacco\\nHigh blood pressure\\n Excessive body fat (obesity)\\n High blood cholesterol \\n People of Caucasian descent have a higher risk of both retinal drusen and age-related macular degeneration.\\nWhen to See a Doctor\\n You should see a doctor or eye specialist if you experience any difficulty seeing. Get urgent medical attention if you have severe or serious\\nloss of vision.\\nTreatment\\n Retinal drusen are common in people over 60 years of age. \\xa0Small drusen may not cause any difficulties at all for some people.\\n SubscribeEye Health Guide \\ue902'),\n",
       " Document(metadata={'producer': 'Skia/PDF m143', 'creator': 'Mozilla/5.0 (X11; Linux x86_64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/143.0.0.0 Safari/537.36', 'creationdate': '2026-01-05T10:07:54+00:00', 'title': 'Retinal Drusen: Everything You Need to Know', 'moddate': '2026-01-05T10:07:54+00:00', 'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf', 'total_pages': 2, 'page': 1, 'page_label': '2'}, page_content='Vitamins: You may lose vision if your age-related macular degeneration reaches an advanced stage. If you have a lot of large and medium-\\nsized drusen, your doctor may ask you to take AREDS2 formula vitamins, which can slow down the growth of your condition to an advanced\\nstage by about 25%. \\nAREDS2 formula vitamins are a combination recommended by the Age-Related Eye Disease Study (AREDS), an NIH clinical trial. According to\\nthe results of the study, when these vitamins are taken, they reduce the risk of getting the disease by as much as 19 % and/or reduce the risk\\nof vision loss by 25%. The formula has Vitamin C, Vitamin E, the antioxidants lutein and zeaxanthin, and minerals zinc and copper in specific\\namounts. Lifestyle and dietary changes: Your doctor may ask you to make lifestyle changes, such as stopping smoking. They may recommend that\\nyour diet has more vegetables, fruits, and fatty fish like salmon and mackerel. You may be asked to eat less red meat in order to lower your\\nblood cholesterol.\\xa0\\nEarly detection:Your doctor may ask you to monitor your vision at home if you have drusen, using a test called the Amsler Grid. If you candetect wet macular degeneration early on, your doctor may be able to help you make your vision stable or improve it with injected\\nmedication. With early detection, you can slow down complications and minimize loss of vision.\\xa0\\nSources Update History\\nPrint\\nView privacy policy, copyright and trust info\\nSave\\nNEXT ARTICLE\\nEyelid Bump \\ue909'),\n",
       " Document(metadata={'producer': 'Skia/PDF m143', 'creator': 'Mozilla/5.0 (X11; Linux x86_64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/143.0.0.0 Safari/537.36', 'creationdate': '2026-01-05T10:00:33+00:00', 'title': 'Diabetic Macular Edema - EyeWiki', 'moddate': '2026-01-05T10:00:33+00:00', 'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf', 'total_pages': 8, 'page': 0, 'page_label': '1'}, page_content='Figure 1: Diabetic macular edema. A: Schematic diagram of DME.\\nMicroaneurysms, or damaged capillaries, resulting from the\\nbreakdown of the blood–retina barrier leak fluid to the extracellular\\nspace, resulting in a swollen retina. Resorption of DME is dependent\\non the adjacent capillaries and retinal pigment epithelium.\\nResorption of fluid may leave behind lipoprotein residues, seen here\\nas exudates. B: OCT image of DME. Published online with\\npermission from the AAO.\\nDiabetic Macular Edema\\nAll content on Eyewiki is protected by copyright law and the Terms of Service. This content may not be reproduced, copied, or put into any artificial intelligence\\nprogram, including large language and generative AI models, without permission from the Academy.\\nDisease Definition\\nDiabetic macular edema (DME) is the accumulation of excess fluid in the extracellular space within the retina in the\\nmacular area, typically in the inner nuclear layer, outer plexiform, Henle’s fiber layer, and subretinal space.\\nPathophysiology\\nChronic hyperglycemia-related accumulation of advanced glycated end products\\ndisrupts the blood–retina barrier (BRB), leading to endothelial cell junction breakdown\\nand pericyte loss. The inner BRB is composed of endothelial cells in the retinal\\ncapillaries, while the outer BRB is composed of retinal pigment epithelium cells. When\\nthe BRB is altered, interstitial fluid is accumulated within and underneath the retina\\nthrough leakage of molecules dependent on intact cell-to-cell junctions (Figure 1).\\nEvidence also shows that DME has an inflammatory component, with several\\nchemokines and cytokines involved in its development. These include vascular\\nendothelial growth factor (VEGF), interleukins (ILs), matrix metalloproteinases, and\\ntumor necrosis factor (TNF). Upregulation of multiple pathways leads to increased\\ninflammation, oxidative stress, and vascular dysfunction.  Significant changes are seen\\nin the neurovascular unit, altering the homeostasis between astrocytes, ganglion cells,\\nMüller cells, retinal vascular endothelial cells, and amacrine cells.  Retinal vascular\\npermeability changes also involve the kallikrein-kinin system, which induces\\nvasorelaxation via bradykinin and nitric oxide.\\nNatural History\\nDME can develop at any stage of diabetic retinopathy (DR), from mild nonproliferative\\ndiabetic retinopathy (NPDR) to proliferative diabetic retinopathy, but is more frequent\\nas the severity of DR increases. DME occurring near to or at the fovea is more likely to\\nresult in blurred vision and metamorphopsia. When the DME involves or threatens the\\nfovea, the risk of moderate visual loss (defined as a ≥ 3-line decrease in visual acuity (VA),\\nequivalent to a doubling of the visual angle) increases; in the Early Treatment of Diabetic\\nRetinopathy Study (ETDRS) study, visual loss decreased by 24% over 3 years without\\ntreatment.  The disease course is variable, with some eyes having chronic persistent\\nDME spanning several years, while other eyes have rapid spontaneous resolution,\\nalthough the risk of recurrence is always present.\\nPrevalence\\nThe Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) found that the\\n25-year incidence of DME in people with type 1 diabetes mellitus (T1DM) was 29%.\\nThe Diabetes Control and Complications Trial (DCCT) reported that 27% of people with\\nT1DM had DME within 9 years of diabetes onset.  The WESDR also found that 25.4%\\nof people with type 2 DM who used insulin and 13.9% of those who did not use insulin\\nhad DME.  Yau et al. estimated the global prevalence of DME to be 6.8% among\\npeople with DM. In the United States, prevalence rates are between 2.7% to 3.8%, with\\nnon-Hispanic White people less likely to have DME than non-Hispanic Black\\npeople.\\nRisk Factors\\nRisk factors for DME and DR are similar. These include a longer DM duration, poor control of DM with elevated glycolated hemoglobin A1c (HbA ) levels,\\nhypertension, and hyperlipidemia. Other secondary risk factors include impaired renal function and the use of thiazolidinediones.\\nPrevention\\nPrimary prevention of DME involves intensive control of DM, blood glucose and lipid levels, hypertension, and other systemic risk factors. The Diabetic\\nRetinopathy Clinical Research (DRCR) Protocol W investigated whether aflibercept injections in eyes with baseline moderate-to-severe NPDR could prevent\\nthe eventual development of center-involved DME (ci-DME) with vision loss.  Vision loss was defined as a ≥ 10-letter decrease in VA at 1 visit or a 5-to 9-\\nletter decrease at 2 consecutive visits, with the decrease in vision attributed to the ci-DME. The 2-year cumulative probability of developing ci-DME with\\nvision loss was 4.1% in patients given aflibercept vs 14.8% of patients given sham injections. However, there was no significant difference in mean VA between\\nArticle initiated by: Cris Martin P. Jacoba, MD, Margalit G. Mitzner, Neelakshi Bhagat, MD, FACS, Marco Attilio Zarbin, MD, PhD, FACS, Jerry\\nCavallerano, OD, PhD, Paolo A. Silva, MD, Lloyd P. Aiello, MD, PhD, Mohamed A. Elmasry, MD, PhD\\nAll contributors: Theodore Leng, MD, MS,\\xa0Koushik Tripathy, MD (AIIMS),\\xa0Neelakshi Bhagat, MD, FACS,\\xa0Jennifer I Lim MD,\\xa0Cris Martin P.\\nJacoba, MD,\\xa0David Kitchen,\\xa0Galin J. Spicer, MD MBA\\nAssigned editor: Neelakshi Bhagat, MD, FACS\\nReview: Assigned status Update Pending\\n\\xa0by Neelakshi Bhagat, MD, FACS on July 6, 2025.\\n[1][2]\\n[3]\\n[4]\\n[5]\\n[6][7][8]\\n[9]\\n[10]\\n[11]\\n[10]\\n[12][13][14]\\n1c[15][16][17]\\n[18]\\nLearn more Accept'),\n",
       " Document(metadata={'producer': 'Skia/PDF m143', 'creator': 'Mozilla/5.0 (X11; Linux x86_64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/143.0.0.0 Safari/537.36', 'creationdate': '2026-01-05T10:00:33+00:00', 'title': 'Diabetic Macular Edema - EyeWiki', 'moddate': '2026-01-05T10:00:33+00:00', 'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf', 'total_pages': 8, 'page': 1, 'page_label': '2'}, page_content=\"Figure 2: Circinate exudates. A: Blue arrows - Circinate exudates,\\ndefined as exudates arranged in a circular appearance. B: OCT b-\\nscan across the fovea, confirming the presence of DME associated\\nwith an elevated foveal contour. The patient’s best-corrected vision\\nwas 20/32.\\nFigure 3: Dense macular exudates involving the fovea. A: Blue\\narrow– Dense foveal exudates. B: Red arrow– OCT b-scan across the\\nfovea, confirming the presence of DME and the dense foveal\\nexudate. The patient’s best-corrected vision was 20/200.\\nFigure 4: Basic structural changes in DME seen on OCT. Yellow\\nbracket– Generalized retinal swelling. Blue arrow– Cystoid macular\\nedema. Red arrow– Subretinal fluid.\\nthe treatment groups. From baseline to the 2-year checkup, eyes treated with sham\\ninjections had a mean (SD) change of −2.0 (6.1) letters, while eyes treated with\\naflibercept had a mean −0.9 (5.8) letter change (adjusted mean difference 0.5 letters;\\n97.5% CI, −1.0 to 1.9 letters; P = 0.47]. However, at present the use of anti-VEGF\\ninjections for the prevention of ci-DME is not the standard of care.\\nDiagnosis\\nHistory\\nDME is suspected in patients with any level of DR who present with blurred vision or\\nmetamorphopsias. A detailed history including the approximate date of onset of\\ndiabetes, the use of insulin versus oral antihyperglycemic agents, and the quality of\\nmetabolic control (e.g., HbA  level) should be elicited. Any associated medical problems\\nsuch as hypertension, hypercholesterolemia, renal disease, and thyroid disease should\\nbe identified, along with a thorough review of medications. It should be noted that mild\\nto extensive DME may be present without symptoms evident to the patient.\\nPhysical Examination\\nPatients suspected of having DME may undergo a detailed biomicroscopic examination\\nwith a slit lamp and indirect ophthalmoscope. Historically, DME classifications were\\nbased on the 1980s-era ETDRS definitions of clinically significant macular edema\\n(CSME). The specific criteria for diagnosing CSME were:\\n1. Retinal thickening at or within 500 μ m of the center of the fovea\\n2. Hard exudates at or within 500 μ m of the center of the fovea if adjacent to an area\\nof retinal thickening\\n3. Retinal thickening of at least 1 disc area, any portion of which is within 1500 μ m\\n(approximately 1 disc diameter) from the center of the fovea\\nThus, CSME, as defined by the ETDRS, is a clinical diagnosis made by slit-lamp\\nexamination using a contact lens. While clinical examinations remain essential for the\\nfull evaluation of DME, optical coherence tomography (OCT) is now routinely used to\\ncomplement physical examination in the diagnosis of DME. The management of DME is\\ncurrently based on the central subfoveal thickness (CST) on the macular OCT.\\nSigns\\nMacular thickening with or without hard exudates may be seen on stereo\\nbiomicroscopy. However, some eyes may present without apparent signs of retinal\\nthickening on clinical examination, despite significant OCT-observed DME. Thickening\\ncan occur in various patterns, including focal, multifocal, and diffuse areas of retina\\nthickening. Despite these terms being frequently used, there are no well-established\\nstandard, consistently used definitions.  In the ETDRS guidelines, focal leakage\\nresulting from microaneurysms may be treated with a fluorescein angiography–guided\\nfocal laser, while diffuse capillary leakage is from a more widespread breakdown of the\\nBRB and may be treated with grid laser.  Hard exudates in various patterns may also\\nbe seen, including circinate rings and focal aggregations of exudates (Figures 2–3). Hard\\nexudates consist of lipoprotein residues of serous leakage from damaged vessels, and\\ncan serve as biomarkers for DME.\\nSymptoms\\nDME may present with decreased visual acuity (VA), metamorphopsia, changes in color\\nperception, and difficulty reading, although it may also present asymptomatically.\\nVision and DME\\nStudies show a poor to modest correlation between VA and CST on OCT, within the\\nrange of 0.3–0.5.  Over 2 years, only around 12%–14% of the change in VA can be\\nattributed to the change in thickness. In a study by the DRCR Network, the slope of the\\nbest fit line shows an approximately 4.4 letter improvement (95% CI, 3.5–5.3) for every\\n100-micron decrease in CST at baseline.  Interestingly, on follow-up after treatment\\nwith macular laser photocoagulation, there were some eyes with paradoxical\\nimprovement in VA with increased CST (7-17% at different time points) and paradoxical\\nworsening of VA with decreased CST (18-26% at different time points). These findings\\nhighlight how OCT measurements cannot be used as a perfect surrogate for visual\\nacuity; however, in clinical and research settings, the technology remains an important\\ntool. The DRCR Network has recommended a 10% change in CST to indicate a real\\nchange that can be considered in clinical decision-making.\\nDiagnostic Procedures\\nOptical Coherence Tomography (OCT)\\nWithin recent years, OCT has quickly become an important ancillary procedure in\\ndiagnosing and treating DME. Three basic structural changes can be seen on OCT:\\nretinal swelling, cystoid macular edema, and subretinal fluid (Figure 4). Macular scans\\ncan quickly and accurately identify even subtle areas of thickening, along with\\nquantitative metrics for different areas. Changes in the anatomic distribution of DME\\ncan be monitored over time, especially the fluid’s relationship to the fovea. This\\ninformation has clinical and research implications for the evaluation and management of\\nDME. The International Council of Ophthalmology's guidelines for diabetic eye care,\\npublished in 2018, adopted the clinical entities of center-involved DME (ci-DME) and\\nnon-center–involved DME (non-ciDME) for the evaluation of macular fluid (Figure 5), as\\nfollows:\\n1. Center-involved DME: Retinal thickening in the macula that involves the central\\nsubfield zone (1 mm in diameter)\\n2. Non-center–involved DME: Retinal thickening in the macula that does not involve\\nthe central subfield zone (1 mm in diameter)\\n[18]\\n1c\\n[19]\\n[20]\\n[21][22]\\n[22]\\nLearn more\"),\n",
       " Document(metadata={'producer': 'Skia/PDF m143', 'creator': 'Mozilla/5.0 (X11; Linux x86_64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/143.0.0.0 Safari/537.36', 'creationdate': '2026-01-05T10:00:33+00:00', 'title': 'Diabetic Macular Edema - EyeWiki', 'moddate': '2026-01-05T10:00:33+00:00', 'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf', 'total_pages': 8, 'page': 2, 'page_label': '3'}, page_content=\"Figure 5: Montage of center-involved vs non-center–involved DME. Top Row A: Non-center–involved DME. Retinal\\nthickening does not involve the central 1-mm subfield zone (innermost circle) per the en-face OCT heatmap, as seen on\\nb-scan. Bottom Row B: Center-involved DME. Retinal thickening involves the central 1-mm subfield zone (innermost\\ncircle) per the en-face OCT heatmap and b-scan. Published online with permission from the AAO.\\nFigure 6: Disorganization of the retinal inner layers. OCT images showing combinations of\\npresence or absence of DRIL and DME. The central 1-mm area is enclosed in the box. Upper\\nimages show segmentation of inner retinal layers, with the white lines demarcating the\\nboundaries between IPL-INL and the INL-OPL. Image credit to: Barham et al., Association of\\nMacular Nonperfusion, Leakage, and DRIL (ARVO poster, 2016)\\nAside from the location of the\\nswelling, the DRCR Network has given\\nrecommendations on CST treatment\\nthresholds based on sex-matched\\nstandards.  The thresholds were\\ndifferent for each OCT machine; since\\nthickness measurements cannot be\\ncompared between different devices,\\neach device has its own normative\\ndatabase and algorithms. In DRCR\\nProtocol T, treatment eligibility\\nthresholds per machine were:\\n1. Heidelberg Spectralis: 320 μ m for\\nmen and 305 μ m for women\\n2. Zeiss Cirrus OCT: 305 μ m for men\\nand 290 μ m for women\\n3. Zeiss Stratus OCT:250 μ m for\\nboth men and women\\nMoreover, OCT is a more sensitive\\nmethod for objective evaluation of\\nvitreomacular interface abnormalities\\n(VMIA), which include vitreomacular\\nadhesion (VMA), vitreomacular\\ntraction (VMT), and epiretinal\\nmembrane (ERM). Identifying VMIA is\\ncrucial when diagnosing the etiology\\nof macular edema, whether primarily\\nfrom DME, from secondary causes of\\nVMIA, or combined mechanism\\nmacular edema.\\nOCT Biomarkers for DME\\nDME's different OCT features have been associated with\\ndisparate prognostic outcomes and treatment responses.\\n[23]\\nLearn more\"),\n",
       " Document(metadata={'producer': 'Skia/PDF m143', 'creator': 'Mozilla/5.0 (X11; Linux x86_64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/143.0.0.0 Safari/537.36', 'creationdate': '2026-01-05T10:00:33+00:00', 'title': 'Diabetic Macular Edema - EyeWiki', 'moddate': '2026-01-05T10:00:33+00:00', 'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf', 'total_pages': 8, 'page': 3, 'page_label': '4'}, page_content=\"Figure 7: External limiting membrane and ellipsoid zone disruption. A: DME with large cystic\\nspaces (blue arrow) and exudates (green arrows). Despite anti-VEGF treatment, DME\\npersisted. The EZ and ELM were still intact, with BCVA of 20/32. B: Five years after photo A,\\nextensive ELM and EZ disruption (red bracket) developed which involved the fovea. A few\\nchronic parafoveal cysts can still be seen. BCVA dropped to 20/63.\\nFigure 8: Epiretinal membrane associated with DME. Dense epiretinal membrane\\noverlying the retinal surface, with an elevated foveal contour and significant\\nintraretinal cystic spaces in a patient with diabetes. Published online with permission\\nfrom the AAO.\\n1. Disorganization of the retinal inner layers (DRIL) is thought to represent damaged cells within the inner retinal layers, indicating a disruption in the normal\\nvisual pathway from the photoreceptors to the ganglion cells.  DRIL is identified on OCT when there is disruption of the demarcating interface lines\\nbetween the ganglion cell-inner plexiform complex, inner nuclear layer (INL), outer plexiform layer (OPL), and outer nuclear layer. Eyes with DRIL have a\\nworse baseline and final VA despite anti–vascular endothelial growth factor (VEGF) injections and have an almost 8× greater risk for poor visual recovery.\\nIn contrast, the resolution of DRIL results in better visual outcomes (Figure 6).  DRIL was better correlated with VA than either glycemic status\\nand CST.\\n2. External limiting membrane (ELM) and ellipsoid zone (EZ) disruption strongly correlate with baseline and final BCVA. At the same time, some studies found\\nthat restoration of the EZ was a requirement for good visual recovery (Figure 7).  The ELM connects a row of zonular adherents to the\\nphotoreceptor cell bodies, while the EZ represents the isthmus between the outer and inner segments of photoreceptors.\\n3. DME associated with VMIA, notably ERM and VMT, has poorer visual outcomes (Figure 8).  VMIA have been observed in 7%–16% of eyes with DME,\\nwith an annual incidence rate of up to 4.5%.  The READ-3 trial showed that eyes with VMIA still had a good response to anti-VEGF therapy.\\nPresence of posterior vitreous detachment (PVD) has been associated with improved visual outcomes. Nasrallah et al. reported that DME was present in\\n55% of eyes with an attached hyaloid, compared with only 20% of eyes with PVD.  Hikishi et al. reported only a 25% rate of spontaneous resolution in\\neyes with attached posterior hyaloid, vs a 55% resolution rate in eyes with PVD.  The role of the vitreous and VMIA in DME, which may be related to\\nchanges in transvitreal oxygenation, hyalocyte proliferation from vitreous remnants on the ILM, and the present growth factors in the premacular hyaloid,\\nis still being investigated.\\nFluorescein Angiography\\nFluorescein angiography (FA) is performed to identify leaking\\nmicroaneurysms or capillaries to help guide laser treatment,\\nand to identify areas of retinal ischemia. Leakage seen with FA\\nis not synonymous with retinal edema. Focal DME is\\ncharacterized by focal leakage from microaneurysms or\\ncapillaries; in contrast, diffuse DME is characterized by poorly\\ndemarcated areas of capillary leakage (Figure 9). Recently,\\nthere has been a decreasing trend in the use of FA in the\\nmanagement of DME, likely due to the procedure being more\\ninvasive and time-consuming than OCT.  Contraindications\\nto the use of FA include pregnancy and allergy associated with\\nthe contrast dye.\\nLaboratory Testing\\nPrimary laboratory testing for DME should involve checking\\nHbA , blood pressure, and lipid levels.\\xa0 Secondary tests can\\ninclude hemoglobin (anemia exacerbates diabetic retinopathy\\nand may be associated with diabetic nephropathy); both fasting\\nand postprandial blood sugar; urea, creatinine, and urine\\nmicroalbumin levels, and a thyroid panel.\\nDifferential Diagnosis\\nOther causes of DME include retinal vein occlusion, ruptured\\nmacroaneurysm, Irvine-Gass syndrome, radiation retinopathy,\\nhypertensive retinopathy, subfoveal choroidal neovascularization,\\nretinal vein occlusion, and VMIA. OCT and FA ancillary diagnostics can\\nhelp to identify these differential diagnoses (Figures 10–11).\\nManagement\\nManagement of DME includes strict control of diabetes, blood glucose,\\nhypertension, and hypercholesterolemia.  This can be achieved by\\npharmacologic methods or by nonpharmacologic methods, such as diet\\nmodification, weight loss, and exercise.\\nPharmacotherapy\\nAt present, anti-VEGF agents are the first-line treatment for DME. The\\nFDA approved ranibizumab for DME in 2012, aflibercept in 2014, and\\nbrolucizumab and faricimab in 2022. \\xa0Since 2005, intravitreal\\nbevacizumab has been used off-label for ocular conditions.\\nDRCR Network Anti-VEGF Treatment\\nAlgorithm\\nThe DRCR anti-VEGF treatment algorithm states that 6 monthly\\ninjections should be given unless VA is 20/20 or better and CST is <320\\nμ m for men or <305 μ m for women (as measured by the Heidelberg Spectralis), in which case treatment may be withheld starting on the 4th month. At the 6th\\nvisit, if stability in vision or CST has been achieved (based on the previous 2 visits' findings) or DME has resolved, further treatment may be withheld. Stability is\\ndefined as:\\n1. Lack of improvement\\nNo BCVA increase of ≥ 5 letters (approximately 1 line on a Snellen chart)\\nNo decrease in OCT-measured CST ≥ 10% (per OCT imaging)\\n2. No worsening\\nBCVA decreases by ≥ 5 letters (approximately 1 line on a Snellen chart) in the setting of persistent DME\\nOCT-measured CST increases by ≥ 10%\\nIf there is worsening on follow-up, anti-VEGF treatment is resumed. In general, eyes showing stability may be followed up in 3–4 months, or sooner as needed.\\nWithholding injections does not require 20/20 vision or a dry macula, only evidence of stability over the previous 2 or more visits. DRCR Protocol I issued the\\nfirst anti-VEGF as-needed treatment algorithm for DME, as long-term data show that even without using a monthly treatment protocol, eyes with persistent\\n[24]\\n[25][26][27]\\n[24]\\n[28][29][30][31][32]\\n[33]\\n[34][35]\\n[36][37] [38]\\n[39]\\n[40]\\n[41][42][43][44]\\n[45]\\n1c\\n[46]\\nLearn more\"),\n",
       " Document(metadata={'producer': 'Skia/PDF m143', 'creator': 'Mozilla/5.0 (X11; Linux x86_64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/143.0.0.0 Safari/537.36', 'creationdate': '2026-01-05T10:00:33+00:00', 'title': 'Diabetic Macular Edema - EyeWiki', 'moddate': '2026-01-05T10:00:33+00:00', 'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf', 'total_pages': 8, 'page': 4, 'page_label': '5'}, page_content='Figure 9: Focal and diffuse DME. A and B: Fundus photo showing circinate exudates,\\nwith adjacent microaneurysms and leakage seen on FA. C and D: Fundus photo with\\nsubtle signs of macular thickening, with diffuse, poorly demarcated capillary leakage\\nseen on FA. Published online with permission from the AAO.\\nFigure 10: Pseudophakic cystoid macular edema/Irvine-Gass Syndrome. A: Color\\nfundus photograph of an optic nerve head and macula 3 months after complex\\ncataract surgery. A small incidental grayish-yellow adult vitelliform dystrophy lesion\\nis present in the subfoveal region (circled). B: A mid-phase FA image demonstrates\\ncystic hyperfluorescence, with a classic petaloid pattern. As is typical in eyes with\\npseudophakic CME, there is mild hyperfluorescence of the nasal portion of the optic\\nnerve head. C: OCT shows cystic retinal thickening and a subfoveal vitelliform lesion.\\nD: Following 8 weeks of topical steroidal and nonsteroidal anti-inflammatory therapy,\\nOCT images indicate that the CME has fully resolved. Published online with\\npermission from the AAO.\\nDME often maintain good BCVA over the long term in clinical trial\\nsettings.  Outside of trial settings, the 5-year extension phase of\\nProtocol T showed that CST remained stable among eyes given anti-\\nVEGF injections; however, mean BCVA worsened between the 2- and\\n5-year time points.  On average, patients are given 6–8 injections in\\nthe first year, 2–4 injections in the second year, and 0–1 injections\\nbeginning the third year.\\nClinical Considerations for Treating DME With\\nAnti-VEGF Agents\\nObservation is recommended for eyes with ci-DME and VA of 20/25 or\\nbetter. This recommendation is based on the findings of DRCR Protocol\\nV, where patients were randomized to receive aflibercept injections,\\nmacular laser, or no treatment (observation). At the 2-year endpoint,\\nthe mean BCVA was 20/20, and the rates of ≥ 5-letter vision loss were\\nsimilar among all 3 groups (16%–19%). Given the risks of ocular\\ninfection and the higher costs associated with intravitreal injections,\\nobservation is a viable option in these patients if they can reliably\\nfollow up and receive appropriate therapy when there is clinical\\ndeterioration. In contrast, among eyes with ci-DME presenting with\\n20/50 vision or worse, Protocol T study results showed that aflibercept\\nwas superior to both ranibizumab and bevacizumab, with area-under-\\nthe-curve analyses showing better visual outcomes over 1 year.\\nHowever, the superiority of aflibercept over ranibizumab was not\\nmaintained at the 2-year follow-up visit.  Bevacizumab thinned the\\nretina the least; however, all 3 medications had similar visual outcomes\\namong eyes with baseline VA of 20/40 or better.\\nNot all treatments result in complete resolution of DME. In Protocol I,\\n40% of eyes still showed persistent DME (defined as never having a CST\\n<250 μ m through 6 months, as seen on time-domain OCT) after 2\\nyears.  Eyes given bevacizumab were more likely to have persistent\\nDME than eyes given aflibercept. The percentage of eyes with complete\\nresolution increased with each ranibizumab or aflibercept injection.\\nAt the 3-year follow-up visit, eyes with chronic persistent DME still had\\na significant (7-letter) mean improvement in VA over baseline, though\\nlower than the 13-letter mean improvement in eyes with complete\\nDME resolution.  Importantly, only 3.4% of eyes with chronic\\npersistent DME lost ≥ 2 lines of vision over 2 years regardless of the\\ntype of anti-VEGF treatment they received.  To summarize, in clinical\\ntrial settings, a substantial proportion of eyes with persistent DME still\\nhad ≥ 2 lines of improvement in vision over the long term, with very few\\neyes developing considerable vision loss.\\nFor eyes that do not respond optimally to one anti-VEGF agent,\\nswitching to another is a treatment option. The switch is typically from\\nbevacizumab to either ranibizumab or aflibercept, or from ranibizumab\\nto aflibercept. The rationale for switching is that aflibercept has 100\\ntimes more affinity for VEGF-A than bevacizumab or ranibizumab,\\nwhile concurrently binding placental growth factor and VEGF-B.\\nAflibercept also has a longer half-life and can negate more cytokines\\nthat promote DME development. Most studies looking at switching\\nwere retrospective and showed a significant reduction in CST; however,\\nvisual outcomes varied.\\nSome eyes may be delayed responders to anti-VEGF treatment, and\\nneed more than the initial 3–6 monthly injections to show significant\\nimprovement, though they eventually catch up with immediate\\nresponders.  It may be viable to continue treatment with the same\\nmedication if there is at least a trend of continued improvement, as\\nbevacizumab and ranibizumab are more cost-effective options. Caution\\nis warranted for switching, as any clinical improvement may be due to\\ncontinued treatment among delayed responders instead of due to a\\nshift in medications.\\nDRCR protocol AC was a randomized controlled trial evaluating the\\nrelative efficacy of administering aflibercept monotherapy vs\\nbevacizumab first with a switch to aflibercept (step therapy) in eyes\\nwith suboptimal response despite treatment. A total of 312 eyes with\\nmoderate vision loss from ci-DME were enrolled. Over a 2-year period,\\nthe mean improvement in VA was 14.0 letters in the bevacizumab-first\\ngroup and 15.0 letters in the aflibercept-monotherapy group (adjusted\\ndifference, 0.8 letters; 95% CI, −0.9 to 2.5; P = 0.37). At 2 years, mean\\nchanges in VA and retinal CST were similar in the two groups.\\nSteroids\\nIntravitreal steroids improve vision and decrease retinal thickness, as\\nthere is an inflammatory component to DME. Steroids have powerful\\nanti-edematous and anti-inflammatory effects, as they decrease several\\npro-inflammatory mediators (IL-6, IL-8, TNF- α , monocyte chemotactic\\nprotein-1, intercellular adhesion molecule-1, VEGF, etc).  However,\\nlong-term results have not shown maintenance of initial clinical\\nimprovement. In DRCR Protocol I, although the group given intravitreal\\ntriamcinolone had a similar response with ranibizumab in the first 6\\nmonths, vision declined due to cataracts. Even with cataract surgery,\\nthe final vision did not recover to the levels seen in the group given\\nranibizumab.  In Protocol U, eyes with persistent DME despite at\\nleast 6 ranibizumab injections were randomized to continue\\n[47]\\n[48]\\n[49]\\n[50]\\n[23]\\n[47]\\n[51]\\n[52]\\n[53]\\n[54]\\n[55][56][57][58][59][60][61][62][63][64][65][66][67][68]\\n[69][70]\\n[71]\\n[72]\\n[47]\\nLearn more'),\n",
       " Document(metadata={'producer': 'Skia/PDF m143', 'creator': 'Mozilla/5.0 (X11; Linux x86_64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/143.0.0.0 Safari/537.36', 'creationdate': '2026-01-05T10:00:33+00:00', 'title': 'Diabetic Macular Edema - EyeWiki', 'moddate': '2026-01-05T10:00:33+00:00', 'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf', 'total_pages': 8, 'page': 5, 'page_label': '6'}, page_content=\"Figure 11: Vitreomacular traction with secondary macular edema. A: Color fundus\\nphotograph of the right eye with pseudohole and epiretinal membrane with tractional\\nmacular edema. B: OCT image of same patient showing vitreomacular traction,\\nepiretinal membrane, and resulting macular edema. C: OCT of the same eye after\\nvitrectomy surgery with epiretinal membrane peeling. Published online with\\npermission from the AAO.\\nranibizumab monotherapy or shift to ranibizumab plus dexamethasone\\n(Ozurdex).  At 6 months, the average visual gain was similar in both\\ngroups, although CST improvement was greater in the combination\\ngroup. Phakic eyes given intravitreal steroids often develop cataracts\\nneeding surgery, and are at risk for intraocular pressure (IOP)\\nelevations leading to glaucoma.\\nLandmark Pharmacotherapy Studies\\nAnti-VEGF Agents\\nBevacizumab: Bevacizumab is a recombinant humanized\\nmonoclonal immunoglobulin G1 (IgG1) antibody that binds VEGF.\\nBevacizumab is given off-label for the treatment of DME, and\\nremains the most cost-effective treatment option among anti-\\nVEGF medications.  In the BOLT study, intravitreal bevacizumab\\n(1.25 mg), given at 6-week intervals, was reported to be more\\neffective than modified ETDRS focal/grid laser in terms of VA\\nimprovement at 12 months.  In DRCR Protocol T, a comparison\\nbetween bevacizumab, ranibizumab, and aflibercept, 1-year results\\nshowed that bevacizumab thinned the retina the least.  However,\\nall 3 medications had similar visual outcomes among eyes with\\nbaseline vision of 20/40 or better.  A study from The Pan-American Collaborative Study Group found improvements in BCVA and reduced macular\\nthickness (seen on OCT) at 24 months with intravitreal bevacizumab doses of 1.25 mg–2.5 mg.\\nRanibizumab: Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds and inhibits VEGF-A.  It is FDA approved for the\\ntreatment of DME.\\n1. DRCR Protocol I was the first definitive phase 3 study demonstrating the effectiveness of ranibizumab for DME treatment.  Four treatment arms\\nwere compared: ranibizumab with immediate grid/focal laser; ranibizumab with macular laser given only for at least 6 months of persistent DME;\\nintravitreal triamcinolone with immediate macular laser; and macular laser with sham injections. Results showed that ranibizumab, given in as-needed\\ntreatment protocol, had efficacy superior to that of laser therapy. At the 1-year end point, eyes treated with ranibizumab gained an average of 8–9\\nletters, vs an average gain of only 3 letters seen with laser therapy. Protocol I revolutionized the treatment protocol for DME when it was published in\\n2011. Before this study, macular laser was consideredfirst-line therapy for DME, a treatment protocol originating from the original ETDRS papers first\\npublished in 1985.\\n2. RISE and RIDE: The 2-year results for ranibizumab 0.3-mg monthly infections showed that 98% of patients maintained vision (lost <15 letters) and\\n34%–45% of patients gained at least 15 letters; the mean VA gain was 10.9–12.5 letters.  Only 45%–49% of patients needed macular laser,\\ncompared with 91%–94% in the control group. No additional benefit was seen with ranibizumab 0.5 mg monthly vs 0.3 mg monthly.\\nAflibercept: Aflibercept is a soluble decoy receptor that binds VEGF-A, VEGF-B, and placental growth factor with high affinity.  It is termed a decoy\\nreceptor or a “VEGF-trap,” as VEGF mistakenly binds with aflibercept instead of the body’s native receptors, reducing VEGF’s activity. It is FDA approved\\nfor the treatment of DME. In the Da Vinci study, patients with DME were randomly assigned to 1 of 5 treatment regimens: aflibercept 0.5 mg every 4\\nweeks (0.5q4), 2 mg every 4 weeks (2q4), 2 mg every 8 weeks after 3 initial monthly doses (2q8), or 2 mg as needed after 3 initial monthly doses (2prn); or\\nmacular laser photocoagulation.  Mean improvements in BCVA in the aflibercept groups at week 52 were 11.0, 13.1, 9.7, and 12.0 letters for the 0.5q4,\\n2q4, 2q8, and 2prn regimens, respectively, vs −1.3 letters for the laser group. The proportion of eyes with gains in BCVA of ≥ 15 ETDRS letters at week 52 in\\nthe aflibercept groups were 40.9%, 45.5%, 23.8%, and 42.2%, respectively, vs 11.4% for laser. Mean reductions in CST in the aflibercept groups at week 52\\nwere −165.4 μ m, −227.4 μ m, −187.8 μ m, and −180.3 μ m, respectively, vs −58.4 μ m for laser.  The PHOTON trial evaluated the use of high-dose\\naflibercept (8 mg) aflibercept every 12 weeks (8q12) or 16 weeks (8q16) vs conventional dosing of 2 mg every 8 weeks (2q8).  When comparing BCVA\\ngains and retinal thinning at 48 weeks, the 8-mg extended interval dosage was noninferior to conventional treatment. There was an increase of 9.2, 8.8,\\nand 7.9 letters and a mean CST reduction of −165 μ m, −172 μ m, and −148 μ m for the 2q8, 8q12, and 8q16 groups at 48 weeks, respectively. Patients in the\\nhigh-dose group with a 50- μ m increase in CST or a 10-letter loss from week 12 onwards had their dosing schedule shortened to either 12 or 8 weeks, but\\n93% of patients remained on dosing intervals of ≥ 12 weeks. There was no increase in hypertension in the high-dose group.\\nFaricimab: Faricimab is a novel combined-mechanism inhibitor that binds both angiopoietin-2 and VEGF-A with high specificity and affinity. The 1-year\\nresults from the phase 2 BOULEVARD study showed that in patients given faricimab 6 mg, there was a statistically significant VA gain of 3.6 letters over\\nthat seen with ranibizumab.  Moreover, improvement in diabetic retinopathy severity, as well as reduced CST, was seen with faricimab; it also had a\\nlonger time to re-treatment than ranibizumab. There were no unexpected safety concerns. The phase 3 YOSEMITE and RHINE noninferiority trials\\ncompared faricimab with aflibercept in patients with DME.  The noninferiority primary endpoint of BCVA was achieved with faricimab given every 8\\nweeks. More than 50% of patients had good results with an every-16-weeks dosing regimen, and more than 70% had good results with faricimab given\\nevery 12 weeks or longer. These results demonstrate the potential of faricimab to decrease patients' treatment burden by extending the intraocular\\ndurability of anti-VEGF treatment. The FDA approved the use of faricimab for DME as 4 monthly loading doses followed by injections every 1–4 months, or\\nas a loading dose of 6 monthly injections followed by injections every 2 months.\\nBrolucizumab: Brolucizumab is a single-chain antibody fragment with a high affinity for VEGF. Brolucizumab’s low molecular weight of 26 kDa allows for\\nmore of the drug to be delivered intraocularly per injection, with the potential for increased durability and effective tissue penetration in the eye. The\\nphase 3 KESTREL and KITE 52-week results found that brolucizumab 6 mg was noninferior to aflibercept in mean improvement of BCVA. More patients\\ntaking brolucizumab had CST <280 μ m without persistent macular fluid than patients taking aflibercept, and >50% of the brolucizumab-treated patients\\nwere maintained on q12w dosing after the loading dose was given.  However, reports of retinal vascular occlusion (RVO) and retinal vasculitis with\\nintraocular inflammation (IOI) have been reported.  Risk factors for developing these adverse reactions include a prior history of IOI or RVO in the 12\\nmonths before brolucizumab initiation, female sex, and same-day bilateral injections.  The FDA approved the use of brolucizumab for the treatment\\nof DME in June 2022, as a 6-mg injection given every 8–12 weeks after a loading dose of 5 injections given every 6 weeks.\\nAflibercept HD: FDA granted approval for the use of 8mg Aflibercept for treating DME in 2023. The results of PHOTON trial for CIDME after 2 years\\nrevealed mean improvement in BCVA with standard Eylea of 8.4 letters, 8.8 letters with the 12-week Eylea HD group, and 7.5 letters with the 16-week\\nEylea HD group.\\nSteroids\\nTriamcinolone: In Protocol B, triamcinolone (1 or 4 mg) preservative-free intravitreal injection was less effective and had more side effects than focal/grid\\nphotocoagulation at the 2-year follow-up visit.\\nDexamethasone: In the 3-year phase 3 MEAD study, dexamethasone 0.7 mg biodegradable implant improved vision by at least 15 letters in 22% of\\npatients.  At this dose, 41.5% of patients needed antiglaucoma medications, with 0.6% needing glaucoma surgery. Around 60% of eyes in the 0.7-mg\\n[73]\\n[74]\\n[75]\\n[23]\\n[53]\\n[76]\\n[77]\\n[47]\\n[78]\\n[79]\\n[79]\\n[80]\\n[79]\\n[81]\\n[82]\\n[83]\\n[84]\\n[85][86]\\n[87][88]\\n[89]\\n[90] Learn more\"),\n",
       " Document(metadata={'producer': 'Skia/PDF m143', 'creator': 'Mozilla/5.0 (X11; Linux x86_64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/143.0.0.0 Safari/537.36', 'creationdate': '2026-01-05T10:00:33+00:00', 'title': 'Diabetic Macular Edema - EyeWiki', 'moddate': '2026-01-05T10:00:33+00:00', 'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf', 'total_pages': 8, 'page': 6, 'page_label': '7'}, page_content='Figure 12: Focal laser for focal CSME. A: Planning of focal laser for focal CSME. Note\\nthe identified treatment areas, specifically the leaking microaneurysms that would be\\nhighlighted on FA. B: Focal laser-treated areas with parameters. Published online with\\npermission from the AAO.\\nFigure 13: Grid laser for diffuse CSME. A: Planning of grid laser for diffuse CSME.\\nNote the identified treatment area, specifically the outlined region with diffuse\\nedema that would be highlighted on FA. B: Grid laser–treated area with parameters.\\nPublished online with permission from the AAO.\\nimplant group had cataract surgery. The 0.7-mg implant has been approved by the FDA for DME, and is effective for approximately 3–6 months.\\nFluocinolone acetonide: The fluocinolone acetonide (Iluvien) 0.19-mg non-biodegradable implant is a sustained-release device that is effective for up to 3\\nyears when administered intraocularly. It is FDA approved to treat DME in patients who have been previously treated with a course of corticosteroids and\\ndid not have a clinically significant rise in IOP.  At the 0.2- μ g/day dosage, BCVA improvement of at least 15 letters was found in 28.7% of patients,\\nwith 38.4% needing anti-glaucoma medications and 4.8% needing glaucoma surgery. The latter figure was reduced to 0% among eyes that did not have a\\nhistory of IOP elevation with a prior steroid challenge. Complications associate with both the fluocinolone and the dexamethasone implants include\\ncataracts and implant migration.\\nLaser Photocoagulation\\nBefore anti-VEGF treatments for DME were approved, the standard\\ntreatment for CSME was macular laser photocoagulation. In “focal”\\nCSME, a focal laser pattern is used to treat leaking microaneurysms\\nidentified on the FA that contribute to the retinal edema (Figure 12). In\\n“diffuse” CSME, intraretinal leakage is noted on the FA from dilated\\nretinal capillary beds or intraretinal microvascular abnormalities\\nwithout isolated, discrete foci of leakage. A macular grid is done in\\ncases of diffuse macular edema (Figure 13). Laser photocoagulation has\\nbeen shown to decrease the risk of moderate visual loss (loss of ≥ 15\\nETDRS letters) from 24% to 12% after 3 years.  After the laser\\ntreatment is administered, the patient will come back in 3 months for a\\nfollow-up examination. If residual CSME is noted, OCT and FA may be\\nperformed to evaluate the benefit and location of repeat laser\\ntreatment. With the FDA approval of anti-VEGF agents for DME,\\nfocal/grid laser is only indicated in patients with non-ciDME. Macular\\nlaser remains a viable treatment option for patients with DME,\\nespecially in resource-limited countries with decreased access to anti-\\nVEGF agents.\\nCombined Therapy\\nIntravitreal ranibizumab with laser: In Protocol I, intravitreal\\nranibizumab with prompt (within 1 week) or deferred (after 24\\nweeks) laser was more effective than focal/grid laser alone for the\\ntreatment of ci-DME.  Ranibizumab is injected intravitreally at\\nbaseline, followed by monthly injections for 4 months followed by\\nthe continuation of injections at 16 weeks if the OCT central\\nsubfield thickness is ≥ 250 um with VA worse than 20/20.\\nSteroid with laser: Protocol B found that intravitreal triamcinolone\\n(IVT) 4 mg plus focal/grid laser (given within a week of injection)\\nwas more effective than laser alone at 4 months. However, long-\\nterm benefit with this combined therapy was not seen, with mean\\nBCVA better in the laser monotherapy group than the combined\\ntherapy group from the 16-month time point until the 2-year end point. Complications of steroid therapy included cataracts, ocular hypertension, and\\nglaucoma. The difference in BCVA could not be attributed fully to the development of cataracts. In Protocol I, 6-month VA improvement in eyes given IVT\\nwith prompt laser was comparable to that seen in eyes given ranibizumab, but vision declined afterward until the 2-year time point.  A subgroup\\nanalysis in pseudophakic eyes given IVT showed that visual improvement was significantly better than in phakic eyes, with 1- and 2-year results\\ncomparable to pseudophakic eyes given ranibizumab.\\nIntravitreal ranibizumab with peripheral targeted retinal photocoagulation (TRP): The DAVE study was a phase 1/2 clinical trial that compared\\nranibizumab plus peripheral TRP and ranibizumab monotherapy for reduce the number of required anti-VEGF injections.  Peripheral TRP was defined as\\nretinal photocoagulation administered outside the macula to areas of retinal capillary nonperfusion identified on widefield FA. The nonperfused hypoxic\\nretina is thought to upregulate hypoxia-inducible factors and cytokines, including VEGF and erythropoietin, with small studies suggesting that TRP can\\ndecrease the anti-VEGF treatment burden.  At the 3-year endpoint, there was no evidence that combined ranibizumab plus TRP reduced\\ntreatment burden or improved vision outcomes compared with ranibizumab alone.\\nSurgery\\nNo well-constructed studies show a definitive benefit of pars plana vitrectomy (PPV) for managing DME. The theoretical basis for PPV as a treatment option\\ncomes from reports that it increases vitreous oxygenation in ischemia, leading to decreased VEGF production, and from the observation that DME is less\\ncommon among eyes with PVD.  Vitreous viscosity also significantly decreases after PPV, which may bring about a greater diffusion of\\npro-inflammatory cytokines away from the macula.  Other studies suggest that PPV plus internal limiting membrane (ILM) peeling brings better resolution\\nof the tractional forces at the vitreoretinal interface known to worsen DME. This procedure also prevents proliferating astrocytes from using the ILM as a\\nscaffold, which may lead to ERM.  In a systematic review looking at PPV for DME, CST was significantly decreased by 102 μ m, and a nonsignificant VA\\nincrease of 2 letters was observed.  However, the anatomic benefit was not maintained by the 12-month time point. A similar meta-analysis looking at PPV\\nplus ILM peeling vs PPV alone showed no significant difference in postoperative vision and macular thickness between the treatments.  DRCR Protocol D, a\\nprospective study of eyes with DME and VMT, found that at 6 months after surgery, 43% of eyes had a reduction in CST to <250 μ m.  However, the median\\nVA did not change at 6 months. In 38% of eyes, the median visual acuity improved by ≥ 10 letters, and in 22% the median VA decreased by ≥ 10 letters. A post\\nhoc analysis of Protocol I showed that previously vitrectomized eyes with ci-DME given anti-VEGF treatments had no improved clinical outcomes compared\\nwith non-vitrectomized eyes.\\nTreatment Complications\\nThe complications listed below may arise from the various treatment modalities. The per-injection risk of developing complications is also listed below, when\\navailable.\\nIntravitreal Injections\\nEndophthalmitis (0.019%–0.05%)\\nIntraocular inflammation (0.09%–0.4%)\\nRetinal tears/detachment (0.01%–0.08%)\\nIncrease in IOP (for intravitreal steroids, IOP ≥ 21 mmHg in 45% at 1 month, 20% at 3 months, and 13% of eyes at 6 months post-injection.)\\nCataract (common after intravitreal steroid injections. By year 3, 83% of patients given IVT needed cataract surgery.)\\nSubconjunctival hemorrhage (10%)\\n[91][92]\\n[9]\\n[47]\\n[47][93]\\n[94]\\n[95][96][97][98][99]\\n[100][101][102][103][104][105]\\n[106]\\n[107]\\n[108]\\n[109]\\n[110]\\n[111]\\n[112][113][114]\\n[115]\\n[116][117][118]\\n[119]\\n[120]\\n[121] Learn more'),\n",
       " Document(metadata={'producer': 'Skia/PDF m143', 'creator': 'Mozilla/5.0 (X11; Linux x86_64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/143.0.0.0 Safari/537.36', 'creationdate': '2026-01-05T10:00:33+00:00', 'title': 'Diabetic Macular Edema - EyeWiki', 'moddate': '2026-01-05T10:00:33+00:00', 'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf', 'total_pages': 8, 'page': 7, 'page_label': '8'}, page_content='Vitreous hemorrhage\\nLaser Photocoagulation\\nSubretinal fibrosis\\nExtension of the laser scar into the fovea\\nChoroidal neovascular membrane\\nParacentral scotoma\\nDecreased visual acuity\\nPars Plana Vitrectomy\\nRetinal tears and retinal detachment\\nVitreous hemorrhage\\nElevated intraocular pressure\\nEndophthalmitis\\nCataract\\nPrognosis\\nClinical factors associated with better visual outcomes with anti-VEGF treatment include lower HbA1c, younger age, less severe diabetic retinopathy, absence\\nof ERM, quick and consistent CST decreases, and absence of prior panretinal photocoagulation.  In terms of anatomic outcomes, eyes with hard\\nexudates within the 6-mm foveal center had a larger CST decrease at the end of 1 year. The presence of exudates may be a marker of BRB abnormalities typical\\nof DME responsive to anti-VEGF therapy. Eyes that lack exudates may have other underlying mechanisms of retinal thickening, including cystoid degeneration,\\ntraction, or ischemia. In contrast, eyes with high baseline CST ( ≥ 570 μ m) had a significantly higher chance of developing persistent DME despite monthly\\nranibizumab therapy.  In terms of response to macular laser therapy, the ETDRS reported that worse clinical outcomes were associated with higher blood\\nlipid levels, presence of hard exudates, and diffuse edema.\\nMatsunaga et al. looked at eyes with DME treated with at least 1 dose of anti-VEGF agents that were then awere lost to follow-up (LTFU) for at least 6 months\\nbefore returning to the clinic.  Vison worsened significantly at the initial return visit, to ~20/69 from ~20/52; however, at the 3-, 6-, and 12-month follow-up\\nvisits and the final checkup, vision recovered with no significant differences from baseline. OCT CST also showed similar trends. Gao et al. found that 25% of\\npatients with NPDR and DME had no follow-up visits for at least 1 year after receiving 1 anti-VEGF injection.  Factors associated with being LTFU included\\nHispanic ethnicity (OR 1.7) and American Indian/Pacific Islander/multiple ethnicities (OR 2.6). Lower adjusted gross income and decreasing baseline vision\\nwere also factors significantly associated with LTFU.\\nSome studies have shown increased risks of end-stage renal disease in patients with concurrent DME. Assessment of renal function should be strongly\\nencouraged in patients with chronic DME.\\nFuture Directions\\nNumerous pharmacotherapy trials for DME treatment are underway. The development of a long-acting anti-VEGF agent that could remain effective in the\\nvitreous for multiple months or years would significantly decrease the treatment burden for patients needing monthly injections. Novel pharmacotherapies\\nbased on different mechanisms of action include anti-VEGF designed ankyrin repeat proteins, growth factor inhibitors, anti-inflammatory medications,\\nhormone modulators, acetylcholine receptor blockers, insulin-like growth factor 1 receptor blockers, and neuroprotective/antiapoptotic agents.  Port\\ndelivery systems that are FDA approved for wet AMD are in development to treat diabetic retinopathy and DME.  These experimental therapies have the\\npotential to significantly decrease the burden of treatment while restoring vision to patients with DME in the coming years ahead. An ophthalmic suspension,\\nOCS-01, a topical dexamethasone that is formulated with nanoparticle technology, in a completed Phase 2 trial has shown a higher reduction in CMT with\\nOCS-01 compared to control. Further phase 3 studies are pending yet.\\nArtificial intelligence (AI) plus tele-ophthalmology models are being used to develop screening tools for diabetic retinopathy and DME. These models can\\ndetect the retinal complications of diabetes remotely, and if this technology is placed in the offices of internists and endocrinologists, it may allow for early\\ndetection and timely intervention.\\nFurther reading\\n1. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54(1):1-32\\n2. Diabetic Retinopathy Clinical Research Network Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt\\nlaser for diabetic macular edema. Ophthalmology. 2010; 117(6):1064-1077.\\n3. Early Treatment Diabetic Retinopathy Study: Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1.\\nEarly Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103(12):1796-1806.\\n4. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic\\nmacular edema (BOLT study) 12 month data: report 2. Ophthalmology. 2010; 117(6):1078-1086.e2.\\n5. Schachat AP. A new approach to the management of diabetic macular edema. Ophthalmology. 2010;117(6):1059-1060.\\nReferences\\n1. Otani T, Kishi S, Maruyama Y. Patterns of diabetic macular edema with\\noptical coherence tomography. Am J Ophthalmol. 1999;127(6):688-693.\\n2. Yanoff M, Fine BS, Brucker AJ, et al. Pathology of human cystoid macular\\nedema. Surv Ophthalmol. 1984;28(suppl):505-511.\\n3. Xu H-Z, Le Y-Z. Significance of outer blood–retina barrier breakdown in\\ndiabetes and ischemia. Invest Ophthalmol Vis Sci. 2011;52(5):2160-2164.\\n4. Brownlee M. The pathobiology of diabetic complications: a unifying\\nmechanism. Diabetes. 2005;54(6):1615-1625.\\n5. Del Zoppo G. The neurovascular unit in the setting of stroke. J Intern Med.\\n2010;267(2):156-171.\\n6. Gao B-B, Clermont A, Rook S, et al. Extracellular carbonic anhydrase\\nmediates hemorrhagic retinal and cerebral vascular permeability through\\nprekallikrein activation. Nat Med. 2007;13(2):181-188.\\n7. Jeppesen P, Aalkjær C, Bek T. Bradykinin relaxation in small porcine\\nretinal arterioles. Invest Ophthalmol Vis Sci. 2002;43(6):1891-1896.\\n8. Parpura V, Basarsky TA, Liu F, et al. Glutamate-mediated astrocyte–\\nneuron signalling. Nature. 1994;369(6483):744-747.\\n9. Early Treatment Diabetic Retinopathy Study Research Group.\\nPhotocoagulation for diabetic macular edema. Arch Ophthalmol.\\n1985;103:1796-1806.\\n10. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of\\ndiabetic retinopathy XV: the long-term incidence of macular edema.\\nOphthalmology. 1995;102(1):7-16.\\n11. White NH, Sun W, Cleary PA, et al. Effect of prior intensive therapy in type\\n1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC:\\ncomparison of adults and adolescents. Diabetes. 2010;59(5):1244-1253.\\n12. Varma R, Bressler NM, Doan QV, et al. Prevalence of and risk factors for\\ndiabetic macular edema in the United States. JAMA Ophthalmology.\\n2014;132(11):1334-1340.\\n13. Wong TY, Klein R, Islam FA, et al. Diabetic retinopathy in a multi-ethnic\\ncohort in the United States. Am J Ophthalmol. 2006;141(3):446-455.e441.\\n14. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk\\nfactors of diabetic retinopathy. Diabetes Care. 2012;35(3):556-564.\\n[122][123]\\n[124]\\n[125]\\n[126]\\n[127]\\n[128]\\n[129]\\n[130][131]\\nLearn more')]"
      ]
     },
     "execution_count": 36,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "extract_pdfs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "1529b352",
   "metadata": {},
   "outputs": [],
   "source": [
    "#filtering out empty documents\n",
    "from typing import List\n",
    "from langchain.schema import Document\n",
    "def filter_minimal(docs: List[Document])-> List[Document]:\n",
    "    \"\"\"\n",
    "    Given a list of Documents objects, retuern a new list of Document objects\n",
    "    containing only {source} and {page_content} attributes.\n",
    "    \"\"\"\n",
    "    filtered_docs : List[Document] = []\n",
    "    for doc in docs:\n",
    "        src = doc.metadata.get(\"source\")\n",
    "        filtered_docs.append(\n",
    "            Document(\n",
    "                page_content=doc.page_content,\n",
    "                metadata={\"source\": src}\n",
    "            )\n",
    "        )\n",
    "    return filtered_docs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "2674b071",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Normal Retina — Comprehensive KB Entry\\n1 — Short Definition\\nA normal retina is a multilayered neural tissue lining the back of the eye, responsible for converting light\\ninto visual signals. On OCT imaging, the normal macula shows a clean foveal depression, well-defined\\nretinal layers, and absence of any fluid, cysts, or abnormal elevations.\\n2 — Basic Anatomy of the Retina (Layer by Layer)\\nFrom inner (vitreous side) to outer (RPE/choroid side), the key layers are:\\n- Internal Limiting Membrane (ILM)\\n- Nerve Fiber Layer (NFL)\\n- Ganglion Cell Layer (GCL)\\n- Inner Plexiform Layer (IPL)\\n- Inner Nuclear Layer (INL)\\n- Outer Plexiform Layer (OPL)\\n- Outer Nuclear Layer (ONL)\\n- External Limiting Membrane (ELM)\\n- Photoreceptor Inner Segments and Outer Segments\\n- Ellipsoid Zone (EZ)\\n- Retinal Pigment Epithelium (RPE)\\n- Bruch’s Membrane and Choroid beneath\\n3 — OCT Characteristics of a Healthy Macula\\n- **Foveal Depression:** Smooth, symmetric curvature with thinnest point at the fovea.\\n- **Layer Clarity:** All retinal layers appear sharply demarcated.\\n- **No Fluid:** No intraretinal cysts (IRF) and no subretinal fluid (SRF).\\n- **Intact Ellipsoid Zone:** Strong hyperreflective band indicating healthy photoreceptors.\\n- **Normal RPE Line:** Continuous, smooth hyperreflective line with no elevation.\\n- **Stable Thickness:** Normal macular thickness without thickening or thinning.\\n4 — What Is NOT Present in a Normal Retina (Important for Classification)\\n- No cystoid spaces.\\n- No drusen or sub-RPE deposits.\\n- No pigment epithelial detachment (PED).\\n- No choroidal neovascularization or subretinal hyperreflective material.\\n- No edema, exudates, or hemorrhage.\\n- No tractional changes or disruption of the photoreceptor bands.\\n5 — Physiological Variations (Still Considered Normal)'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- Mild inter-individual variation in foveal pit shape.\\n- Slight differences in reflectivity due to age.\\n- Occasional benign vitreomacular adhesion (VMA) without traction.\\n6 — Importance in Machine Learning / Classification\\nA “normal” OCT class acts as:\\n- The baseline template for retinal architecture.\\n- The reference to detect abnormalities such as fluid, drusen, or neovascular membranes.\\n- A stabilizing anchor in the model for contrast between pathological and healthy states.\\n7 — Clinical Significance of Normal Findings\\n- Normal OCT suggests no active retinal disease.\\n- Clear layers and intact EZ correspond to good visual potential.\\n- Important for ruling out diabetic macular edema, drusen, and CNV.\\n8 — Patient Education (Chatbot-Friendly Snippets)\\n- “A normal retina has smooth, well-organized layers with no swelling or abnormal fluid.”\\n- “Your OCT scan shows no signs of leakage, deposits, or damage.”\\n- “An intact photoreceptor layer means healthy visual function.”\\n9 — When Normal OCT Occurs Despite Symptoms\\nA patient may feel symptoms but still have a normal OCT due to:\\n- Dry eye symptoms (not retinal).\\n- Migraine aura.\\n- Functional visual disturbances.\\n- Early disease not yet visible structurally.\\n10 — Safety & Advice for Patients with Normal OCT\\n- If vision symptoms persist, a clinical exam may still be needed.\\n- Monitor for any new distortion or vision changes.\\n- Maintain regular eye health practices (good lighting, glucose control if diabetic, etc.).\\n11 — Decision Flow (for Chatbot Use)\\n- OCT shows no fluid + intact layers → classify as NORMAL.\\n- If symptoms but OCT normal → recommend clinical evaluation for non-retinal causes.\\n- If minimal benign variations → still NORMAL unless accompanied by structural abnormalities.\\n12 — Snippets for Embedding\\n- “Normal OCT: clear layers, no fluid, intact RPE and photoreceptors.”\\n- “Healthy macula shows a smooth foveal dip with no cysts or swelling.”'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- “No signs of drusen, edema, or abnormal vessels.”\\n13 — Disclaimer\\nThis information is for educational use only and should not replace clinical assessment by an eye care\\nprofessional.'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='Type 1 CNV. Type 1 neovascular lesion is located\\nbelow the RPE as seen in the B-scan frame. In the\\nOCT-A frame, a neovascular coralliform network is\\nobserved which emanates from the choroidal\\nvasculature and extends to the sub-RPE space.\\nType 2 CNV. In B-scan and OCT-A, a neovascular\\nlesion is identified that extends from the choroidal\\nvessels through the Bruch\\'s membrane and RPE\\nand grows into the subretinal space. The En Face\\nimage shows a change in color in macula secondary\\nto edema and serous detachment of the retina.\\nChoroidal Neovascularization: OCT Angiography Findings\\nAll content on Eyewiki is protected by copyright law and the Terms of Service. This content may not be reproduced, copied, or put into any artificial intelligence\\nprogram, including large language and generative AI models, without permission from the Academy.\\nDisease Entity\\nDisease\\nChoroidal neovascularization (CNV) is part of the spectrum of exudative age-related macular\\ndegeneration (AMD) that consists of an abnormal growth of vessels from the choroidal vasculature to\\nthe neurosensory retina through the Bruch\\'s membrane.  CNV can also develop in a number of other\\nconditions such as myopic degeneration, chronic central serous chorioretinopathy, macular\\ntelangiectasia type 2, various white dot syndromes and other uveitic processes, and some choroidal\\ntumors.  Leakage of retinal edema and hemorrhage from CNV threatens visual acuity.\\nEtiology\\nEtiology of CNV is multifactorial. Alterations in Bruch\\'s membrane, migration of macrophages and\\nproduction of vascular endothelium growth factor (VEGF), play an important role in the development of\\nthis disease.\\nRisk Factors\\nThe incidence and progression of AMD are related to age and genetic factors.  With aging, the\\nlysosomal activity for the degradation of external segments of photoreceptors decreases. This leads to\\nsubsequent accumulation of lipofuscin, which affects the normal function of the RPE. Another important\\nrisk factor for the development of CNV is the presence of large, confluent soft drusen.\\nOxidative stress may play an important role in AMD.  Several modifiable risk factors have been\\nidentified, including quitting smoking, dietary intake of omega-3 fatty acids, consuming vegetables and\\nfruit with antioxidants including lutein and zeaxanthin, exercise, wearing sunglasses, and maintaining a\\nhealthy weight.\\nPathophysiology\\nAlterations in the normal transport of metabolites, ions and water through Bruch\\'s membrane in AMD,\\nalter the nutrition and stability of retinal pigment epithelium (RPE) from choriocapillaris and the\\ntransport of waste out from the neurosensory retina. Hypoxia leads to VEGF being released by the RPE,\\nwhich initiates a cascade of angiogenic responses at the level of the choroidal endothelium. Bruch´s\\nmembrane damage is required to allow the passage of abnormal neovascular vessels from the choroidal\\nvasculature through the breaks in Bruch’s membrane to the retina. This impairment is part of the\\npathological course of AMD.\\nClassification\\nHistologically, neovascular membranes are classified into:\\nType 1 (\"occult\"), when the neovascular membrane is located below the RPE. Type 1 CNV\\ndemonstrates occult leakage on fluorescein angiography. Polypoidal choroidal vasculoplathy (PCV) is\\na subtype of Type 1 CNV that is characterized by the presence of polyp-like aneurysmal dilations of\\nthe branching vascular network.\\nType 2 (\"classic\"), passes through the RPE and is located above the RPE in the subretinal space. This\\nis related to the angiographic classification of a classic CNV.\\nArticle initiated by: Andrea Tamine Hoyos Dumar, MD, Juan.David.Arias\\nAll contributors: Leo A. Kim, MD, PhD,\\xa0Sun Young (Sunny) Lee, MD, PhD,\\xa0Koushik Tripathy, MD (AIIMS),\\xa0Andrea Tamine Hoyos Dumar,\\nMD,\\xa0Diana V. Do, MD,\\xa0Talisa de Carlo, MD,\\xa0Neelakshi Bhagat, MD, FACS,\\xa0Jennifer I Lim MD,\\xa0Aidan Lee, MD\\nAssigned editor: Sun Young (Sunny) Lee, MD, PhD\\nReview: Assigned status Up to Date\\n\\xa0by Sun Young (Sunny) Lee, MD, PhD on September 18, 2025.\\nChoroidal Neovascularization\\nDiseasesDB 32400\\nICD-10 H35.3\\nMeSH D020256\\n[1]\\n[2][3]\\n[4][5][6][7]\\n[8]\\n[9]\\n[10]\\n[11]\\n[12][13]\\nLearn more Accept'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content=\"Type 3 CNV. \\xa0An intraretinal neovascular lesion is\\nobserved. The color photo identifies typical\\npunctate hemorrhages. The OCT B-scan shows\\nretinal edema without disruption of Bruch's\\nmembrane or RPE. OCT-A depicts an anastomosis\\noriginating in the neurosensory retina.\\nType 3 is defined as Retinal Angiomatous Proliferation (RAP), which corresponds to neovascularization that develops within the neurosensory retina an\\nprogresses posteriorly into the subretinal space.\\nDiagnosis\\nClinical findings\\nIn the presence of CNV, the patient experiences an acute decrease in visual acuity, relative scotoma,\\nand/or metamorphopsia. The retinal examination shows a grayish macular lesion associated with\\nsubretinal fluid, macular edema, exudation, and/or hemorrhages.\\nDiagnostic Procedures\\nOCT Angiography\\nEn face OCT angiography (OCTA) is a new technology that has the great ability to show the retinal and\\nchoroidal microcirculation in detail without invasive means.  Instead of intraocular contrast, it uses\\nmotion contrast by comparing the decorrelation signal between repeated B-scans obtained at a given\\nretinal cross-section to detect blood flow. It utilizes the principle that theoretically only the circulating\\nRBCs within the retinal vasculature would be moving between the B-scans. Each en face OCT angiogram\\nis cross-registered with the corresponding OCT B-scans, an OCT thickness map, and a structural en face\\nOCT, which allows for concurrent visualization of structure and blood flow. OCTA is available on both\\nspectral domain and swept source OCT devices.\\nThe conventional CNV evaluation often consists of multimodal imaging with fluorescein angiography\\n(FA) combined with indocyanine green angiography (ICGA) and OCT. These well-established modalities\\ncan guide effective CNV management but have their limitations, especially when characterizing vascular\\nstructures at different depths. For example, FA only allows for evaluation of the superficial capillary\\nplexus within the retina. OCTA, on the other hand, allows for noninvasive three-dimensional analysis of\\nthe retinal and choroidal vasculature and can be segmented to view each of the vascular plexuses\\nindividually.\\nThis ability to visualize vascular structures at different depths/layers of the retina makes OCTA a tool well suited to evaluate CNV. For the purpose of\\nvisualizing changes in eyes with CNV or suspected CNV, a segmentation of the outer retina (extending from the outer plexiform layer to Bruch’s membrane)\\nand a segmentation of the choriocapillaris (approximately 20um thick region just below the RPE) are most useful. CNV can be seen as a seafan or coraliform\\nneovascular complex within the outer retina, which is ordinarily devoid of blood flow in normal eyes. Type 1 CNV is observed in OCTA as a neovascular complex\\nbetween the RPE and Bruch's membrane, originating in the choroid.  The type 2 CNV is visualized as a neovascular network that grows from the choroid\\nvasculature and traverses the RPE-Bruch's membrane complex into the subretinal space.  Type 3 CNV is clinically seen as tiny intra- and subretinal\\nhemorrhages that correlate on OCTA as an intraretinal anastomosis originating in the deep capillary plexus of the retina.\\nThe PCV subtype of CNV can also be seen as a branching neovascular network within the outer retina but with concurrent aneurysmal dilations. After repeat\\npharmacologic intervention the large branches of the CNV become pruned and the smaller capillaries and any polyps may no longer be visualized (whether due\\nto slow or absent flow, or complete regression). The choriocapillaris layer may demonstrate decreased flow or flow voids adjacent to the CNV complex.\\nAdditionally, choriocapillaris hypoperfusion may be seen underlying any areas of RPE atrophy.\\nThe use of OCTA in CNV imagining is not without challenges.  OCTA is susceptible to several imaging artifacts. Some of these, such as motion or signal\\nattenuation, may be mitigated through patient instruction and technician training. Projection artifacts arise when blood flow of su perficial layers of the retina is\\nprojected onto deeper structures below, which can cause false flow signal in deeper anatomical layers. CNV assessment suffers since proper visualization\\nrequires high-quality images of the outer retina, where projection artifacts are especially prominent due to proximity to the highly reflective RPE layer.\\nFurthermore, the eruption of CNV can lead to segmentation artifact via the distortion of the retinal layers. This may require manual adjustment of the\\nsegmentation slabs, which may be time consuming and lower the repeatability of the test. Tools for automatic segmentation through deep learning and\\nmodality of OCTA such as projection-resolved OCTA (PR-OCTA) algorithm have been reported to improve the quality and repeatability of OCTA studies.\\nManagement\\nTreatment\\nTaking into account the numerous recent studies on the treatment of CNV in AMD, it has been shown that antiangiogenic therapy shows the best result both\\nhistologically with the regression of the neovascular lesion and functionally with improvement of the visual acuity. Although the treatment is the same for all\\ntypes of CNV, it is important to differentiate them, since they do not all respond identically and some of them have a higher rate of recurrence.\\nReferences\\n1. Turbert, D. (2020, March 18). What are Choroidal Neovascular\\nmembranes? Reviewed by Ninel Z Gregori, MD. American Academy of\\nOphthalmology. https://www.aao.org/eye-health/diseases/choroidal-\\nneovascular-membranes.\\n2. Cheung C. et al. “Myopic Choroidal Neovascularization: Review,\\nGuidance, and Consensus Statement on Management”. Ophthalmology.\\n2017 Nov;124(11):1690-1711. doi: 10.1016/j.ophtha.2017.04.028\\n3. Agarwal A. et al. “An update on inflammatory choroidal\\nneovascularization: epidemiology, multimodal imaging, and management”.\\nJ Ophthalmic Inflamm Infect. Vol: 8(13). doi: 10.1186/s12348-018-0155-\\n6\\n4. Kennedy CJ, Rakoczy PE, Constable IJ. Lipofuscin of the retinal pigment\\nepithelium: a review. Eye 1995;9:763–71.\\n5. Rakoczy PE, Zhang D, Robertson T, et al. Progressive age-related changes\\nsimilar to age-related macular degeneration in a transgenic mouse model.\\nAm J Pathol 2002;161:1515–24\\n6. Hageman GS, Mullins RF. Molecular composition of drusen as related to\\nsubstructural phenotype. Mol Vis 1999;5:28.\\n7. Spillsbury K. et al. “Overexpression of Vascular Endothelial Growth Factor\\n(VEGF) in the Retinal Pigment Epithelium Leads to the Development of\\nChoroidal Neovascularization”. Am J Pathol. 2000 Jul; 157(1): 135–144.\\ndoi: 10.1016/S0002-9440(10)64525-7\\n8. Klein R, Klein BE, Jensen SC, et al. The five-year incidence and progression\\nof age-related maculopathy: the Beaver Dam Eye Study [see comments].\\nOphthalmology 1997;104:7–21.\\n9. Mullins RF, Russell SR, Anderson DH, et al. Drusen associated with aging\\nand age-related macular degeneration contain proteins common to\\nextracel- lular deposits associated with atherosclerosis, elastosis,\\namyloidosis, and dense deposit disease. FASEB J 2000;14:835–46.\\n10. Sarks JP, Sarks SH, Killingsworth MC. Evolution of soft drusen in age-\\nrelated macular degeneration. Eye 1994;8:269–83.\\n11. The Age-Related Eye Disease Study 2 (AREDS2) Research Group*. Lutein\\n+ Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular\\nDegeneration: The Age-Related Eye Disease Study 2 (AREDS2)\\nRandomized Clinical Trial. JAMA. 2013;309(19):2005–2015.\\ndoi:10.1001/jama.2013.4997\\n12. Abdelsalam A, Del Priore L, Zarbin MA. Drusen in age-related macular\\ndegeneration: pathogenesis, natural course, and laser photocoagulation-\\ninduced regression. Surv Ophthalmol 1999;44:1–29.\\n13. Tombran-Tink J, Shivaram SM, Chader GJ, et al. Expression, secretion, and\\nage-related downregulation of pigment epithelium-derived factor, a\\nserpin with neurotrophic activity. J Neurosci 1995;15:4992–5003.\\n14. de Carlo TE, Bonini Filho MA, Chin AT, et al. Spectral-domain optical\\ncoherence tomography angiography of choroidal neovascularization.\\nOphthalmology. 2015;122(6):1228-38.\\n[14]\\n[15]\\n[16]\\n[17]\\n[18]\\n[19]\\n[20]\\n[21][22]\\nLearn more\"),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='What Are Retinal Drusen?\\nWritten by WebMD Editorial Contributors Medically Reviewed by Timothy G. Murray,\\xa0MBA,\\xa0MD,\\xa0FACS on August 01, 2025\\n4 min read\\nRetinal drusen are yellow/white-colored spots seen under the retina of your eye that are made up of proteins and a type of fat called lipids.\\nThe retina is the layer of cells lining the inside surface of the back of your eye that sends signals to your brain and enables you to see. \\nSmall drusen may not cause problems for some people, but larger drusen can increase your risk of a medical condition called age-related\\nmacular degeneration (AMD). Drusen can be a sign that you already have age-related macular degeneration.\\xa0\\nIn age-related macular degeneration, the cells of the macula, a part of the retina, start to change because of aging. Dry macular\\ndegeneration comes first. Wet macular degeneration is an advanced form of the condition. A second type of advanced maculardegeneration is called geographic atrophy (GA).\\nTypes of Retinal Drusen\\n There are two types of retinal drusen: hard and soft.\\n Hard drusen are small, dotted, yellow-colored, and abnormal tissue growths. When the drusen is hard, there is a lower risk of losingyour vision in the future.\\nSoft drusen look large and raised, are pale yellow or grayish-white in color, and have a dome shape. There is a higher risk of losing\\nvision in the future if you have many large or medium-sized soft drusen.\\xa0\\nCauses of Retinal Drusen\\n Retinal drusen can occur as a result of aging. It is common to see drusen in people over 60 years of age. 90% of drusen are caused by dry\\nmacular degeneration. The remaining 10% of drusen are caused by wet macular degeneration. \\nIn dry macular degeneration, your central vision becomes blurry or lessens because of the thinning of the part of your retina called the\\nmacula. Dry macular degeneration can cause you to lose vision slowly over time.  \\nIn wet macular degeneration, your vision gets blurred or you may see a blind spot in your field of vision. This condition is caused by\\nabnormal blood vessels that break, bleed, or leak fluid into the macula and may cause sudden and severe loss of vision.\\nSymptoms\\n Sometimes you may have retinal drusen and not experience any symptoms. You may not find out you have them until your doctor seesthem during a routine eye exam. Having a few small drusen doesn’t mean that you have eye disease.\\xa0 \\nWhen you have a lot of larger drusen, it can mean that you have age-related macular degeneration. You could then see the symptoms linked\\nto age-related macular degeneration:\\n Dim or cloudy vision\\n Difficulty seeing when the light changes from bright to dim light\\nA blank or blurry spot in your central vision\\nRisk Factors\\n Retinal drusen can be commonly seen in people over 60 years of age. But other factors can increase your risk of getting this condition:\\n Family history of retinal drusen\\n Smoking tobacco\\nHigh blood pressure\\n Excessive body fat (obesity)\\n High blood cholesterol \\n People of Caucasian descent have a higher risk of both retinal drusen and age-related macular degeneration.\\nWhen to See a Doctor\\n You should see a doctor or eye specialist if you experience any difficulty seeing. Get urgent medical attention if you have severe or serious\\nloss of vision.\\nTreatment\\n Retinal drusen are common in people over 60 years of age. \\xa0Small drusen may not cause any difficulties at all for some people.\\n SubscribeEye Health Guide \\ue902'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='Vitamins: You may lose vision if your age-related macular degeneration reaches an advanced stage. If you have a lot of large and medium-\\nsized drusen, your doctor may ask you to take AREDS2 formula vitamins, which can slow down the growth of your condition to an advanced\\nstage by about 25%. \\nAREDS2 formula vitamins are a combination recommended by the Age-Related Eye Disease Study (AREDS), an NIH clinical trial. According to\\nthe results of the study, when these vitamins are taken, they reduce the risk of getting the disease by as much as 19 % and/or reduce the risk\\nof vision loss by 25%. The formula has Vitamin C, Vitamin E, the antioxidants lutein and zeaxanthin, and minerals zinc and copper in specific\\namounts. Lifestyle and dietary changes: Your doctor may ask you to make lifestyle changes, such as stopping smoking. They may recommend that\\nyour diet has more vegetables, fruits, and fatty fish like salmon and mackerel. You may be asked to eat less red meat in order to lower your\\nblood cholesterol.\\xa0\\nEarly detection:Your doctor may ask you to monitor your vision at home if you have drusen, using a test called the Amsler Grid. If you candetect wet macular degeneration early on, your doctor may be able to help you make your vision stable or improve it with injected\\nmedication. With early detection, you can slow down complications and minimize loss of vision.\\xa0\\nSources Update History\\nPrint\\nView privacy policy, copyright and trust info\\nSave\\nNEXT ARTICLE\\nEyelid Bump \\ue909'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Figure 1: Diabetic macular edema. A: Schematic diagram of DME.\\nMicroaneurysms, or damaged capillaries, resulting from the\\nbreakdown of the blood–retina barrier leak fluid to the extracellular\\nspace, resulting in a swollen retina. Resorption of DME is dependent\\non the adjacent capillaries and retinal pigment epithelium.\\nResorption of fluid may leave behind lipoprotein residues, seen here\\nas exudates. B: OCT image of DME. Published online with\\npermission from the AAO.\\nDiabetic Macular Edema\\nAll content on Eyewiki is protected by copyright law and the Terms of Service. This content may not be reproduced, copied, or put into any artificial intelligence\\nprogram, including large language and generative AI models, without permission from the Academy.\\nDisease Definition\\nDiabetic macular edema (DME) is the accumulation of excess fluid in the extracellular space within the retina in the\\nmacular area, typically in the inner nuclear layer, outer plexiform, Henle’s fiber layer, and subretinal space.\\nPathophysiology\\nChronic hyperglycemia-related accumulation of advanced glycated end products\\ndisrupts the blood–retina barrier (BRB), leading to endothelial cell junction breakdown\\nand pericyte loss. The inner BRB is composed of endothelial cells in the retinal\\ncapillaries, while the outer BRB is composed of retinal pigment epithelium cells. When\\nthe BRB is altered, interstitial fluid is accumulated within and underneath the retina\\nthrough leakage of molecules dependent on intact cell-to-cell junctions (Figure 1).\\nEvidence also shows that DME has an inflammatory component, with several\\nchemokines and cytokines involved in its development. These include vascular\\nendothelial growth factor (VEGF), interleukins (ILs), matrix metalloproteinases, and\\ntumor necrosis factor (TNF). Upregulation of multiple pathways leads to increased\\ninflammation, oxidative stress, and vascular dysfunction.  Significant changes are seen\\nin the neurovascular unit, altering the homeostasis between astrocytes, ganglion cells,\\nMüller cells, retinal vascular endothelial cells, and amacrine cells.  Retinal vascular\\npermeability changes also involve the kallikrein-kinin system, which induces\\nvasorelaxation via bradykinin and nitric oxide.\\nNatural History\\nDME can develop at any stage of diabetic retinopathy (DR), from mild nonproliferative\\ndiabetic retinopathy (NPDR) to proliferative diabetic retinopathy, but is more frequent\\nas the severity of DR increases. DME occurring near to or at the fovea is more likely to\\nresult in blurred vision and metamorphopsia. When the DME involves or threatens the\\nfovea, the risk of moderate visual loss (defined as a ≥ 3-line decrease in visual acuity (VA),\\nequivalent to a doubling of the visual angle) increases; in the Early Treatment of Diabetic\\nRetinopathy Study (ETDRS) study, visual loss decreased by 24% over 3 years without\\ntreatment.  The disease course is variable, with some eyes having chronic persistent\\nDME spanning several years, while other eyes have rapid spontaneous resolution,\\nalthough the risk of recurrence is always present.\\nPrevalence\\nThe Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) found that the\\n25-year incidence of DME in people with type 1 diabetes mellitus (T1DM) was 29%.\\nThe Diabetes Control and Complications Trial (DCCT) reported that 27% of people with\\nT1DM had DME within 9 years of diabetes onset.  The WESDR also found that 25.4%\\nof people with type 2 DM who used insulin and 13.9% of those who did not use insulin\\nhad DME.  Yau et al. estimated the global prevalence of DME to be 6.8% among\\npeople with DM. In the United States, prevalence rates are between 2.7% to 3.8%, with\\nnon-Hispanic White people less likely to have DME than non-Hispanic Black\\npeople.\\nRisk Factors\\nRisk factors for DME and DR are similar. These include a longer DM duration, poor control of DM with elevated glycolated hemoglobin A1c (HbA ) levels,\\nhypertension, and hyperlipidemia. Other secondary risk factors include impaired renal function and the use of thiazolidinediones.\\nPrevention\\nPrimary prevention of DME involves intensive control of DM, blood glucose and lipid levels, hypertension, and other systemic risk factors. The Diabetic\\nRetinopathy Clinical Research (DRCR) Protocol W investigated whether aflibercept injections in eyes with baseline moderate-to-severe NPDR could prevent\\nthe eventual development of center-involved DME (ci-DME) with vision loss.  Vision loss was defined as a ≥ 10-letter decrease in VA at 1 visit or a 5-to 9-\\nletter decrease at 2 consecutive visits, with the decrease in vision attributed to the ci-DME. The 2-year cumulative probability of developing ci-DME with\\nvision loss was 4.1% in patients given aflibercept vs 14.8% of patients given sham injections. However, there was no significant difference in mean VA between\\nArticle initiated by: Cris Martin P. Jacoba, MD, Margalit G. Mitzner, Neelakshi Bhagat, MD, FACS, Marco Attilio Zarbin, MD, PhD, FACS, Jerry\\nCavallerano, OD, PhD, Paolo A. Silva, MD, Lloyd P. Aiello, MD, PhD, Mohamed A. Elmasry, MD, PhD\\nAll contributors: Theodore Leng, MD, MS,\\xa0Koushik Tripathy, MD (AIIMS),\\xa0Neelakshi Bhagat, MD, FACS,\\xa0Jennifer I Lim MD,\\xa0Cris Martin P.\\nJacoba, MD,\\xa0David Kitchen,\\xa0Galin J. Spicer, MD MBA\\nAssigned editor: Neelakshi Bhagat, MD, FACS\\nReview: Assigned status Update Pending\\n\\xa0by Neelakshi Bhagat, MD, FACS on July 6, 2025.\\n[1][2]\\n[3]\\n[4]\\n[5]\\n[6][7][8]\\n[9]\\n[10]\\n[11]\\n[10]\\n[12][13][14]\\n1c[15][16][17]\\n[18]\\nLearn more Accept'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content=\"Figure 2: Circinate exudates. A: Blue arrows - Circinate exudates,\\ndefined as exudates arranged in a circular appearance. B: OCT b-\\nscan across the fovea, confirming the presence of DME associated\\nwith an elevated foveal contour. The patient’s best-corrected vision\\nwas 20/32.\\nFigure 3: Dense macular exudates involving the fovea. A: Blue\\narrow– Dense foveal exudates. B: Red arrow– OCT b-scan across the\\nfovea, confirming the presence of DME and the dense foveal\\nexudate. The patient’s best-corrected vision was 20/200.\\nFigure 4: Basic structural changes in DME seen on OCT. Yellow\\nbracket– Generalized retinal swelling. Blue arrow– Cystoid macular\\nedema. Red arrow– Subretinal fluid.\\nthe treatment groups. From baseline to the 2-year checkup, eyes treated with sham\\ninjections had a mean (SD) change of −2.0 (6.1) letters, while eyes treated with\\naflibercept had a mean −0.9 (5.8) letter change (adjusted mean difference 0.5 letters;\\n97.5% CI, −1.0 to 1.9 letters; P = 0.47]. However, at present the use of anti-VEGF\\ninjections for the prevention of ci-DME is not the standard of care.\\nDiagnosis\\nHistory\\nDME is suspected in patients with any level of DR who present with blurred vision or\\nmetamorphopsias. A detailed history including the approximate date of onset of\\ndiabetes, the use of insulin versus oral antihyperglycemic agents, and the quality of\\nmetabolic control (e.g., HbA  level) should be elicited. Any associated medical problems\\nsuch as hypertension, hypercholesterolemia, renal disease, and thyroid disease should\\nbe identified, along with a thorough review of medications. It should be noted that mild\\nto extensive DME may be present without symptoms evident to the patient.\\nPhysical Examination\\nPatients suspected of having DME may undergo a detailed biomicroscopic examination\\nwith a slit lamp and indirect ophthalmoscope. Historically, DME classifications were\\nbased on the 1980s-era ETDRS definitions of clinically significant macular edema\\n(CSME). The specific criteria for diagnosing CSME were:\\n1. Retinal thickening at or within 500 μ m of the center of the fovea\\n2. Hard exudates at or within 500 μ m of the center of the fovea if adjacent to an area\\nof retinal thickening\\n3. Retinal thickening of at least 1 disc area, any portion of which is within 1500 μ m\\n(approximately 1 disc diameter) from the center of the fovea\\nThus, CSME, as defined by the ETDRS, is a clinical diagnosis made by slit-lamp\\nexamination using a contact lens. While clinical examinations remain essential for the\\nfull evaluation of DME, optical coherence tomography (OCT) is now routinely used to\\ncomplement physical examination in the diagnosis of DME. The management of DME is\\ncurrently based on the central subfoveal thickness (CST) on the macular OCT.\\nSigns\\nMacular thickening with or without hard exudates may be seen on stereo\\nbiomicroscopy. However, some eyes may present without apparent signs of retinal\\nthickening on clinical examination, despite significant OCT-observed DME. Thickening\\ncan occur in various patterns, including focal, multifocal, and diffuse areas of retina\\nthickening. Despite these terms being frequently used, there are no well-established\\nstandard, consistently used definitions.  In the ETDRS guidelines, focal leakage\\nresulting from microaneurysms may be treated with a fluorescein angiography–guided\\nfocal laser, while diffuse capillary leakage is from a more widespread breakdown of the\\nBRB and may be treated with grid laser.  Hard exudates in various patterns may also\\nbe seen, including circinate rings and focal aggregations of exudates (Figures 2–3). Hard\\nexudates consist of lipoprotein residues of serous leakage from damaged vessels, and\\ncan serve as biomarkers for DME.\\nSymptoms\\nDME may present with decreased visual acuity (VA), metamorphopsia, changes in color\\nperception, and difficulty reading, although it may also present asymptomatically.\\nVision and DME\\nStudies show a poor to modest correlation between VA and CST on OCT, within the\\nrange of 0.3–0.5.  Over 2 years, only around 12%–14% of the change in VA can be\\nattributed to the change in thickness. In a study by the DRCR Network, the slope of the\\nbest fit line shows an approximately 4.4 letter improvement (95% CI, 3.5–5.3) for every\\n100-micron decrease in CST at baseline.  Interestingly, on follow-up after treatment\\nwith macular laser photocoagulation, there were some eyes with paradoxical\\nimprovement in VA with increased CST (7-17% at different time points) and paradoxical\\nworsening of VA with decreased CST (18-26% at different time points). These findings\\nhighlight how OCT measurements cannot be used as a perfect surrogate for visual\\nacuity; however, in clinical and research settings, the technology remains an important\\ntool. The DRCR Network has recommended a 10% change in CST to indicate a real\\nchange that can be considered in clinical decision-making.\\nDiagnostic Procedures\\nOptical Coherence Tomography (OCT)\\nWithin recent years, OCT has quickly become an important ancillary procedure in\\ndiagnosing and treating DME. Three basic structural changes can be seen on OCT:\\nretinal swelling, cystoid macular edema, and subretinal fluid (Figure 4). Macular scans\\ncan quickly and accurately identify even subtle areas of thickening, along with\\nquantitative metrics for different areas. Changes in the anatomic distribution of DME\\ncan be monitored over time, especially the fluid’s relationship to the fovea. This\\ninformation has clinical and research implications for the evaluation and management of\\nDME. The International Council of Ophthalmology's guidelines for diabetic eye care,\\npublished in 2018, adopted the clinical entities of center-involved DME (ci-DME) and\\nnon-center–involved DME (non-ciDME) for the evaluation of macular fluid (Figure 5), as\\nfollows:\\n1. Center-involved DME: Retinal thickening in the macula that involves the central\\nsubfield zone (1 mm in diameter)\\n2. Non-center–involved DME: Retinal thickening in the macula that does not involve\\nthe central subfield zone (1 mm in diameter)\\n[18]\\n1c\\n[19]\\n[20]\\n[21][22]\\n[22]\\nLearn more\"),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content=\"Figure 5: Montage of center-involved vs non-center–involved DME. Top Row A: Non-center–involved DME. Retinal\\nthickening does not involve the central 1-mm subfield zone (innermost circle) per the en-face OCT heatmap, as seen on\\nb-scan. Bottom Row B: Center-involved DME. Retinal thickening involves the central 1-mm subfield zone (innermost\\ncircle) per the en-face OCT heatmap and b-scan. Published online with permission from the AAO.\\nFigure 6: Disorganization of the retinal inner layers. OCT images showing combinations of\\npresence or absence of DRIL and DME. The central 1-mm area is enclosed in the box. Upper\\nimages show segmentation of inner retinal layers, with the white lines demarcating the\\nboundaries between IPL-INL and the INL-OPL. Image credit to: Barham et al., Association of\\nMacular Nonperfusion, Leakage, and DRIL (ARVO poster, 2016)\\nAside from the location of the\\nswelling, the DRCR Network has given\\nrecommendations on CST treatment\\nthresholds based on sex-matched\\nstandards.  The thresholds were\\ndifferent for each OCT machine; since\\nthickness measurements cannot be\\ncompared between different devices,\\neach device has its own normative\\ndatabase and algorithms. In DRCR\\nProtocol T, treatment eligibility\\nthresholds per machine were:\\n1. Heidelberg Spectralis: 320 μ m for\\nmen and 305 μ m for women\\n2. Zeiss Cirrus OCT: 305 μ m for men\\nand 290 μ m for women\\n3. Zeiss Stratus OCT:250 μ m for\\nboth men and women\\nMoreover, OCT is a more sensitive\\nmethod for objective evaluation of\\nvitreomacular interface abnormalities\\n(VMIA), which include vitreomacular\\nadhesion (VMA), vitreomacular\\ntraction (VMT), and epiretinal\\nmembrane (ERM). Identifying VMIA is\\ncrucial when diagnosing the etiology\\nof macular edema, whether primarily\\nfrom DME, from secondary causes of\\nVMIA, or combined mechanism\\nmacular edema.\\nOCT Biomarkers for DME\\nDME's different OCT features have been associated with\\ndisparate prognostic outcomes and treatment responses.\\n[23]\\nLearn more\"),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content=\"Figure 7: External limiting membrane and ellipsoid zone disruption. A: DME with large cystic\\nspaces (blue arrow) and exudates (green arrows). Despite anti-VEGF treatment, DME\\npersisted. The EZ and ELM were still intact, with BCVA of 20/32. B: Five years after photo A,\\nextensive ELM and EZ disruption (red bracket) developed which involved the fovea. A few\\nchronic parafoveal cysts can still be seen. BCVA dropped to 20/63.\\nFigure 8: Epiretinal membrane associated with DME. Dense epiretinal membrane\\noverlying the retinal surface, with an elevated foveal contour and significant\\nintraretinal cystic spaces in a patient with diabetes. Published online with permission\\nfrom the AAO.\\n1. Disorganization of the retinal inner layers (DRIL) is thought to represent damaged cells within the inner retinal layers, indicating a disruption in the normal\\nvisual pathway from the photoreceptors to the ganglion cells.  DRIL is identified on OCT when there is disruption of the demarcating interface lines\\nbetween the ganglion cell-inner plexiform complex, inner nuclear layer (INL), outer plexiform layer (OPL), and outer nuclear layer. Eyes with DRIL have a\\nworse baseline and final VA despite anti–vascular endothelial growth factor (VEGF) injections and have an almost 8× greater risk for poor visual recovery.\\nIn contrast, the resolution of DRIL results in better visual outcomes (Figure 6).  DRIL was better correlated with VA than either glycemic status\\nand CST.\\n2. External limiting membrane (ELM) and ellipsoid zone (EZ) disruption strongly correlate with baseline and final BCVA. At the same time, some studies found\\nthat restoration of the EZ was a requirement for good visual recovery (Figure 7).  The ELM connects a row of zonular adherents to the\\nphotoreceptor cell bodies, while the EZ represents the isthmus between the outer and inner segments of photoreceptors.\\n3. DME associated with VMIA, notably ERM and VMT, has poorer visual outcomes (Figure 8).  VMIA have been observed in 7%–16% of eyes with DME,\\nwith an annual incidence rate of up to 4.5%.  The READ-3 trial showed that eyes with VMIA still had a good response to anti-VEGF therapy.\\nPresence of posterior vitreous detachment (PVD) has been associated with improved visual outcomes. Nasrallah et al. reported that DME was present in\\n55% of eyes with an attached hyaloid, compared with only 20% of eyes with PVD.  Hikishi et al. reported only a 25% rate of spontaneous resolution in\\neyes with attached posterior hyaloid, vs a 55% resolution rate in eyes with PVD.  The role of the vitreous and VMIA in DME, which may be related to\\nchanges in transvitreal oxygenation, hyalocyte proliferation from vitreous remnants on the ILM, and the present growth factors in the premacular hyaloid,\\nis still being investigated.\\nFluorescein Angiography\\nFluorescein angiography (FA) is performed to identify leaking\\nmicroaneurysms or capillaries to help guide laser treatment,\\nand to identify areas of retinal ischemia. Leakage seen with FA\\nis not synonymous with retinal edema. Focal DME is\\ncharacterized by focal leakage from microaneurysms or\\ncapillaries; in contrast, diffuse DME is characterized by poorly\\ndemarcated areas of capillary leakage (Figure 9). Recently,\\nthere has been a decreasing trend in the use of FA in the\\nmanagement of DME, likely due to the procedure being more\\ninvasive and time-consuming than OCT.  Contraindications\\nto the use of FA include pregnancy and allergy associated with\\nthe contrast dye.\\nLaboratory Testing\\nPrimary laboratory testing for DME should involve checking\\nHbA , blood pressure, and lipid levels.\\xa0 Secondary tests can\\ninclude hemoglobin (anemia exacerbates diabetic retinopathy\\nand may be associated with diabetic nephropathy); both fasting\\nand postprandial blood sugar; urea, creatinine, and urine\\nmicroalbumin levels, and a thyroid panel.\\nDifferential Diagnosis\\nOther causes of DME include retinal vein occlusion, ruptured\\nmacroaneurysm, Irvine-Gass syndrome, radiation retinopathy,\\nhypertensive retinopathy, subfoveal choroidal neovascularization,\\nretinal vein occlusion, and VMIA. OCT and FA ancillary diagnostics can\\nhelp to identify these differential diagnoses (Figures 10–11).\\nManagement\\nManagement of DME includes strict control of diabetes, blood glucose,\\nhypertension, and hypercholesterolemia.  This can be achieved by\\npharmacologic methods or by nonpharmacologic methods, such as diet\\nmodification, weight loss, and exercise.\\nPharmacotherapy\\nAt present, anti-VEGF agents are the first-line treatment for DME. The\\nFDA approved ranibizumab for DME in 2012, aflibercept in 2014, and\\nbrolucizumab and faricimab in 2022. \\xa0Since 2005, intravitreal\\nbevacizumab has been used off-label for ocular conditions.\\nDRCR Network Anti-VEGF Treatment\\nAlgorithm\\nThe DRCR anti-VEGF treatment algorithm states that 6 monthly\\ninjections should be given unless VA is 20/20 or better and CST is <320\\nμ m for men or <305 μ m for women (as measured by the Heidelberg Spectralis), in which case treatment may be withheld starting on the 4th month. At the 6th\\nvisit, if stability in vision or CST has been achieved (based on the previous 2 visits' findings) or DME has resolved, further treatment may be withheld. Stability is\\ndefined as:\\n1. Lack of improvement\\nNo BCVA increase of ≥ 5 letters (approximately 1 line on a Snellen chart)\\nNo decrease in OCT-measured CST ≥ 10% (per OCT imaging)\\n2. No worsening\\nBCVA decreases by ≥ 5 letters (approximately 1 line on a Snellen chart) in the setting of persistent DME\\nOCT-measured CST increases by ≥ 10%\\nIf there is worsening on follow-up, anti-VEGF treatment is resumed. In general, eyes showing stability may be followed up in 3–4 months, or sooner as needed.\\nWithholding injections does not require 20/20 vision or a dry macula, only evidence of stability over the previous 2 or more visits. DRCR Protocol I issued the\\nfirst anti-VEGF as-needed treatment algorithm for DME, as long-term data show that even without using a monthly treatment protocol, eyes with persistent\\n[24]\\n[25][26][27]\\n[24]\\n[28][29][30][31][32]\\n[33]\\n[34][35]\\n[36][37] [38]\\n[39]\\n[40]\\n[41][42][43][44]\\n[45]\\n1c\\n[46]\\nLearn more\"),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Figure 9: Focal and diffuse DME. A and B: Fundus photo showing circinate exudates,\\nwith adjacent microaneurysms and leakage seen on FA. C and D: Fundus photo with\\nsubtle signs of macular thickening, with diffuse, poorly demarcated capillary leakage\\nseen on FA. Published online with permission from the AAO.\\nFigure 10: Pseudophakic cystoid macular edema/Irvine-Gass Syndrome. A: Color\\nfundus photograph of an optic nerve head and macula 3 months after complex\\ncataract surgery. A small incidental grayish-yellow adult vitelliform dystrophy lesion\\nis present in the subfoveal region (circled). B: A mid-phase FA image demonstrates\\ncystic hyperfluorescence, with a classic petaloid pattern. As is typical in eyes with\\npseudophakic CME, there is mild hyperfluorescence of the nasal portion of the optic\\nnerve head. C: OCT shows cystic retinal thickening and a subfoveal vitelliform lesion.\\nD: Following 8 weeks of topical steroidal and nonsteroidal anti-inflammatory therapy,\\nOCT images indicate that the CME has fully resolved. Published online with\\npermission from the AAO.\\nDME often maintain good BCVA over the long term in clinical trial\\nsettings.  Outside of trial settings, the 5-year extension phase of\\nProtocol T showed that CST remained stable among eyes given anti-\\nVEGF injections; however, mean BCVA worsened between the 2- and\\n5-year time points.  On average, patients are given 6–8 injections in\\nthe first year, 2–4 injections in the second year, and 0–1 injections\\nbeginning the third year.\\nClinical Considerations for Treating DME With\\nAnti-VEGF Agents\\nObservation is recommended for eyes with ci-DME and VA of 20/25 or\\nbetter. This recommendation is based on the findings of DRCR Protocol\\nV, where patients were randomized to receive aflibercept injections,\\nmacular laser, or no treatment (observation). At the 2-year endpoint,\\nthe mean BCVA was 20/20, and the rates of ≥ 5-letter vision loss were\\nsimilar among all 3 groups (16%–19%). Given the risks of ocular\\ninfection and the higher costs associated with intravitreal injections,\\nobservation is a viable option in these patients if they can reliably\\nfollow up and receive appropriate therapy when there is clinical\\ndeterioration. In contrast, among eyes with ci-DME presenting with\\n20/50 vision or worse, Protocol T study results showed that aflibercept\\nwas superior to both ranibizumab and bevacizumab, with area-under-\\nthe-curve analyses showing better visual outcomes over 1 year.\\nHowever, the superiority of aflibercept over ranibizumab was not\\nmaintained at the 2-year follow-up visit.  Bevacizumab thinned the\\nretina the least; however, all 3 medications had similar visual outcomes\\namong eyes with baseline VA of 20/40 or better.\\nNot all treatments result in complete resolution of DME. In Protocol I,\\n40% of eyes still showed persistent DME (defined as never having a CST\\n<250 μ m through 6 months, as seen on time-domain OCT) after 2\\nyears.  Eyes given bevacizumab were more likely to have persistent\\nDME than eyes given aflibercept. The percentage of eyes with complete\\nresolution increased with each ranibizumab or aflibercept injection.\\nAt the 3-year follow-up visit, eyes with chronic persistent DME still had\\na significant (7-letter) mean improvement in VA over baseline, though\\nlower than the 13-letter mean improvement in eyes with complete\\nDME resolution.  Importantly, only 3.4% of eyes with chronic\\npersistent DME lost ≥ 2 lines of vision over 2 years regardless of the\\ntype of anti-VEGF treatment they received.  To summarize, in clinical\\ntrial settings, a substantial proportion of eyes with persistent DME still\\nhad ≥ 2 lines of improvement in vision over the long term, with very few\\neyes developing considerable vision loss.\\nFor eyes that do not respond optimally to one anti-VEGF agent,\\nswitching to another is a treatment option. The switch is typically from\\nbevacizumab to either ranibizumab or aflibercept, or from ranibizumab\\nto aflibercept. The rationale for switching is that aflibercept has 100\\ntimes more affinity for VEGF-A than bevacizumab or ranibizumab,\\nwhile concurrently binding placental growth factor and VEGF-B.\\nAflibercept also has a longer half-life and can negate more cytokines\\nthat promote DME development. Most studies looking at switching\\nwere retrospective and showed a significant reduction in CST; however,\\nvisual outcomes varied.\\nSome eyes may be delayed responders to anti-VEGF treatment, and\\nneed more than the initial 3–6 monthly injections to show significant\\nimprovement, though they eventually catch up with immediate\\nresponders.  It may be viable to continue treatment with the same\\nmedication if there is at least a trend of continued improvement, as\\nbevacizumab and ranibizumab are more cost-effective options. Caution\\nis warranted for switching, as any clinical improvement may be due to\\ncontinued treatment among delayed responders instead of due to a\\nshift in medications.\\nDRCR protocol AC was a randomized controlled trial evaluating the\\nrelative efficacy of administering aflibercept monotherapy vs\\nbevacizumab first with a switch to aflibercept (step therapy) in eyes\\nwith suboptimal response despite treatment. A total of 312 eyes with\\nmoderate vision loss from ci-DME were enrolled. Over a 2-year period,\\nthe mean improvement in VA was 14.0 letters in the bevacizumab-first\\ngroup and 15.0 letters in the aflibercept-monotherapy group (adjusted\\ndifference, 0.8 letters; 95% CI, −0.9 to 2.5; P = 0.37). At 2 years, mean\\nchanges in VA and retinal CST were similar in the two groups.\\nSteroids\\nIntravitreal steroids improve vision and decrease retinal thickness, as\\nthere is an inflammatory component to DME. Steroids have powerful\\nanti-edematous and anti-inflammatory effects, as they decrease several\\npro-inflammatory mediators (IL-6, IL-8, TNF- α , monocyte chemotactic\\nprotein-1, intercellular adhesion molecule-1, VEGF, etc).  However,\\nlong-term results have not shown maintenance of initial clinical\\nimprovement. In DRCR Protocol I, although the group given intravitreal\\ntriamcinolone had a similar response with ranibizumab in the first 6\\nmonths, vision declined due to cataracts. Even with cataract surgery,\\nthe final vision did not recover to the levels seen in the group given\\nranibizumab.  In Protocol U, eyes with persistent DME despite at\\nleast 6 ranibizumab injections were randomized to continue\\n[47]\\n[48]\\n[49]\\n[50]\\n[23]\\n[47]\\n[51]\\n[52]\\n[53]\\n[54]\\n[55][56][57][58][59][60][61][62][63][64][65][66][67][68]\\n[69][70]\\n[71]\\n[72]\\n[47]\\nLearn more'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content=\"Figure 11: Vitreomacular traction with secondary macular edema. A: Color fundus\\nphotograph of the right eye with pseudohole and epiretinal membrane with tractional\\nmacular edema. B: OCT image of same patient showing vitreomacular traction,\\nepiretinal membrane, and resulting macular edema. C: OCT of the same eye after\\nvitrectomy surgery with epiretinal membrane peeling. Published online with\\npermission from the AAO.\\nranibizumab monotherapy or shift to ranibizumab plus dexamethasone\\n(Ozurdex).  At 6 months, the average visual gain was similar in both\\ngroups, although CST improvement was greater in the combination\\ngroup. Phakic eyes given intravitreal steroids often develop cataracts\\nneeding surgery, and are at risk for intraocular pressure (IOP)\\nelevations leading to glaucoma.\\nLandmark Pharmacotherapy Studies\\nAnti-VEGF Agents\\nBevacizumab: Bevacizumab is a recombinant humanized\\nmonoclonal immunoglobulin G1 (IgG1) antibody that binds VEGF.\\nBevacizumab is given off-label for the treatment of DME, and\\nremains the most cost-effective treatment option among anti-\\nVEGF medications.  In the BOLT study, intravitreal bevacizumab\\n(1.25 mg), given at 6-week intervals, was reported to be more\\neffective than modified ETDRS focal/grid laser in terms of VA\\nimprovement at 12 months.  In DRCR Protocol T, a comparison\\nbetween bevacizumab, ranibizumab, and aflibercept, 1-year results\\nshowed that bevacizumab thinned the retina the least.  However,\\nall 3 medications had similar visual outcomes among eyes with\\nbaseline vision of 20/40 or better.  A study from The Pan-American Collaborative Study Group found improvements in BCVA and reduced macular\\nthickness (seen on OCT) at 24 months with intravitreal bevacizumab doses of 1.25 mg–2.5 mg.\\nRanibizumab: Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds and inhibits VEGF-A.  It is FDA approved for the\\ntreatment of DME.\\n1. DRCR Protocol I was the first definitive phase 3 study demonstrating the effectiveness of ranibizumab for DME treatment.  Four treatment arms\\nwere compared: ranibizumab with immediate grid/focal laser; ranibizumab with macular laser given only for at least 6 months of persistent DME;\\nintravitreal triamcinolone with immediate macular laser; and macular laser with sham injections. Results showed that ranibizumab, given in as-needed\\ntreatment protocol, had efficacy superior to that of laser therapy. At the 1-year end point, eyes treated with ranibizumab gained an average of 8–9\\nletters, vs an average gain of only 3 letters seen with laser therapy. Protocol I revolutionized the treatment protocol for DME when it was published in\\n2011. Before this study, macular laser was consideredfirst-line therapy for DME, a treatment protocol originating from the original ETDRS papers first\\npublished in 1985.\\n2. RISE and RIDE: The 2-year results for ranibizumab 0.3-mg monthly infections showed that 98% of patients maintained vision (lost <15 letters) and\\n34%–45% of patients gained at least 15 letters; the mean VA gain was 10.9–12.5 letters.  Only 45%–49% of patients needed macular laser,\\ncompared with 91%–94% in the control group. No additional benefit was seen with ranibizumab 0.5 mg monthly vs 0.3 mg monthly.\\nAflibercept: Aflibercept is a soluble decoy receptor that binds VEGF-A, VEGF-B, and placental growth factor with high affinity.  It is termed a decoy\\nreceptor or a “VEGF-trap,” as VEGF mistakenly binds with aflibercept instead of the body’s native receptors, reducing VEGF’s activity. It is FDA approved\\nfor the treatment of DME. In the Da Vinci study, patients with DME were randomly assigned to 1 of 5 treatment regimens: aflibercept 0.5 mg every 4\\nweeks (0.5q4), 2 mg every 4 weeks (2q4), 2 mg every 8 weeks after 3 initial monthly doses (2q8), or 2 mg as needed after 3 initial monthly doses (2prn); or\\nmacular laser photocoagulation.  Mean improvements in BCVA in the aflibercept groups at week 52 were 11.0, 13.1, 9.7, and 12.0 letters for the 0.5q4,\\n2q4, 2q8, and 2prn regimens, respectively, vs −1.3 letters for the laser group. The proportion of eyes with gains in BCVA of ≥ 15 ETDRS letters at week 52 in\\nthe aflibercept groups were 40.9%, 45.5%, 23.8%, and 42.2%, respectively, vs 11.4% for laser. Mean reductions in CST in the aflibercept groups at week 52\\nwere −165.4 μ m, −227.4 μ m, −187.8 μ m, and −180.3 μ m, respectively, vs −58.4 μ m for laser.  The PHOTON trial evaluated the use of high-dose\\naflibercept (8 mg) aflibercept every 12 weeks (8q12) or 16 weeks (8q16) vs conventional dosing of 2 mg every 8 weeks (2q8).  When comparing BCVA\\ngains and retinal thinning at 48 weeks, the 8-mg extended interval dosage was noninferior to conventional treatment. There was an increase of 9.2, 8.8,\\nand 7.9 letters and a mean CST reduction of −165 μ m, −172 μ m, and −148 μ m for the 2q8, 8q12, and 8q16 groups at 48 weeks, respectively. Patients in the\\nhigh-dose group with a 50- μ m increase in CST or a 10-letter loss from week 12 onwards had their dosing schedule shortened to either 12 or 8 weeks, but\\n93% of patients remained on dosing intervals of ≥ 12 weeks. There was no increase in hypertension in the high-dose group.\\nFaricimab: Faricimab is a novel combined-mechanism inhibitor that binds both angiopoietin-2 and VEGF-A with high specificity and affinity. The 1-year\\nresults from the phase 2 BOULEVARD study showed that in patients given faricimab 6 mg, there was a statistically significant VA gain of 3.6 letters over\\nthat seen with ranibizumab.  Moreover, improvement in diabetic retinopathy severity, as well as reduced CST, was seen with faricimab; it also had a\\nlonger time to re-treatment than ranibizumab. There were no unexpected safety concerns. The phase 3 YOSEMITE and RHINE noninferiority trials\\ncompared faricimab with aflibercept in patients with DME.  The noninferiority primary endpoint of BCVA was achieved with faricimab given every 8\\nweeks. More than 50% of patients had good results with an every-16-weeks dosing regimen, and more than 70% had good results with faricimab given\\nevery 12 weeks or longer. These results demonstrate the potential of faricimab to decrease patients' treatment burden by extending the intraocular\\ndurability of anti-VEGF treatment. The FDA approved the use of faricimab for DME as 4 monthly loading doses followed by injections every 1–4 months, or\\nas a loading dose of 6 monthly injections followed by injections every 2 months.\\nBrolucizumab: Brolucizumab is a single-chain antibody fragment with a high affinity for VEGF. Brolucizumab’s low molecular weight of 26 kDa allows for\\nmore of the drug to be delivered intraocularly per injection, with the potential for increased durability and effective tissue penetration in the eye. The\\nphase 3 KESTREL and KITE 52-week results found that brolucizumab 6 mg was noninferior to aflibercept in mean improvement of BCVA. More patients\\ntaking brolucizumab had CST <280 μ m without persistent macular fluid than patients taking aflibercept, and >50% of the brolucizumab-treated patients\\nwere maintained on q12w dosing after the loading dose was given.  However, reports of retinal vascular occlusion (RVO) and retinal vasculitis with\\nintraocular inflammation (IOI) have been reported.  Risk factors for developing these adverse reactions include a prior history of IOI or RVO in the 12\\nmonths before brolucizumab initiation, female sex, and same-day bilateral injections.  The FDA approved the use of brolucizumab for the treatment\\nof DME in June 2022, as a 6-mg injection given every 8–12 weeks after a loading dose of 5 injections given every 6 weeks.\\nAflibercept HD: FDA granted approval for the use of 8mg Aflibercept for treating DME in 2023. The results of PHOTON trial for CIDME after 2 years\\nrevealed mean improvement in BCVA with standard Eylea of 8.4 letters, 8.8 letters with the 12-week Eylea HD group, and 7.5 letters with the 16-week\\nEylea HD group.\\nSteroids\\nTriamcinolone: In Protocol B, triamcinolone (1 or 4 mg) preservative-free intravitreal injection was less effective and had more side effects than focal/grid\\nphotocoagulation at the 2-year follow-up visit.\\nDexamethasone: In the 3-year phase 3 MEAD study, dexamethasone 0.7 mg biodegradable implant improved vision by at least 15 letters in 22% of\\npatients.  At this dose, 41.5% of patients needed antiglaucoma medications, with 0.6% needing glaucoma surgery. Around 60% of eyes in the 0.7-mg\\n[73]\\n[74]\\n[75]\\n[23]\\n[53]\\n[76]\\n[77]\\n[47]\\n[78]\\n[79]\\n[79]\\n[80]\\n[79]\\n[81]\\n[82]\\n[83]\\n[84]\\n[85][86]\\n[87][88]\\n[89]\\n[90] Learn more\"),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Figure 12: Focal laser for focal CSME. A: Planning of focal laser for focal CSME. Note\\nthe identified treatment areas, specifically the leaking microaneurysms that would be\\nhighlighted on FA. B: Focal laser-treated areas with parameters. Published online with\\npermission from the AAO.\\nFigure 13: Grid laser for diffuse CSME. A: Planning of grid laser for diffuse CSME.\\nNote the identified treatment area, specifically the outlined region with diffuse\\nedema that would be highlighted on FA. B: Grid laser–treated area with parameters.\\nPublished online with permission from the AAO.\\nimplant group had cataract surgery. The 0.7-mg implant has been approved by the FDA for DME, and is effective for approximately 3–6 months.\\nFluocinolone acetonide: The fluocinolone acetonide (Iluvien) 0.19-mg non-biodegradable implant is a sustained-release device that is effective for up to 3\\nyears when administered intraocularly. It is FDA approved to treat DME in patients who have been previously treated with a course of corticosteroids and\\ndid not have a clinically significant rise in IOP.  At the 0.2- μ g/day dosage, BCVA improvement of at least 15 letters was found in 28.7% of patients,\\nwith 38.4% needing anti-glaucoma medications and 4.8% needing glaucoma surgery. The latter figure was reduced to 0% among eyes that did not have a\\nhistory of IOP elevation with a prior steroid challenge. Complications associate with both the fluocinolone and the dexamethasone implants include\\ncataracts and implant migration.\\nLaser Photocoagulation\\nBefore anti-VEGF treatments for DME were approved, the standard\\ntreatment for CSME was macular laser photocoagulation. In “focal”\\nCSME, a focal laser pattern is used to treat leaking microaneurysms\\nidentified on the FA that contribute to the retinal edema (Figure 12). In\\n“diffuse” CSME, intraretinal leakage is noted on the FA from dilated\\nretinal capillary beds or intraretinal microvascular abnormalities\\nwithout isolated, discrete foci of leakage. A macular grid is done in\\ncases of diffuse macular edema (Figure 13). Laser photocoagulation has\\nbeen shown to decrease the risk of moderate visual loss (loss of ≥ 15\\nETDRS letters) from 24% to 12% after 3 years.  After the laser\\ntreatment is administered, the patient will come back in 3 months for a\\nfollow-up examination. If residual CSME is noted, OCT and FA may be\\nperformed to evaluate the benefit and location of repeat laser\\ntreatment. With the FDA approval of anti-VEGF agents for DME,\\nfocal/grid laser is only indicated in patients with non-ciDME. Macular\\nlaser remains a viable treatment option for patients with DME,\\nespecially in resource-limited countries with decreased access to anti-\\nVEGF agents.\\nCombined Therapy\\nIntravitreal ranibizumab with laser: In Protocol I, intravitreal\\nranibizumab with prompt (within 1 week) or deferred (after 24\\nweeks) laser was more effective than focal/grid laser alone for the\\ntreatment of ci-DME.  Ranibizumab is injected intravitreally at\\nbaseline, followed by monthly injections for 4 months followed by\\nthe continuation of injections at 16 weeks if the OCT central\\nsubfield thickness is ≥ 250 um with VA worse than 20/20.\\nSteroid with laser: Protocol B found that intravitreal triamcinolone\\n(IVT) 4 mg plus focal/grid laser (given within a week of injection)\\nwas more effective than laser alone at 4 months. However, long-\\nterm benefit with this combined therapy was not seen, with mean\\nBCVA better in the laser monotherapy group than the combined\\ntherapy group from the 16-month time point until the 2-year end point. Complications of steroid therapy included cataracts, ocular hypertension, and\\nglaucoma. The difference in BCVA could not be attributed fully to the development of cataracts. In Protocol I, 6-month VA improvement in eyes given IVT\\nwith prompt laser was comparable to that seen in eyes given ranibizumab, but vision declined afterward until the 2-year time point.  A subgroup\\nanalysis in pseudophakic eyes given IVT showed that visual improvement was significantly better than in phakic eyes, with 1- and 2-year results\\ncomparable to pseudophakic eyes given ranibizumab.\\nIntravitreal ranibizumab with peripheral targeted retinal photocoagulation (TRP): The DAVE study was a phase 1/2 clinical trial that compared\\nranibizumab plus peripheral TRP and ranibizumab monotherapy for reduce the number of required anti-VEGF injections.  Peripheral TRP was defined as\\nretinal photocoagulation administered outside the macula to areas of retinal capillary nonperfusion identified on widefield FA. The nonperfused hypoxic\\nretina is thought to upregulate hypoxia-inducible factors and cytokines, including VEGF and erythropoietin, with small studies suggesting that TRP can\\ndecrease the anti-VEGF treatment burden.  At the 3-year endpoint, there was no evidence that combined ranibizumab plus TRP reduced\\ntreatment burden or improved vision outcomes compared with ranibizumab alone.\\nSurgery\\nNo well-constructed studies show a definitive benefit of pars plana vitrectomy (PPV) for managing DME. The theoretical basis for PPV as a treatment option\\ncomes from reports that it increases vitreous oxygenation in ischemia, leading to decreased VEGF production, and from the observation that DME is less\\ncommon among eyes with PVD.  Vitreous viscosity also significantly decreases after PPV, which may bring about a greater diffusion of\\npro-inflammatory cytokines away from the macula.  Other studies suggest that PPV plus internal limiting membrane (ILM) peeling brings better resolution\\nof the tractional forces at the vitreoretinal interface known to worsen DME. This procedure also prevents proliferating astrocytes from using the ILM as a\\nscaffold, which may lead to ERM.  In a systematic review looking at PPV for DME, CST was significantly decreased by 102 μ m, and a nonsignificant VA\\nincrease of 2 letters was observed.  However, the anatomic benefit was not maintained by the 12-month time point. A similar meta-analysis looking at PPV\\nplus ILM peeling vs PPV alone showed no significant difference in postoperative vision and macular thickness between the treatments.  DRCR Protocol D, a\\nprospective study of eyes with DME and VMT, found that at 6 months after surgery, 43% of eyes had a reduction in CST to <250 μ m.  However, the median\\nVA did not change at 6 months. In 38% of eyes, the median visual acuity improved by ≥ 10 letters, and in 22% the median VA decreased by ≥ 10 letters. A post\\nhoc analysis of Protocol I showed that previously vitrectomized eyes with ci-DME given anti-VEGF treatments had no improved clinical outcomes compared\\nwith non-vitrectomized eyes.\\nTreatment Complications\\nThe complications listed below may arise from the various treatment modalities. The per-injection risk of developing complications is also listed below, when\\navailable.\\nIntravitreal Injections\\nEndophthalmitis (0.019%–0.05%)\\nIntraocular inflammation (0.09%–0.4%)\\nRetinal tears/detachment (0.01%–0.08%)\\nIncrease in IOP (for intravitreal steroids, IOP ≥ 21 mmHg in 45% at 1 month, 20% at 3 months, and 13% of eyes at 6 months post-injection.)\\nCataract (common after intravitreal steroid injections. By year 3, 83% of patients given IVT needed cataract surgery.)\\nSubconjunctival hemorrhage (10%)\\n[91][92]\\n[9]\\n[47]\\n[47][93]\\n[94]\\n[95][96][97][98][99]\\n[100][101][102][103][104][105]\\n[106]\\n[107]\\n[108]\\n[109]\\n[110]\\n[111]\\n[112][113][114]\\n[115]\\n[116][117][118]\\n[119]\\n[120]\\n[121] Learn more'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Vitreous hemorrhage\\nLaser Photocoagulation\\nSubretinal fibrosis\\nExtension of the laser scar into the fovea\\nChoroidal neovascular membrane\\nParacentral scotoma\\nDecreased visual acuity\\nPars Plana Vitrectomy\\nRetinal tears and retinal detachment\\nVitreous hemorrhage\\nElevated intraocular pressure\\nEndophthalmitis\\nCataract\\nPrognosis\\nClinical factors associated with better visual outcomes with anti-VEGF treatment include lower HbA1c, younger age, less severe diabetic retinopathy, absence\\nof ERM, quick and consistent CST decreases, and absence of prior panretinal photocoagulation.  In terms of anatomic outcomes, eyes with hard\\nexudates within the 6-mm foveal center had a larger CST decrease at the end of 1 year. The presence of exudates may be a marker of BRB abnormalities typical\\nof DME responsive to anti-VEGF therapy. Eyes that lack exudates may have other underlying mechanisms of retinal thickening, including cystoid degeneration,\\ntraction, or ischemia. In contrast, eyes with high baseline CST ( ≥ 570 μ m) had a significantly higher chance of developing persistent DME despite monthly\\nranibizumab therapy.  In terms of response to macular laser therapy, the ETDRS reported that worse clinical outcomes were associated with higher blood\\nlipid levels, presence of hard exudates, and diffuse edema.\\nMatsunaga et al. looked at eyes with DME treated with at least 1 dose of anti-VEGF agents that were then awere lost to follow-up (LTFU) for at least 6 months\\nbefore returning to the clinic.  Vison worsened significantly at the initial return visit, to ~20/69 from ~20/52; however, at the 3-, 6-, and 12-month follow-up\\nvisits and the final checkup, vision recovered with no significant differences from baseline. OCT CST also showed similar trends. Gao et al. found that 25% of\\npatients with NPDR and DME had no follow-up visits for at least 1 year after receiving 1 anti-VEGF injection.  Factors associated with being LTFU included\\nHispanic ethnicity (OR 1.7) and American Indian/Pacific Islander/multiple ethnicities (OR 2.6). Lower adjusted gross income and decreasing baseline vision\\nwere also factors significantly associated with LTFU.\\nSome studies have shown increased risks of end-stage renal disease in patients with concurrent DME. Assessment of renal function should be strongly\\nencouraged in patients with chronic DME.\\nFuture Directions\\nNumerous pharmacotherapy trials for DME treatment are underway. The development of a long-acting anti-VEGF agent that could remain effective in the\\nvitreous for multiple months or years would significantly decrease the treatment burden for patients needing monthly injections. Novel pharmacotherapies\\nbased on different mechanisms of action include anti-VEGF designed ankyrin repeat proteins, growth factor inhibitors, anti-inflammatory medications,\\nhormone modulators, acetylcholine receptor blockers, insulin-like growth factor 1 receptor blockers, and neuroprotective/antiapoptotic agents.  Port\\ndelivery systems that are FDA approved for wet AMD are in development to treat diabetic retinopathy and DME.  These experimental therapies have the\\npotential to significantly decrease the burden of treatment while restoring vision to patients with DME in the coming years ahead. An ophthalmic suspension,\\nOCS-01, a topical dexamethasone that is formulated with nanoparticle technology, in a completed Phase 2 trial has shown a higher reduction in CMT with\\nOCS-01 compared to control. Further phase 3 studies are pending yet.\\nArtificial intelligence (AI) plus tele-ophthalmology models are being used to develop screening tools for diabetic retinopathy and DME. These models can\\ndetect the retinal complications of diabetes remotely, and if this technology is placed in the offices of internists and endocrinologists, it may allow for early\\ndetection and timely intervention.\\nFurther reading\\n1. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54(1):1-32\\n2. Diabetic Retinopathy Clinical Research Network Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt\\nlaser for diabetic macular edema. Ophthalmology. 2010; 117(6):1064-1077.\\n3. Early Treatment Diabetic Retinopathy Study: Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1.\\nEarly Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103(12):1796-1806.\\n4. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic\\nmacular edema (BOLT study) 12 month data: report 2. Ophthalmology. 2010; 117(6):1078-1086.e2.\\n5. Schachat AP. A new approach to the management of diabetic macular edema. Ophthalmology. 2010;117(6):1059-1060.\\nReferences\\n1. Otani T, Kishi S, Maruyama Y. Patterns of diabetic macular edema with\\noptical coherence tomography. Am J Ophthalmol. 1999;127(6):688-693.\\n2. Yanoff M, Fine BS, Brucker AJ, et al. Pathology of human cystoid macular\\nedema. Surv Ophthalmol. 1984;28(suppl):505-511.\\n3. Xu H-Z, Le Y-Z. Significance of outer blood–retina barrier breakdown in\\ndiabetes and ischemia. Invest Ophthalmol Vis Sci. 2011;52(5):2160-2164.\\n4. Brownlee M. The pathobiology of diabetic complications: a unifying\\nmechanism. Diabetes. 2005;54(6):1615-1625.\\n5. Del Zoppo G. The neurovascular unit in the setting of stroke. J Intern Med.\\n2010;267(2):156-171.\\n6. Gao B-B, Clermont A, Rook S, et al. Extracellular carbonic anhydrase\\nmediates hemorrhagic retinal and cerebral vascular permeability through\\nprekallikrein activation. Nat Med. 2007;13(2):181-188.\\n7. Jeppesen P, Aalkjær C, Bek T. Bradykinin relaxation in small porcine\\nretinal arterioles. Invest Ophthalmol Vis Sci. 2002;43(6):1891-1896.\\n8. Parpura V, Basarsky TA, Liu F, et al. Glutamate-mediated astrocyte–\\nneuron signalling. Nature. 1994;369(6483):744-747.\\n9. Early Treatment Diabetic Retinopathy Study Research Group.\\nPhotocoagulation for diabetic macular edema. Arch Ophthalmol.\\n1985;103:1796-1806.\\n10. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of\\ndiabetic retinopathy XV: the long-term incidence of macular edema.\\nOphthalmology. 1995;102(1):7-16.\\n11. White NH, Sun W, Cleary PA, et al. Effect of prior intensive therapy in type\\n1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC:\\ncomparison of adults and adolescents. Diabetes. 2010;59(5):1244-1253.\\n12. Varma R, Bressler NM, Doan QV, et al. Prevalence of and risk factors for\\ndiabetic macular edema in the United States. JAMA Ophthalmology.\\n2014;132(11):1334-1340.\\n13. Wong TY, Klein R, Islam FA, et al. Diabetic retinopathy in a multi-ethnic\\ncohort in the United States. Am J Ophthalmol. 2006;141(3):446-455.e441.\\n14. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk\\nfactors of diabetic retinopathy. Diabetes Care. 2012;35(3):556-564.\\n[122][123]\\n[124]\\n[125]\\n[126]\\n[127]\\n[128]\\n[129]\\n[130][131]\\nLearn more')]"
      ]
     },
     "execution_count": 38,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "filtered_docs = filter_minimal(extract_pdfs)\n",
    "filtered_docs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "448fbe63",
   "metadata": {},
   "outputs": [],
   "source": [
    "import re\n",
    "\n",
    "def clean_text(docs: List[Document]) -> List[Document]:\n",
    "    \"\"\"\n",
    "    Clean page_content for all documents in the list.\n",
    "    \"\"\"\n",
    "    cleaned_docs = []\n",
    "    for doc in docs:\n",
    "        # Remove non-ASCII characters and unwanted blocks\n",
    "        cleaned = re.sub(r'[^\\x00-\\x7F]+', '', doc.page_content)  # Remove non-ASCII\n",
    "        cleaned = re.sub(r'\\s+', ' ', cleaned).strip()  # Normalize whitespace\n",
    "        if cleaned:  # Skip empty after cleaning\n",
    "            cleaned_docs.append(Document(page_content=cleaned, metadata=doc.metadata))\n",
    "    return cleaned_docs\n",
    "\n",
    "# Apply to all filtered_docs\n",
    "cleaned_docs = clean_text(filtered_docs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "370a020e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Normal Retina Comprehensive KB Entry 1 Short Definition A normal retina is a multilayered neural tissue lining the back of the eye, responsible for converting light into visual signals. On OCT imaging, the normal macula shows a clean foveal depression, well-defined retinal layers, and absence of any fluid, cysts, or abnormal elevations. 2 Basic Anatomy of the Retina (Layer by Layer) From inner (vitreous side) to outer (RPE/choroid side), the key layers are: - Internal Limiting Membrane (ILM) - Nerve Fiber Layer (NFL) - Ganglion Cell Layer (GCL) - Inner Plexiform Layer (IPL) - Inner Nuclear Layer (INL) - Outer Plexiform Layer (OPL) - Outer Nuclear Layer (ONL) - External Limiting Membrane (ELM) - Photoreceptor Inner Segments and Outer Segments - Ellipsoid Zone (EZ) - Retinal Pigment Epithelium (RPE) - Bruchs Membrane and Choroid beneath 3 OCT Characteristics of a Healthy Macula - **Foveal Depression:** Smooth, symmetric curvature with thinnest point at the fovea. - **Layer Clarity:** All retinal layers appear sharply demarcated. - **No Fluid:** No intraretinal cysts (IRF) and no subretinal fluid (SRF). - **Intact Ellipsoid Zone:** Strong hyperreflective band indicating healthy photoreceptors. - **Normal RPE Line:** Continuous, smooth hyperreflective line with no elevation. - **Stable Thickness:** Normal macular thickness without thickening or thinning. 4 What Is NOT Present in a Normal Retina (Important for Classification) - No cystoid spaces. - No drusen or sub-RPE deposits. - No pigment epithelial detachment (PED). - No choroidal neovascularization or subretinal hyperreflective material. - No edema, exudates, or hemorrhage. - No tractional changes or disruption of the photoreceptor bands. 5 Physiological Variations (Still Considered Normal)'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- Mild inter-individual variation in foveal pit shape. - Slight differences in reflectivity due to age. - Occasional benign vitreomacular adhesion (VMA) without traction. 6 Importance in Machine Learning / Classification A normal OCT class acts as: - The baseline template for retinal architecture. - The reference to detect abnormalities such as fluid, drusen, or neovascular membranes. - A stabilizing anchor in the model for contrast between pathological and healthy states. 7 Clinical Significance of Normal Findings - Normal OCT suggests no active retinal disease. - Clear layers and intact EZ correspond to good visual potential. - Important for ruling out diabetic macular edema, drusen, and CNV. 8 Patient Education (Chatbot-Friendly Snippets) - A normal retina has smooth, well-organized layers with no swelling or abnormal fluid. - Your OCT scan shows no signs of leakage, deposits, or damage. - An intact photoreceptor layer means healthy visual function. 9 When Normal OCT Occurs Despite Symptoms A patient may feel symptoms but still have a normal OCT due to: - Dry eye symptoms (not retinal). - Migraine aura. - Functional visual disturbances. - Early disease not yet visible structurally. 10 Safety & Advice for Patients with Normal OCT - If vision symptoms persist, a clinical exam may still be needed. - Monitor for any new distortion or vision changes. - Maintain regular eye health practices (good lighting, glucose control if diabetic, etc.). 11 Decision Flow (for Chatbot Use) - OCT shows no fluid + intact layers classify as NORMAL. - If symptoms but OCT normal recommend clinical evaluation for non-retinal causes. - If minimal benign variations still NORMAL unless accompanied by structural abnormalities. 12 Snippets for Embedding - Normal OCT: clear layers, no fluid, intact RPE and photoreceptors. - Healthy macula shows a smooth foveal dip with no cysts or swelling.'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- No signs of drusen, edema, or abnormal vessels. 13 Disclaimer This information is for educational use only and should not replace clinical assessment by an eye care professional.'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='Type 1 CNV. Type 1 neovascular lesion is located below the RPE as seen in the B-scan frame. In the OCT-A frame, a neovascular coralliform network is observed which emanates from the choroidal vasculature and extends to the sub-RPE space. Type 2 CNV. In B-scan and OCT-A, a neovascular lesion is identified that extends from the choroidal vessels through the Bruch\\'s membrane and RPE and grows into the subretinal space. The En Face image shows a change in color in macula secondary to edema and serous detachment of the retina. Choroidal Neovascularization: OCT Angiography Findings All content on Eyewiki is protected by copyright law and the Terms of Service. This content may not be reproduced, copied, or put into any artificial intelligence program, including large language and generative AI models, without permission from the Academy. Disease Entity Disease Choroidal neovascularization (CNV) is part of the spectrum of exudative age-related macular degeneration (AMD) that consists of an abnormal growth of vessels from the choroidal vasculature to the neurosensory retina through the Bruch\\'s membrane. CNV can also develop in a number of other conditions such as myopic degeneration, chronic central serous chorioretinopathy, macular telangiectasia type 2, various white dot syndromes and other uveitic processes, and some choroidal tumors. Leakage of retinal edema and hemorrhage from CNV threatens visual acuity. Etiology Etiology of CNV is multifactorial. Alterations in Bruch\\'s membrane, migration of macrophages and production of vascular endothelium growth factor (VEGF), play an important role in the development of this disease. Risk Factors The incidence and progression of AMD are related to age and genetic factors. With aging, the lysosomal activity for the degradation of external segments of photoreceptors decreases. This leads to subsequent accumulation of lipofuscin, which affects the normal function of the RPE. Another important risk factor for the development of CNV is the presence of large, confluent soft drusen. Oxidative stress may play an important role in AMD. Several modifiable risk factors have been identified, including quitting smoking, dietary intake of omega-3 fatty acids, consuming vegetables and fruit with antioxidants including lutein and zeaxanthin, exercise, wearing sunglasses, and maintaining a healthy weight. Pathophysiology Alterations in the normal transport of metabolites, ions and water through Bruch\\'s membrane in AMD, alter the nutrition and stability of retinal pigment epithelium (RPE) from choriocapillaris and the transport of waste out from the neurosensory retina. Hypoxia leads to VEGF being released by the RPE, which initiates a cascade of angiogenic responses at the level of the choroidal endothelium. Bruchs membrane damage is required to allow the passage of abnormal neovascular vessels from the choroidal vasculature through the breaks in Bruchs membrane to the retina. This impairment is part of the pathological course of AMD. Classification Histologically, neovascular membranes are classified into: Type 1 (\"occult\"), when the neovascular membrane is located below the RPE. Type 1 CNV demonstrates occult leakage on fluorescein angiography. Polypoidal choroidal vasculoplathy (PCV) is a subtype of Type 1 CNV that is characterized by the presence of polyp-like aneurysmal dilations of the branching vascular network. Type 2 (\"classic\"), passes through the RPE and is located above the RPE in the subretinal space. This is related to the angiographic classification of a classic CNV. Article initiated by: Andrea Tamine Hoyos Dumar, MD, Juan.David.Arias All contributors: Leo A. Kim, MD, PhD,Sun Young (Sunny) Lee, MD, PhD,Koushik Tripathy, MD (AIIMS),Andrea Tamine Hoyos Dumar, MD,Diana V. Do, MD,Talisa de Carlo, MD,Neelakshi Bhagat, MD, FACS,Jennifer I Lim MD,Aidan Lee, MD Assigned editor: Sun Young (Sunny) Lee, MD, PhD Review: Assigned status Up to Date by Sun Young (Sunny) Lee, MD, PhD on September 18, 2025. Choroidal Neovascularization DiseasesDB 32400 ICD-10 H35.3 MeSH D020256 [1] [2][3] [4][5][6][7] [8] [9] [10] [11] [12][13] Learn more Accept'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content=\"Type 3 CNV. An intraretinal neovascular lesion is observed. The color photo identifies typical punctate hemorrhages. The OCT B-scan shows retinal edema without disruption of Bruch's membrane or RPE. OCT-A depicts an anastomosis originating in the neurosensory retina. Type 3 is defined as Retinal Angiomatous Proliferation (RAP), which corresponds to neovascularization that develops within the neurosensory retina an progresses posteriorly into the subretinal space. Diagnosis Clinical findings In the presence of CNV, the patient experiences an acute decrease in visual acuity, relative scotoma, and/or metamorphopsia. The retinal examination shows a grayish macular lesion associated with subretinal fluid, macular edema, exudation, and/or hemorrhages. Diagnostic Procedures OCT Angiography En face OCT angiography (OCTA) is a new technology that has the great ability to show the retinal and choroidal microcirculation in detail without invasive means. Instead of intraocular contrast, it uses motion contrast by comparing the decorrelation signal between repeated B-scans obtained at a given retinal cross-section to detect blood flow. It utilizes the principle that theoretically only the circulating RBCs within the retinal vasculature would be moving between the B-scans. Each en face OCT angiogram is cross-registered with the corresponding OCT B-scans, an OCT thickness map, and a structural en face OCT, which allows for concurrent visualization of structure and blood flow. OCTA is available on both spectral domain and swept source OCT devices. The conventional CNV evaluation often consists of multimodal imaging with fluorescein angiography (FA) combined with indocyanine green angiography (ICGA) and OCT. These well-established modalities can guide effective CNV management but have their limitations, especially when characterizing vascular structures at different depths. For example, FA only allows for evaluation of the superficial capillary plexus within the retina. OCTA, on the other hand, allows for noninvasive three-dimensional analysis of the retinal and choroidal vasculature and can be segmented to view each of the vascular plexuses individually. This ability to visualize vascular structures at different depths/layers of the retina makes OCTA a tool well suited to evaluate CNV. For the purpose of visualizing changes in eyes with CNV or suspected CNV, a segmentation of the outer retina (extending from the outer plexiform layer to Bruchs membrane) and a segmentation of the choriocapillaris (approximately 20um thick region just below the RPE) are most useful. CNV can be seen as a seafan or coraliform neovascular complex within the outer retina, which is ordinarily devoid of blood flow in normal eyes. Type 1 CNV is observed in OCTA as a neovascular complex between the RPE and Bruch's membrane, originating in the choroid. The type 2 CNV is visualized as a neovascular network that grows from the choroid vasculature and traverses the RPE-Bruch's membrane complex into the subretinal space. Type 3 CNV is clinically seen as tiny intra- and subretinal hemorrhages that correlate on OCTA as an intraretinal anastomosis originating in the deep capillary plexus of the retina. The PCV subtype of CNV can also be seen as a branching neovascular network within the outer retina but with concurrent aneurysmal dilations. After repeat pharmacologic intervention the large branches of the CNV become pruned and the smaller capillaries and any polyps may no longer be visualized (whether due to slow or absent flow, or complete regression). The choriocapillaris layer may demonstrate decreased flow or flow voids adjacent to the CNV complex. Additionally, choriocapillaris hypoperfusion may be seen underlying any areas of RPE atrophy. The use of OCTA in CNV imagining is not without challenges. OCTA is susceptible to several imaging artifacts. Some of these, such as motion or signal attenuation, may be mitigated through patient instruction and technician training. Projection artifacts arise when blood flow of su perficial layers of the retina is projected onto deeper structures below, which can cause false flow signal in deeper anatomical layers. CNV assessment suffers since proper visualization requires high-quality images of the outer retina, where projection artifacts are especially prominent due to proximity to the highly reflective RPE layer. Furthermore, the eruption of CNV can lead to segmentation artifact via the distortion of the retinal layers. This may require manual adjustment of the segmentation slabs, which may be time consuming and lower the repeatability of the test. Tools for automatic segmentation through deep learning and modality of OCTA such as projection-resolved OCTA (PR-OCTA) algorithm have been reported to improve the quality and repeatability of OCTA studies. Management Treatment Taking into account the numerous recent studies on the treatment of CNV in AMD, it has been shown that antiangiogenic therapy shows the best result both histologically with the regression of the neovascular lesion and functionally with improvement of the visual acuity. Although the treatment is the same for all types of CNV, it is important to differentiate them, since they do not all respond identically and some of them have a higher rate of recurrence. References 1. Turbert, D. (2020, March 18). What are Choroidal Neovascular membranes? Reviewed by Ninel Z Gregori, MD. American Academy of Ophthalmology. https://www.aao.org/eye-health/diseases/choroidal- neovascular-membranes. 2. Cheung C. et al. Myopic Choroidal Neovascularization: Review, Guidance, and Consensus Statement on Management. Ophthalmology. 2017 Nov;124(11):1690-1711. doi: 10.1016/j.ophtha.2017.04.028 3. Agarwal A. et al. An update on inflammatory choroidal neovascularization: epidemiology, multimodal imaging, and management. J Ophthalmic Inflamm Infect. Vol: 8(13). doi: 10.1186/s12348-018-0155- 6 4. Kennedy CJ, Rakoczy PE, Constable IJ. Lipofuscin of the retinal pigment epithelium: a review. Eye 1995;9:76371. 5. Rakoczy PE, Zhang D, Robertson T, et al. Progressive age-related changes similar to age-related macular degeneration in a transgenic mouse model. Am J Pathol 2002;161:151524 6. Hageman GS, Mullins RF. Molecular composition of drusen as related to substructural phenotype. Mol Vis 1999;5:28. 7. Spillsbury K. et al. Overexpression of Vascular Endothelial Growth Factor (VEGF) in the Retinal Pigment Epithelium Leads to the Development of Choroidal Neovascularization. Am J Pathol. 2000 Jul; 157(1): 135144. doi: 10.1016/S0002-9440(10)64525-7 8. Klein R, Klein BE, Jensen SC, et al. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study [see comments]. Ophthalmology 1997;104:721. 9. Mullins RF, Russell SR, Anderson DH, et al. Drusen associated with aging and age-related macular degeneration contain proteins common to extracel- lular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J 2000;14:83546. 10. Sarks JP, Sarks SH, Killingsworth MC. Evolution of soft drusen in age- related macular degeneration. Eye 1994;8:26983. 11. The Age-Related Eye Disease Study 2 (AREDS2) Research Group*. Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration: The Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial. JAMA. 2013;309(19):20052015. doi:10.1001/jama.2013.4997 12. Abdelsalam A, Del Priore L, Zarbin MA. Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation- induced regression. Surv Ophthalmol 1999;44:129. 13. Tombran-Tink J, Shivaram SM, Chader GJ, et al. Expression, secretion, and age-related downregulation of pigment epithelium-derived factor, a serpin with neurotrophic activity. J Neurosci 1995;15:49925003. 14. de Carlo TE, Bonini Filho MA, Chin AT, et al. Spectral-domain optical coherence tomography angiography of choroidal neovascularization. Ophthalmology. 2015;122(6):1228-38. [14] [15] [16] [17] [18] [19] [20] [21][22] Learn more\"),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='What Are Retinal Drusen? Written by WebMD Editorial Contributors Medically Reviewed by Timothy G. Murray,MBA,MD,FACS on August 01, 2025 4 min read Retinal drusen are yellow/white-colored spots seen under the retina of your eye that are made up of proteins and a type of fat called lipids. The retina is the layer of cells lining the inside surface of the back of your eye that sends signals to your brain and enables you to see. Small drusen may not cause problems for some people, but larger drusen can increase your risk of a medical condition called age-related macular degeneration (AMD). Drusen can be a sign that you already have age-related macular degeneration. In age-related macular degeneration, the cells of the macula, a part of the retina, start to change because of aging. Dry macular degeneration comes first. Wet macular degeneration is an advanced form of the condition. A second type of advanced maculardegeneration is called geographic atrophy (GA). Types of Retinal Drusen There are two types of retinal drusen: hard and soft. Hard drusen are small, dotted, yellow-colored, and abnormal tissue growths. When the drusen is hard, there is a lower risk of losingyour vision in the future. Soft drusen look large and raised, are pale yellow or grayish-white in color, and have a dome shape. There is a higher risk of losing vision in the future if you have many large or medium-sized soft drusen. Causes of Retinal Drusen Retinal drusen can occur as a result of aging. It is common to see drusen in people over 60 years of age. 90% of drusen are caused by dry macular degeneration. The remaining 10% of drusen are caused by wet macular degeneration. In dry macular degeneration, your central vision becomes blurry or lessens because of the thinning of the part of your retina called the macula. Dry macular degeneration can cause you to lose vision slowly over time. In wet macular degeneration, your vision gets blurred or you may see a blind spot in your field of vision. This condition is caused by abnormal blood vessels that break, bleed, or leak fluid into the macula and may cause sudden and severe loss of vision. Symptoms Sometimes you may have retinal drusen and not experience any symptoms. You may not find out you have them until your doctor seesthem during a routine eye exam. Having a few small drusen doesnt mean that you have eye disease. When you have a lot of larger drusen, it can mean that you have age-related macular degeneration. You could then see the symptoms linked to age-related macular degeneration: Dim or cloudy vision Difficulty seeing when the light changes from bright to dim light A blank or blurry spot in your central vision Risk Factors Retinal drusen can be commonly seen in people over 60 years of age. But other factors can increase your risk of getting this condition: Family history of retinal drusen Smoking tobacco High blood pressure Excessive body fat (obesity) High blood cholesterol People of Caucasian descent have a higher risk of both retinal drusen and age-related macular degeneration. When to See a Doctor You should see a doctor or eye specialist if you experience any difficulty seeing. Get urgent medical attention if you have severe or serious loss of vision. Treatment Retinal drusen are common in people over 60 years of age. Small drusen may not cause any difficulties at all for some people. SubscribeEye Health Guide'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='Vitamins: You may lose vision if your age-related macular degeneration reaches an advanced stage. If you have a lot of large and medium- sized drusen, your doctor may ask you to take AREDS2 formula vitamins, which can slow down the growth of your condition to an advanced stage by about 25%. AREDS2 formula vitamins are a combination recommended by the Age-Related Eye Disease Study (AREDS), an NIH clinical trial. According to the results of the study, when these vitamins are taken, they reduce the risk of getting the disease by as much as 19 % and/or reduce the risk of vision loss by 25%. The formula has Vitamin C, Vitamin E, the antioxidants lutein and zeaxanthin, and minerals zinc and copper in specific amounts. Lifestyle and dietary changes: Your doctor may ask you to make lifestyle changes, such as stopping smoking. They may recommend that your diet has more vegetables, fruits, and fatty fish like salmon and mackerel. You may be asked to eat less red meat in order to lower your blood cholesterol. Early detection:Your doctor may ask you to monitor your vision at home if you have drusen, using a test called the Amsler Grid. If you candetect wet macular degeneration early on, your doctor may be able to help you make your vision stable or improve it with injected medication. With early detection, you can slow down complications and minimize loss of vision. Sources Update History Print View privacy policy, copyright and trust info Save NEXT ARTICLE Eyelid Bump'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Figure 1: Diabetic macular edema. A: Schematic diagram of DME. Microaneurysms, or damaged capillaries, resulting from the breakdown of the bloodretina barrier leak fluid to the extracellular space, resulting in a swollen retina. Resorption of DME is dependent on the adjacent capillaries and retinal pigment epithelium. Resorption of fluid may leave behind lipoprotein residues, seen here as exudates. B: OCT image of DME. Published online with permission from the AAO. Diabetic Macular Edema All content on Eyewiki is protected by copyright law and the Terms of Service. This content may not be reproduced, copied, or put into any artificial intelligence program, including large language and generative AI models, without permission from the Academy. Disease Definition Diabetic macular edema (DME) is the accumulation of excess fluid in the extracellular space within the retina in the macular area, typically in the inner nuclear layer, outer plexiform, Henles fiber layer, and subretinal space. Pathophysiology Chronic hyperglycemia-related accumulation of advanced glycated end products disrupts the bloodretina barrier (BRB), leading to endothelial cell junction breakdown and pericyte loss. The inner BRB is composed of endothelial cells in the retinal capillaries, while the outer BRB is composed of retinal pigment epithelium cells. When the BRB is altered, interstitial fluid is accumulated within and underneath the retina through leakage of molecules dependent on intact cell-to-cell junctions (Figure 1). Evidence also shows that DME has an inflammatory component, with several chemokines and cytokines involved in its development. These include vascular endothelial growth factor (VEGF), interleukins (ILs), matrix metalloproteinases, and tumor necrosis factor (TNF). Upregulation of multiple pathways leads to increased inflammation, oxidative stress, and vascular dysfunction. Significant changes are seen in the neurovascular unit, altering the homeostasis between astrocytes, ganglion cells, Mller cells, retinal vascular endothelial cells, and amacrine cells. Retinal vascular permeability changes also involve the kallikrein-kinin system, which induces vasorelaxation via bradykinin and nitric oxide. Natural History DME can develop at any stage of diabetic retinopathy (DR), from mild nonproliferative diabetic retinopathy (NPDR) to proliferative diabetic retinopathy, but is more frequent as the severity of DR increases. DME occurring near to or at the fovea is more likely to result in blurred vision and metamorphopsia. When the DME involves or threatens the fovea, the risk of moderate visual loss (defined as a 3-line decrease in visual acuity (VA), equivalent to a doubling of the visual angle) increases; in the Early Treatment of Diabetic Retinopathy Study (ETDRS) study, visual loss decreased by 24% over 3 years without treatment. The disease course is variable, with some eyes having chronic persistent DME spanning several years, while other eyes have rapid spontaneous resolution, although the risk of recurrence is always present. Prevalence The Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) found that the 25-year incidence of DME in people with type 1 diabetes mellitus (T1DM) was 29%. The Diabetes Control and Complications Trial (DCCT) reported that 27% of people with T1DM had DME within 9 years of diabetes onset. The WESDR also found that 25.4% of people with type 2 DM who used insulin and 13.9% of those who did not use insulin had DME. Yau et al. estimated the global prevalence of DME to be 6.8% among people with DM. In the United States, prevalence rates are between 2.7% to 3.8%, with non-Hispanic White people less likely to have DME than non-Hispanic Black people. Risk Factors Risk factors for DME and DR are similar. These include a longer DM duration, poor control of DM with elevated glycolated hemoglobin A1c (HbA ) levels, hypertension, and hyperlipidemia. Other secondary risk factors include impaired renal function and the use of thiazolidinediones. Prevention Primary prevention of DME involves intensive control of DM, blood glucose and lipid levels, hypertension, and other systemic risk factors. The Diabetic Retinopathy Clinical Research (DRCR) Protocol W investigated whether aflibercept injections in eyes with baseline moderate-to-severe NPDR could prevent the eventual development of center-involved DME (ci-DME) with vision loss. Vision loss was defined as a 10-letter decrease in VA at 1 visit or a 5-to 9- letter decrease at 2 consecutive visits, with the decrease in vision attributed to the ci-DME. The 2-year cumulative probability of developing ci-DME with vision loss was 4.1% in patients given aflibercept vs 14.8% of patients given sham injections. However, there was no significant difference in mean VA between Article initiated by: Cris Martin P. Jacoba, MD, Margalit G. Mitzner, Neelakshi Bhagat, MD, FACS, Marco Attilio Zarbin, MD, PhD, FACS, Jerry Cavallerano, OD, PhD, Paolo A. Silva, MD, Lloyd P. Aiello, MD, PhD, Mohamed A. Elmasry, MD, PhD All contributors: Theodore Leng, MD, MS,Koushik Tripathy, MD (AIIMS),Neelakshi Bhagat, MD, FACS,Jennifer I Lim MD,Cris Martin P. Jacoba, MD,David Kitchen,Galin J. Spicer, MD MBA Assigned editor: Neelakshi Bhagat, MD, FACS Review: Assigned status Update Pending by Neelakshi Bhagat, MD, FACS on July 6, 2025. [1][2] [3] [4] [5] [6][7][8] [9] [10] [11] [10] [12][13][14] 1c[15][16][17] [18] Learn more Accept'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content=\"Figure 2: Circinate exudates. A: Blue arrows - Circinate exudates, defined as exudates arranged in a circular appearance. B: OCT b- scan across the fovea, confirming the presence of DME associated with an elevated foveal contour. The patients best-corrected vision was 20/32. Figure 3: Dense macular exudates involving the fovea. A: Blue arrow Dense foveal exudates. B: Red arrow OCT b-scan across the fovea, confirming the presence of DME and the dense foveal exudate. The patients best-corrected vision was 20/200. Figure 4: Basic structural changes in DME seen on OCT. Yellow bracket Generalized retinal swelling. Blue arrow Cystoid macular edema. Red arrow Subretinal fluid. the treatment groups. From baseline to the 2-year checkup, eyes treated with sham injections had a mean (SD) change of 2.0 (6.1) letters, while eyes treated with aflibercept had a mean 0.9 (5.8) letter change (adjusted mean difference 0.5 letters; 97.5% CI, 1.0 to 1.9 letters; P = 0.47]. However, at present the use of anti-VEGF injections for the prevention of ci-DME is not the standard of care. Diagnosis History DME is suspected in patients with any level of DR who present with blurred vision or metamorphopsias. A detailed history including the approximate date of onset of diabetes, the use of insulin versus oral antihyperglycemic agents, and the quality of metabolic control (e.g., HbA level) should be elicited. Any associated medical problems such as hypertension, hypercholesterolemia, renal disease, and thyroid disease should be identified, along with a thorough review of medications. It should be noted that mild to extensive DME may be present without symptoms evident to the patient. Physical Examination Patients suspected of having DME may undergo a detailed biomicroscopic examination with a slit lamp and indirect ophthalmoscope. Historically, DME classifications were based on the 1980s-era ETDRS definitions of clinically significant macular edema (CSME). The specific criteria for diagnosing CSME were: 1. Retinal thickening at or within 500 m of the center of the fovea 2. Hard exudates at or within 500 m of the center of the fovea if adjacent to an area of retinal thickening 3. Retinal thickening of at least 1 disc area, any portion of which is within 1500 m (approximately 1 disc diameter) from the center of the fovea Thus, CSME, as defined by the ETDRS, is a clinical diagnosis made by slit-lamp examination using a contact lens. While clinical examinations remain essential for the full evaluation of DME, optical coherence tomography (OCT) is now routinely used to complement physical examination in the diagnosis of DME. The management of DME is currently based on the central subfoveal thickness (CST) on the macular OCT. Signs Macular thickening with or without hard exudates may be seen on stereo biomicroscopy. However, some eyes may present without apparent signs of retinal thickening on clinical examination, despite significant OCT-observed DME. Thickening can occur in various patterns, including focal, multifocal, and diffuse areas of retina thickening. Despite these terms being frequently used, there are no well-established standard, consistently used definitions. In the ETDRS guidelines, focal leakage resulting from microaneurysms may be treated with a fluorescein angiographyguided focal laser, while diffuse capillary leakage is from a more widespread breakdown of the BRB and may be treated with grid laser. Hard exudates in various patterns may also be seen, including circinate rings and focal aggregations of exudates (Figures 23). Hard exudates consist of lipoprotein residues of serous leakage from damaged vessels, and can serve as biomarkers for DME. Symptoms DME may present with decreased visual acuity (VA), metamorphopsia, changes in color perception, and difficulty reading, although it may also present asymptomatically. Vision and DME Studies show a poor to modest correlation between VA and CST on OCT, within the range of 0.30.5. Over 2 years, only around 12%14% of the change in VA can be attributed to the change in thickness. In a study by the DRCR Network, the slope of the best fit line shows an approximately 4.4 letter improvement (95% CI, 3.55.3) for every 100-micron decrease in CST at baseline. Interestingly, on follow-up after treatment with macular laser photocoagulation, there were some eyes with paradoxical improvement in VA with increased CST (7-17% at different time points) and paradoxical worsening of VA with decreased CST (18-26% at different time points). These findings highlight how OCT measurements cannot be used as a perfect surrogate for visual acuity; however, in clinical and research settings, the technology remains an important tool. The DRCR Network has recommended a 10% change in CST to indicate a real change that can be considered in clinical decision-making. Diagnostic Procedures Optical Coherence Tomography (OCT) Within recent years, OCT has quickly become an important ancillary procedure in diagnosing and treating DME. Three basic structural changes can be seen on OCT: retinal swelling, cystoid macular edema, and subretinal fluid (Figure 4). Macular scans can quickly and accurately identify even subtle areas of thickening, along with quantitative metrics for different areas. Changes in the anatomic distribution of DME can be monitored over time, especially the fluids relationship to the fovea. This information has clinical and research implications for the evaluation and management of DME. The International Council of Ophthalmology's guidelines for diabetic eye care, published in 2018, adopted the clinical entities of center-involved DME (ci-DME) and non-centerinvolved DME (non-ciDME) for the evaluation of macular fluid (Figure 5), as follows: 1. Center-involved DME: Retinal thickening in the macula that involves the central subfield zone (1 mm in diameter) 2. Non-centerinvolved DME: Retinal thickening in the macula that does not involve the central subfield zone (1 mm in diameter) [18] 1c [19] [20] [21][22] [22] Learn more\"),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content=\"Figure 5: Montage of center-involved vs non-centerinvolved DME. Top Row A: Non-centerinvolved DME. Retinal thickening does not involve the central 1-mm subfield zone (innermost circle) per the en-face OCT heatmap, as seen on b-scan. Bottom Row B: Center-involved DME. Retinal thickening involves the central 1-mm subfield zone (innermost circle) per the en-face OCT heatmap and b-scan. Published online with permission from the AAO. Figure 6: Disorganization of the retinal inner layers. OCT images showing combinations of presence or absence of DRIL and DME. The central 1-mm area is enclosed in the box. Upper images show segmentation of inner retinal layers, with the white lines demarcating the boundaries between IPL-INL and the INL-OPL. Image credit to: Barham et al., Association of Macular Nonperfusion, Leakage, and DRIL (ARVO poster, 2016) Aside from the location of the swelling, the DRCR Network has given recommendations on CST treatment thresholds based on sex-matched standards. The thresholds were different for each OCT machine; since thickness measurements cannot be compared between different devices, each device has its own normative database and algorithms. In DRCR Protocol T, treatment eligibility thresholds per machine were: 1. Heidelberg Spectralis: 320 m for men and 305 m for women 2. Zeiss Cirrus OCT: 305 m for men and 290 m for women 3. Zeiss Stratus OCT:250 m for both men and women Moreover, OCT is a more sensitive method for objective evaluation of vitreomacular interface abnormalities (VMIA), which include vitreomacular adhesion (VMA), vitreomacular traction (VMT), and epiretinal membrane (ERM). Identifying VMIA is crucial when diagnosing the etiology of macular edema, whether primarily from DME, from secondary causes of VMIA, or combined mechanism macular edema. OCT Biomarkers for DME DME's different OCT features have been associated with disparate prognostic outcomes and treatment responses. [23] Learn more\"),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content=\"Figure 7: External limiting membrane and ellipsoid zone disruption. A: DME with large cystic spaces (blue arrow) and exudates (green arrows). Despite anti-VEGF treatment, DME persisted. The EZ and ELM were still intact, with BCVA of 20/32. B: Five years after photo A, extensive ELM and EZ disruption (red bracket) developed which involved the fovea. A few chronic parafoveal cysts can still be seen. BCVA dropped to 20/63. Figure 8: Epiretinal membrane associated with DME. Dense epiretinal membrane overlying the retinal surface, with an elevated foveal contour and significant intraretinal cystic spaces in a patient with diabetes. Published online with permission from the AAO. 1. Disorganization of the retinal inner layers (DRIL) is thought to represent damaged cells within the inner retinal layers, indicating a disruption in the normal visual pathway from the photoreceptors to the ganglion cells. DRIL is identified on OCT when there is disruption of the demarcating interface lines between the ganglion cell-inner plexiform complex, inner nuclear layer (INL), outer plexiform layer (OPL), and outer nuclear layer. Eyes with DRIL have a worse baseline and final VA despite antivascular endothelial growth factor (VEGF) injections and have an almost 8 greater risk for poor visual recovery. In contrast, the resolution of DRIL results in better visual outcomes (Figure 6). DRIL was better correlated with VA than either glycemic status and CST. 2. External limiting membrane (ELM) and ellipsoid zone (EZ) disruption strongly correlate with baseline and final BCVA. At the same time, some studies found that restoration of the EZ was a requirement for good visual recovery (Figure 7). The ELM connects a row of zonular adherents to the photoreceptor cell bodies, while the EZ represents the isthmus between the outer and inner segments of photoreceptors. 3. DME associated with VMIA, notably ERM and VMT, has poorer visual outcomes (Figure 8). VMIA have been observed in 7%16% of eyes with DME, with an annual incidence rate of up to 4.5%. The READ-3 trial showed that eyes with VMIA still had a good response to anti-VEGF therapy. Presence of posterior vitreous detachment (PVD) has been associated with improved visual outcomes. Nasrallah et al. reported that DME was present in 55% of eyes with an attached hyaloid, compared with only 20% of eyes with PVD. Hikishi et al. reported only a 25% rate of spontaneous resolution in eyes with attached posterior hyaloid, vs a 55% resolution rate in eyes with PVD. The role of the vitreous and VMIA in DME, which may be related to changes in transvitreal oxygenation, hyalocyte proliferation from vitreous remnants on the ILM, and the present growth factors in the premacular hyaloid, is still being investigated. Fluorescein Angiography Fluorescein angiography (FA) is performed to identify leaking microaneurysms or capillaries to help guide laser treatment, and to identify areas of retinal ischemia. Leakage seen with FA is not synonymous with retinal edema. Focal DME is characterized by focal leakage from microaneurysms or capillaries; in contrast, diffuse DME is characterized by poorly demarcated areas of capillary leakage (Figure 9). Recently, there has been a decreasing trend in the use of FA in the management of DME, likely due to the procedure being more invasive and time-consuming than OCT. Contraindications to the use of FA include pregnancy and allergy associated with the contrast dye. Laboratory Testing Primary laboratory testing for DME should involve checking HbA , blood pressure, and lipid levels. Secondary tests can include hemoglobin (anemia exacerbates diabetic retinopathy and may be associated with diabetic nephropathy); both fasting and postprandial blood sugar; urea, creatinine, and urine microalbumin levels, and a thyroid panel. Differential Diagnosis Other causes of DME include retinal vein occlusion, ruptured macroaneurysm, Irvine-Gass syndrome, radiation retinopathy, hypertensive retinopathy, subfoveal choroidal neovascularization, retinal vein occlusion, and VMIA. OCT and FA ancillary diagnostics can help to identify these differential diagnoses (Figures 1011). Management Management of DME includes strict control of diabetes, blood glucose, hypertension, and hypercholesterolemia. This can be achieved by pharmacologic methods or by nonpharmacologic methods, such as diet modification, weight loss, and exercise. Pharmacotherapy At present, anti-VEGF agents are the first-line treatment for DME. The FDA approved ranibizumab for DME in 2012, aflibercept in 2014, and brolucizumab and faricimab in 2022. Since 2005, intravitreal bevacizumab has been used off-label for ocular conditions. DRCR Network Anti-VEGF Treatment Algorithm The DRCR anti-VEGF treatment algorithm states that 6 monthly injections should be given unless VA is 20/20 or better and CST is <320 m for men or <305 m for women (as measured by the Heidelberg Spectralis), in which case treatment may be withheld starting on the 4th month. At the 6th visit, if stability in vision or CST has been achieved (based on the previous 2 visits' findings) or DME has resolved, further treatment may be withheld. Stability is defined as: 1. Lack of improvement No BCVA increase of 5 letters (approximately 1 line on a Snellen chart) No decrease in OCT-measured CST 10% (per OCT imaging) 2. No worsening BCVA decreases by 5 letters (approximately 1 line on a Snellen chart) in the setting of persistent DME OCT-measured CST increases by 10% If there is worsening on follow-up, anti-VEGF treatment is resumed. In general, eyes showing stability may be followed up in 34 months, or sooner as needed. Withholding injections does not require 20/20 vision or a dry macula, only evidence of stability over the previous 2 or more visits. DRCR Protocol I issued the first anti-VEGF as-needed treatment algorithm for DME, as long-term data show that even without using a monthly treatment protocol, eyes with persistent [24] [25][26][27] [24] [28][29][30][31][32] [33] [34][35] [36][37] [38] [39] [40] [41][42][43][44] [45] 1c [46] Learn more\"),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Figure 9: Focal and diffuse DME. A and B: Fundus photo showing circinate exudates, with adjacent microaneurysms and leakage seen on FA. C and D: Fundus photo with subtle signs of macular thickening, with diffuse, poorly demarcated capillary leakage seen on FA. Published online with permission from the AAO. Figure 10: Pseudophakic cystoid macular edema/Irvine-Gass Syndrome. A: Color fundus photograph of an optic nerve head and macula 3 months after complex cataract surgery. A small incidental grayish-yellow adult vitelliform dystrophy lesion is present in the subfoveal region (circled). B: A mid-phase FA image demonstrates cystic hyperfluorescence, with a classic petaloid pattern. As is typical in eyes with pseudophakic CME, there is mild hyperfluorescence of the nasal portion of the optic nerve head. C: OCT shows cystic retinal thickening and a subfoveal vitelliform lesion. D: Following 8 weeks of topical steroidal and nonsteroidal anti-inflammatory therapy, OCT images indicate that the CME has fully resolved. Published online with permission from the AAO. DME often maintain good BCVA over the long term in clinical trial settings. Outside of trial settings, the 5-year extension phase of Protocol T showed that CST remained stable among eyes given anti- VEGF injections; however, mean BCVA worsened between the 2- and 5-year time points. On average, patients are given 68 injections in the first year, 24 injections in the second year, and 01 injections beginning the third year. Clinical Considerations for Treating DME With Anti-VEGF Agents Observation is recommended for eyes with ci-DME and VA of 20/25 or better. This recommendation is based on the findings of DRCR Protocol V, where patients were randomized to receive aflibercept injections, macular laser, or no treatment (observation). At the 2-year endpoint, the mean BCVA was 20/20, and the rates of 5-letter vision loss were similar among all 3 groups (16%19%). Given the risks of ocular infection and the higher costs associated with intravitreal injections, observation is a viable option in these patients if they can reliably follow up and receive appropriate therapy when there is clinical deterioration. In contrast, among eyes with ci-DME presenting with 20/50 vision or worse, Protocol T study results showed that aflibercept was superior to both ranibizumab and bevacizumab, with area-under- the-curve analyses showing better visual outcomes over 1 year. However, the superiority of aflibercept over ranibizumab was not maintained at the 2-year follow-up visit. Bevacizumab thinned the retina the least; however, all 3 medications had similar visual outcomes among eyes with baseline VA of 20/40 or better. Not all treatments result in complete resolution of DME. In Protocol I, 40% of eyes still showed persistent DME (defined as never having a CST <250 m through 6 months, as seen on time-domain OCT) after 2 years. Eyes given bevacizumab were more likely to have persistent DME than eyes given aflibercept. The percentage of eyes with complete resolution increased with each ranibizumab or aflibercept injection. At the 3-year follow-up visit, eyes with chronic persistent DME still had a significant (7-letter) mean improvement in VA over baseline, though lower than the 13-letter mean improvement in eyes with complete DME resolution. Importantly, only 3.4% of eyes with chronic persistent DME lost 2 lines of vision over 2 years regardless of the type of anti-VEGF treatment they received. To summarize, in clinical trial settings, a substantial proportion of eyes with persistent DME still had 2 lines of improvement in vision over the long term, with very few eyes developing considerable vision loss. For eyes that do not respond optimally to one anti-VEGF agent, switching to another is a treatment option. The switch is typically from bevacizumab to either ranibizumab or aflibercept, or from ranibizumab to aflibercept. The rationale for switching is that aflibercept has 100 times more affinity for VEGF-A than bevacizumab or ranibizumab, while concurrently binding placental growth factor and VEGF-B. Aflibercept also has a longer half-life and can negate more cytokines that promote DME development. Most studies looking at switching were retrospective and showed a significant reduction in CST; however, visual outcomes varied. Some eyes may be delayed responders to anti-VEGF treatment, and need more than the initial 36 monthly injections to show significant improvement, though they eventually catch up with immediate responders. It may be viable to continue treatment with the same medication if there is at least a trend of continued improvement, as bevacizumab and ranibizumab are more cost-effective options. Caution is warranted for switching, as any clinical improvement may be due to continued treatment among delayed responders instead of due to a shift in medications. DRCR protocol AC was a randomized controlled trial evaluating the relative efficacy of administering aflibercept monotherapy vs bevacizumab first with a switch to aflibercept (step therapy) in eyes with suboptimal response despite treatment. A total of 312 eyes with moderate vision loss from ci-DME were enrolled. Over a 2-year period, the mean improvement in VA was 14.0 letters in the bevacizumab-first group and 15.0 letters in the aflibercept-monotherapy group (adjusted difference, 0.8 letters; 95% CI, 0.9 to 2.5; P = 0.37). At 2 years, mean changes in VA and retinal CST were similar in the two groups. Steroids Intravitreal steroids improve vision and decrease retinal thickness, as there is an inflammatory component to DME. Steroids have powerful anti-edematous and anti-inflammatory effects, as they decrease several pro-inflammatory mediators (IL-6, IL-8, TNF- , monocyte chemotactic protein-1, intercellular adhesion molecule-1, VEGF, etc). However, long-term results have not shown maintenance of initial clinical improvement. In DRCR Protocol I, although the group given intravitreal triamcinolone had a similar response with ranibizumab in the first 6 months, vision declined due to cataracts. Even with cataract surgery, the final vision did not recover to the levels seen in the group given ranibizumab. In Protocol U, eyes with persistent DME despite at least 6 ranibizumab injections were randomized to continue [47] [48] [49] [50] [23] [47] [51] [52] [53] [54] [55][56][57][58][59][60][61][62][63][64][65][66][67][68] [69][70] [71] [72] [47] Learn more'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content=\"Figure 11: Vitreomacular traction with secondary macular edema. A: Color fundus photograph of the right eye with pseudohole and epiretinal membrane with tractional macular edema. B: OCT image of same patient showing vitreomacular traction, epiretinal membrane, and resulting macular edema. C: OCT of the same eye after vitrectomy surgery with epiretinal membrane peeling. Published online with permission from the AAO. ranibizumab monotherapy or shift to ranibizumab plus dexamethasone (Ozurdex). At 6 months, the average visual gain was similar in both groups, although CST improvement was greater in the combination group. Phakic eyes given intravitreal steroids often develop cataracts needing surgery, and are at risk for intraocular pressure (IOP) elevations leading to glaucoma. Landmark Pharmacotherapy Studies Anti-VEGF Agents Bevacizumab: Bevacizumab is a recombinant humanized monoclonal immunoglobulin G1 (IgG1) antibody that binds VEGF. Bevacizumab is given off-label for the treatment of DME, and remains the most cost-effective treatment option among anti- VEGF medications. In the BOLT study, intravitreal bevacizumab (1.25 mg), given at 6-week intervals, was reported to be more effective than modified ETDRS focal/grid laser in terms of VA improvement at 12 months. In DRCR Protocol T, a comparison between bevacizumab, ranibizumab, and aflibercept, 1-year results showed that bevacizumab thinned the retina the least. However, all 3 medications had similar visual outcomes among eyes with baseline vision of 20/40 or better. A study from The Pan-American Collaborative Study Group found improvements in BCVA and reduced macular thickness (seen on OCT) at 24 months with intravitreal bevacizumab doses of 1.25 mg2.5 mg. Ranibizumab: Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds and inhibits VEGF-A. It is FDA approved for the treatment of DME. 1. DRCR Protocol I was the first definitive phase 3 study demonstrating the effectiveness of ranibizumab for DME treatment. Four treatment arms were compared: ranibizumab with immediate grid/focal laser; ranibizumab with macular laser given only for at least 6 months of persistent DME; intravitreal triamcinolone with immediate macular laser; and macular laser with sham injections. Results showed that ranibizumab, given in as-needed treatment protocol, had efficacy superior to that of laser therapy. At the 1-year end point, eyes treated with ranibizumab gained an average of 89 letters, vs an average gain of only 3 letters seen with laser therapy. Protocol I revolutionized the treatment protocol for DME when it was published in 2011. Before this study, macular laser was consideredfirst-line therapy for DME, a treatment protocol originating from the original ETDRS papers first published in 1985. 2. RISE and RIDE: The 2-year results for ranibizumab 0.3-mg monthly infections showed that 98% of patients maintained vision (lost <15 letters) and 34%45% of patients gained at least 15 letters; the mean VA gain was 10.912.5 letters. Only 45%49% of patients needed macular laser, compared with 91%94% in the control group. No additional benefit was seen with ranibizumab 0.5 mg monthly vs 0.3 mg monthly. Aflibercept: Aflibercept is a soluble decoy receptor that binds VEGF-A, VEGF-B, and placental growth factor with high affinity. It is termed a decoy receptor or a VEGF-trap, as VEGF mistakenly binds with aflibercept instead of the bodys native receptors, reducing VEGFs activity. It is FDA approved for the treatment of DME. In the Da Vinci study, patients with DME were randomly assigned to 1 of 5 treatment regimens: aflibercept 0.5 mg every 4 weeks (0.5q4), 2 mg every 4 weeks (2q4), 2 mg every 8 weeks after 3 initial monthly doses (2q8), or 2 mg as needed after 3 initial monthly doses (2prn); or macular laser photocoagulation. Mean improvements in BCVA in the aflibercept groups at week 52 were 11.0, 13.1, 9.7, and 12.0 letters for the 0.5q4, 2q4, 2q8, and 2prn regimens, respectively, vs 1.3 letters for the laser group. The proportion of eyes with gains in BCVA of 15 ETDRS letters at week 52 in the aflibercept groups were 40.9%, 45.5%, 23.8%, and 42.2%, respectively, vs 11.4% for laser. Mean reductions in CST in the aflibercept groups at week 52 were 165.4 m, 227.4 m, 187.8 m, and 180.3 m, respectively, vs 58.4 m for laser. The PHOTON trial evaluated the use of high-dose aflibercept (8 mg) aflibercept every 12 weeks (8q12) or 16 weeks (8q16) vs conventional dosing of 2 mg every 8 weeks (2q8). When comparing BCVA gains and retinal thinning at 48 weeks, the 8-mg extended interval dosage was noninferior to conventional treatment. There was an increase of 9.2, 8.8, and 7.9 letters and a mean CST reduction of 165 m, 172 m, and 148 m for the 2q8, 8q12, and 8q16 groups at 48 weeks, respectively. Patients in the high-dose group with a 50- m increase in CST or a 10-letter loss from week 12 onwards had their dosing schedule shortened to either 12 or 8 weeks, but 93% of patients remained on dosing intervals of 12 weeks. There was no increase in hypertension in the high-dose group. Faricimab: Faricimab is a novel combined-mechanism inhibitor that binds both angiopoietin-2 and VEGF-A with high specificity and affinity. The 1-year results from the phase 2 BOULEVARD study showed that in patients given faricimab 6 mg, there was a statistically significant VA gain of 3.6 letters over that seen with ranibizumab. Moreover, improvement in diabetic retinopathy severity, as well as reduced CST, was seen with faricimab; it also had a longer time to re-treatment than ranibizumab. There were no unexpected safety concerns. The phase 3 YOSEMITE and RHINE noninferiority trials compared faricimab with aflibercept in patients with DME. The noninferiority primary endpoint of BCVA was achieved with faricimab given every 8 weeks. More than 50% of patients had good results with an every-16-weeks dosing regimen, and more than 70% had good results with faricimab given every 12 weeks or longer. These results demonstrate the potential of faricimab to decrease patients' treatment burden by extending the intraocular durability of anti-VEGF treatment. The FDA approved the use of faricimab for DME as 4 monthly loading doses followed by injections every 14 months, or as a loading dose of 6 monthly injections followed by injections every 2 months. Brolucizumab: Brolucizumab is a single-chain antibody fragment with a high affinity for VEGF. Brolucizumabs low molecular weight of 26 kDa allows for more of the drug to be delivered intraocularly per injection, with the potential for increased durability and effective tissue penetration in the eye. The phase 3 KESTREL and KITE 52-week results found that brolucizumab 6 mg was noninferior to aflibercept in mean improvement of BCVA. More patients taking brolucizumab had CST <280 m without persistent macular fluid than patients taking aflibercept, and >50% of the brolucizumab-treated patients were maintained on q12w dosing after the loading dose was given. However, reports of retinal vascular occlusion (RVO) and retinal vasculitis with intraocular inflammation (IOI) have been reported. Risk factors for developing these adverse reactions include a prior history of IOI or RVO in the 12 months before brolucizumab initiation, female sex, and same-day bilateral injections. The FDA approved the use of brolucizumab for the treatment of DME in June 2022, as a 6-mg injection given every 812 weeks after a loading dose of 5 injections given every 6 weeks. Aflibercept HD: FDA granted approval for the use of 8mg Aflibercept for treating DME in 2023. The results of PHOTON trial for CIDME after 2 years revealed mean improvement in BCVA with standard Eylea of 8.4 letters, 8.8 letters with the 12-week Eylea HD group, and 7.5 letters with the 16-week Eylea HD group. Steroids Triamcinolone: In Protocol B, triamcinolone (1 or 4 mg) preservative-free intravitreal injection was less effective and had more side effects than focal/grid photocoagulation at the 2-year follow-up visit. Dexamethasone: In the 3-year phase 3 MEAD study, dexamethasone 0.7 mg biodegradable implant improved vision by at least 15 letters in 22% of patients. At this dose, 41.5% of patients needed antiglaucoma medications, with 0.6% needing glaucoma surgery. Around 60% of eyes in the 0.7-mg [73] [74] [75] [23] [53] [76] [77] [47] [78] [79] [79] [80] [79] [81] [82] [83] [84] [85][86] [87][88] [89] [90] Learn more\"),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Figure 12: Focal laser for focal CSME. A: Planning of focal laser for focal CSME. Note the identified treatment areas, specifically the leaking microaneurysms that would be highlighted on FA. B: Focal laser-treated areas with parameters. Published online with permission from the AAO. Figure 13: Grid laser for diffuse CSME. A: Planning of grid laser for diffuse CSME. Note the identified treatment area, specifically the outlined region with diffuse edema that would be highlighted on FA. B: Grid lasertreated area with parameters. Published online with permission from the AAO. implant group had cataract surgery. The 0.7-mg implant has been approved by the FDA for DME, and is effective for approximately 36 months. Fluocinolone acetonide: The fluocinolone acetonide (Iluvien) 0.19-mg non-biodegradable implant is a sustained-release device that is effective for up to 3 years when administered intraocularly. It is FDA approved to treat DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in IOP. At the 0.2- g/day dosage, BCVA improvement of at least 15 letters was found in 28.7% of patients, with 38.4% needing anti-glaucoma medications and 4.8% needing glaucoma surgery. The latter figure was reduced to 0% among eyes that did not have a history of IOP elevation with a prior steroid challenge. Complications associate with both the fluocinolone and the dexamethasone implants include cataracts and implant migration. Laser Photocoagulation Before anti-VEGF treatments for DME were approved, the standard treatment for CSME was macular laser photocoagulation. In focal CSME, a focal laser pattern is used to treat leaking microaneurysms identified on the FA that contribute to the retinal edema (Figure 12). In diffuse CSME, intraretinal leakage is noted on the FA from dilated retinal capillary beds or intraretinal microvascular abnormalities without isolated, discrete foci of leakage. A macular grid is done in cases of diffuse macular edema (Figure 13). Laser photocoagulation has been shown to decrease the risk of moderate visual loss (loss of 15 ETDRS letters) from 24% to 12% after 3 years. After the laser treatment is administered, the patient will come back in 3 months for a follow-up examination. If residual CSME is noted, OCT and FA may be performed to evaluate the benefit and location of repeat laser treatment. With the FDA approval of anti-VEGF agents for DME, focal/grid laser is only indicated in patients with non-ciDME. Macular laser remains a viable treatment option for patients with DME, especially in resource-limited countries with decreased access to anti- VEGF agents. Combined Therapy Intravitreal ranibizumab with laser: In Protocol I, intravitreal ranibizumab with prompt (within 1 week) or deferred (after 24 weeks) laser was more effective than focal/grid laser alone for the treatment of ci-DME. Ranibizumab is injected intravitreally at baseline, followed by monthly injections for 4 months followed by the continuation of injections at 16 weeks if the OCT central subfield thickness is 250 um with VA worse than 20/20. Steroid with laser: Protocol B found that intravitreal triamcinolone (IVT) 4 mg plus focal/grid laser (given within a week of injection) was more effective than laser alone at 4 months. However, long- term benefit with this combined therapy was not seen, with mean BCVA better in the laser monotherapy group than the combined therapy group from the 16-month time point until the 2-year end point. Complications of steroid therapy included cataracts, ocular hypertension, and glaucoma. The difference in BCVA could not be attributed fully to the development of cataracts. In Protocol I, 6-month VA improvement in eyes given IVT with prompt laser was comparable to that seen in eyes given ranibizumab, but vision declined afterward until the 2-year time point. A subgroup analysis in pseudophakic eyes given IVT showed that visual improvement was significantly better than in phakic eyes, with 1- and 2-year results comparable to pseudophakic eyes given ranibizumab. Intravitreal ranibizumab with peripheral targeted retinal photocoagulation (TRP): The DAVE study was a phase 1/2 clinical trial that compared ranibizumab plus peripheral TRP and ranibizumab monotherapy for reduce the number of required anti-VEGF injections. Peripheral TRP was defined as retinal photocoagulation administered outside the macula to areas of retinal capillary nonperfusion identified on widefield FA. The nonperfused hypoxic retina is thought to upregulate hypoxia-inducible factors and cytokines, including VEGF and erythropoietin, with small studies suggesting that TRP can decrease the anti-VEGF treatment burden. At the 3-year endpoint, there was no evidence that combined ranibizumab plus TRP reduced treatment burden or improved vision outcomes compared with ranibizumab alone. Surgery No well-constructed studies show a definitive benefit of pars plana vitrectomy (PPV) for managing DME. The theoretical basis for PPV as a treatment option comes from reports that it increases vitreous oxygenation in ischemia, leading to decreased VEGF production, and from the observation that DME is less common among eyes with PVD. Vitreous viscosity also significantly decreases after PPV, which may bring about a greater diffusion of pro-inflammatory cytokines away from the macula. Other studies suggest that PPV plus internal limiting membrane (ILM) peeling brings better resolution of the tractional forces at the vitreoretinal interface known to worsen DME. This procedure also prevents proliferating astrocytes from using the ILM as a scaffold, which may lead to ERM. In a systematic review looking at PPV for DME, CST was significantly decreased by 102 m, and a nonsignificant VA increase of 2 letters was observed. However, the anatomic benefit was not maintained by the 12-month time point. A similar meta-analysis looking at PPV plus ILM peeling vs PPV alone showed no significant difference in postoperative vision and macular thickness between the treatments. DRCR Protocol D, a prospective study of eyes with DME and VMT, found that at 6 months after surgery, 43% of eyes had a reduction in CST to <250 m. However, the median VA did not change at 6 months. In 38% of eyes, the median visual acuity improved by 10 letters, and in 22% the median VA decreased by 10 letters. A post hoc analysis of Protocol I showed that previously vitrectomized eyes with ci-DME given anti-VEGF treatments had no improved clinical outcomes compared with non-vitrectomized eyes. Treatment Complications The complications listed below may arise from the various treatment modalities. The per-injection risk of developing complications is also listed below, when available. Intravitreal Injections Endophthalmitis (0.019%0.05%) Intraocular inflammation (0.09%0.4%) Retinal tears/detachment (0.01%0.08%) Increase in IOP (for intravitreal steroids, IOP 21 mmHg in 45% at 1 month, 20% at 3 months, and 13% of eyes at 6 months post-injection.) Cataract (common after intravitreal steroid injections. By year 3, 83% of patients given IVT needed cataract surgery.) Subconjunctival hemorrhage (10%) [91][92] [9] [47] [47][93] [94] [95][96][97][98][99] [100][101][102][103][104][105] [106] [107] [108] [109] [110] [111] [112][113][114] [115] [116][117][118] [119] [120] [121] Learn more'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Vitreous hemorrhage Laser Photocoagulation Subretinal fibrosis Extension of the laser scar into the fovea Choroidal neovascular membrane Paracentral scotoma Decreased visual acuity Pars Plana Vitrectomy Retinal tears and retinal detachment Vitreous hemorrhage Elevated intraocular pressure Endophthalmitis Cataract Prognosis Clinical factors associated with better visual outcomes with anti-VEGF treatment include lower HbA1c, younger age, less severe diabetic retinopathy, absence of ERM, quick and consistent CST decreases, and absence of prior panretinal photocoagulation. In terms of anatomic outcomes, eyes with hard exudates within the 6-mm foveal center had a larger CST decrease at the end of 1 year. The presence of exudates may be a marker of BRB abnormalities typical of DME responsive to anti-VEGF therapy. Eyes that lack exudates may have other underlying mechanisms of retinal thickening, including cystoid degeneration, traction, or ischemia. In contrast, eyes with high baseline CST ( 570 m) had a significantly higher chance of developing persistent DME despite monthly ranibizumab therapy. In terms of response to macular laser therapy, the ETDRS reported that worse clinical outcomes were associated with higher blood lipid levels, presence of hard exudates, and diffuse edema. Matsunaga et al. looked at eyes with DME treated with at least 1 dose of anti-VEGF agents that were then awere lost to follow-up (LTFU) for at least 6 months before returning to the clinic. Vison worsened significantly at the initial return visit, to ~20/69 from ~20/52; however, at the 3-, 6-, and 12-month follow-up visits and the final checkup, vision recovered with no significant differences from baseline. OCT CST also showed similar trends. Gao et al. found that 25% of patients with NPDR and DME had no follow-up visits for at least 1 year after receiving 1 anti-VEGF injection. Factors associated with being LTFU included Hispanic ethnicity (OR 1.7) and American Indian/Pacific Islander/multiple ethnicities (OR 2.6). Lower adjusted gross income and decreasing baseline vision were also factors significantly associated with LTFU. Some studies have shown increased risks of end-stage renal disease in patients with concurrent DME. Assessment of renal function should be strongly encouraged in patients with chronic DME. Future Directions Numerous pharmacotherapy trials for DME treatment are underway. The development of a long-acting anti-VEGF agent that could remain effective in the vitreous for multiple months or years would significantly decrease the treatment burden for patients needing monthly injections. Novel pharmacotherapies based on different mechanisms of action include anti-VEGF designed ankyrin repeat proteins, growth factor inhibitors, anti-inflammatory medications, hormone modulators, acetylcholine receptor blockers, insulin-like growth factor 1 receptor blockers, and neuroprotective/antiapoptotic agents. Port delivery systems that are FDA approved for wet AMD are in development to treat diabetic retinopathy and DME. These experimental therapies have the potential to significantly decrease the burden of treatment while restoring vision to patients with DME in the coming years ahead. An ophthalmic suspension, OCS-01, a topical dexamethasone that is formulated with nanoparticle technology, in a completed Phase 2 trial has shown a higher reduction in CMT with OCS-01 compared to control. Further phase 3 studies are pending yet. Artificial intelligence (AI) plus tele-ophthalmology models are being used to develop screening tools for diabetic retinopathy and DME. These models can detect the retinal complications of diabetes remotely, and if this technology is placed in the offices of internists and endocrinologists, it may allow for early detection and timely intervention. Further reading 1. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54(1):1-32 2. Diabetic Retinopathy Clinical Research Network Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010; 117(6):1064-1077. 3. Early Treatment Diabetic Retinopathy Study: Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103(12):1796-1806. 4. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12 month data: report 2. Ophthalmology. 2010; 117(6):1078-1086.e2. 5. Schachat AP. A new approach to the management of diabetic macular edema. Ophthalmology. 2010;117(6):1059-1060. References 1. Otani T, Kishi S, Maruyama Y. Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol. 1999;127(6):688-693. 2. Yanoff M, Fine BS, Brucker AJ, et al. Pathology of human cystoid macular edema. Surv Ophthalmol. 1984;28(suppl):505-511. 3. Xu H-Z, Le Y-Z. Significance of outer bloodretina barrier breakdown in diabetes and ischemia. Invest Ophthalmol Vis Sci. 2011;52(5):2160-2164. 4. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615-1625. 5. Del Zoppo G. The neurovascular unit in the setting of stroke. J Intern Med. 2010;267(2):156-171. 6. Gao B-B, Clermont A, Rook S, et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med. 2007;13(2):181-188. 7. Jeppesen P, Aalkjr C, Bek T. Bradykinin relaxation in small porcine retinal arterioles. Invest Ophthalmol Vis Sci. 2002;43(6):1891-1896. 8. Parpura V, Basarsky TA, Liu F, et al. Glutamate-mediated astrocyte neuron signalling. Nature. 1994;369(6483):744-747. 9. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Arch Ophthalmol. 1985;103:1796-1806. 10. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy XV: the long-term incidence of macular edema. Ophthalmology. 1995;102(1):7-16. 11. White NH, Sun W, Cleary PA, et al. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes. 2010;59(5):1244-1253. 12. Varma R, Bressler NM, Doan QV, et al. Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmology. 2014;132(11):1334-1340. 13. Wong TY, Klein R, Islam FA, et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol. 2006;141(3):446-455.e441. 14. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556-564. [122][123] [124] [125] [126] [127] [128] [129] [130][131] Learn more')]"
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cleaned_docs"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "913f8080",
   "metadata": {},
   "source": [
    "Chucking\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "4d2ed2c1",
   "metadata": {},
   "outputs": [],
   "source": [
    "#splitting documents into smaller chunks\n",
    "def text_split(cleaned_docs):\n",
    "    text_splitter = RecursiveCharacterTextSplitter(\n",
    "        chunk_size=85,\n",
    "        chunk_overlap=16\n",
    "    )\n",
    "    text_chunks = text_splitter.split_documents(cleaned_docs)\n",
    "    return text_chunks"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "00c1fff8",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of text chunks: 1015\n"
     ]
    }
   ],
   "source": [
    "text_chunks=text_split(cleaned_docs)\n",
    "print(f\"Number of text chunks: {len(text_chunks)}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "cebe00dc",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Normal Retina Comprehensive KB Entry 1 Short Definition A normal retina is a'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='retina is a multilayered neural tissue lining the back of the eye, responsible for'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='responsible for converting light into visual signals. On OCT imaging, the normal'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='the normal macula shows a clean foveal depression, well-defined retinal layers, and'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='layers, and absence of any fluid, cysts, or abnormal elevations. 2 Basic Anatomy of'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Anatomy of the Retina (Layer by Layer) From inner (vitreous side) to outer'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='side) to outer (RPE/choroid side), the key layers are: - Internal Limiting Membrane'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Membrane (ILM) - Nerve Fiber Layer (NFL) - Ganglion Cell Layer (GCL) - Inner'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='(GCL) - Inner Plexiform Layer (IPL) - Inner Nuclear Layer (INL) - Outer Plexiform'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Outer Plexiform Layer (OPL) - Outer Nuclear Layer (ONL) - External Limiting Membrane'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Membrane (ELM) - Photoreceptor Inner Segments and Outer Segments - Ellipsoid Zone'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Ellipsoid Zone (EZ) - Retinal Pigment Epithelium (RPE) - Bruchs Membrane and Choroid'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='and Choroid beneath 3 OCT Characteristics of a Healthy Macula - **Foveal'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- **Foveal Depression:** Smooth, symmetric curvature with thinnest point at the'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='point at the fovea. - **Layer Clarity:** All retinal layers appear sharply'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='appear sharply demarcated. - **No Fluid:** No intraretinal cysts (IRF) and no'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='(IRF) and no subretinal fluid (SRF). - **Intact Ellipsoid Zone:** Strong'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Zone:** Strong hyperreflective band indicating healthy photoreceptors. - **Normal'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- **Normal RPE Line:** Continuous, smooth hyperreflective line with no elevation. -'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='no elevation. - **Stable Thickness:** Normal macular thickness without thickening or'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='thickening or thinning. 4 What Is NOT Present in a Normal Retina (Important for'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='(Important for Classification) - No cystoid spaces. - No drusen or sub-RPE deposits.'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='deposits. - No pigment epithelial detachment (PED). - No choroidal'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- No choroidal neovascularization or subretinal hyperreflective material. - No'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='material. - No edema, exudates, or hemorrhage. - No tractional changes or disruption'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='or disruption of the photoreceptor bands. 5 Physiological Variations (Still'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='(Still Considered Normal)'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- Mild inter-individual variation in foveal pit shape. - Slight differences in'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='differences in reflectivity due to age. - Occasional benign vitreomacular adhesion'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='adhesion (VMA) without traction. 6 Importance in Machine Learning / Classification A'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='A normal OCT class acts as: - The baseline template for retinal architecture. - The'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- The reference to detect abnormalities such as fluid, drusen, or neovascular'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='or neovascular membranes. - A stabilizing anchor in the model for contrast between'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='between pathological and healthy states. 7 Clinical Significance of Normal Findings'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Normal Findings - Normal OCT suggests no active retinal disease. - Clear layers and'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='layers and intact EZ correspond to good visual potential. - Important for ruling out'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='for ruling out diabetic macular edema, drusen, and CNV. 8 Patient Education'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Education (Chatbot-Friendly Snippets) - A normal retina has smooth, well-organized'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='well-organized layers with no swelling or abnormal fluid. - Your OCT scan shows no'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='scan shows no signs of leakage, deposits, or damage. - An intact photoreceptor layer'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='layer means healthy visual function. 9 When Normal OCT Occurs Despite Symptoms A'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Symptoms A patient may feel symptoms but still have a normal OCT due to: - Dry eye'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='to: - Dry eye symptoms (not retinal). - Migraine aura. - Functional visual'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='visual disturbances. - Early disease not yet visible structurally. 10 Safety &'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='10 Safety & Advice for Patients with Normal OCT - If vision symptoms persist, a'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='persist, a clinical exam may still be needed. - Monitor for any new distortion or'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='distortion or vision changes. - Maintain regular eye health practices (good'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='practices (good lighting, glucose control if diabetic, etc.). 11 Decision Flow (for'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Flow (for Chatbot Use) - OCT shows no fluid + intact layers classify as NORMAL. - If'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='as NORMAL. - If symptoms but OCT normal recommend clinical evaluation for'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='evaluation for non-retinal causes. - If minimal benign variations still NORMAL'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='still NORMAL unless accompanied by structural abnormalities. 12 Snippets for'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='12 Snippets for Embedding - Normal OCT: clear layers, no fluid, intact RPE and'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='intact RPE and photoreceptors. - Healthy macula shows a smooth foveal dip with no'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='dip with no cysts or swelling.'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- No signs of drusen, edema, or abnormal vessels. 13 Disclaimer This information is'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='information is for educational use only and should not replace clinical assessment'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='assessment by an eye care professional.'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='Type 1 CNV. Type 1 neovascular lesion is located below the RPE as seen in the B-scan'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='in the B-scan frame. In the OCT-A frame, a neovascular coralliform network is'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='network is observed which emanates from the choroidal vasculature and extends to the'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='extends to the sub-RPE space. Type 2 CNV. In B-scan and OCT-A, a neovascular lesion'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content=\"lesion is identified that extends from the choroidal vessels through the Bruch's\"),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content=\"the Bruch's membrane and RPE and grows into the subretinal space. The En Face image\"),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='En Face image shows a change in color in macula secondary to edema and serous'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='and serous detachment of the retina. Choroidal Neovascularization: OCT Angiography'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='OCT Angiography Findings All content on Eyewiki is protected by copyright law and'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='law and the Terms of Service. This content may not be reproduced, copied, or put'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='copied, or put into any artificial intelligence program, including large language'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='large language and generative AI models, without permission from the Academy.'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='the Academy. Disease Entity Disease Choroidal neovascularization (CNV) is part of'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='is part of the spectrum of exudative age-related macular degeneration (AMD) that'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='(AMD) that consists of an abnormal growth of vessels from the choroidal vasculature'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content=\"vasculature to the neurosensory retina through the Bruch's membrane. CNV can also\"),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='CNV can also develop in a number of other conditions such as myopic degeneration,'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='degeneration, chronic central serous chorioretinopathy, macular telangiectasia type'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='type 2, various white dot syndromes and other uveitic processes, and some choroidal'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='some choroidal tumors. Leakage of retinal edema and hemorrhage from CNV threatens'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='CNV threatens visual acuity. Etiology Etiology of CNV is multifactorial. Alterations'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content=\"Alterations in Bruch's membrane, migration of macrophages and production of vascular\"),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='of vascular endothelium growth factor (VEGF), play an important role in the'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='role in the development of this disease. Risk Factors The incidence and progression'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='and progression of AMD are related to age and genetic factors. With aging, the'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='With aging, the lysosomal activity for the degradation of external segments of'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='segments of photoreceptors decreases. This leads to subsequent accumulation of'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='accumulation of lipofuscin, which affects the normal function of the RPE. Another'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='RPE. Another important risk factor for the development of CNV is the presence of'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='the presence of large, confluent soft drusen. Oxidative stress may play an important'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='an important role in AMD. Several modifiable risk factors have been identified,'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='identified, including quitting smoking, dietary intake of omega-3 fatty acids,'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='fatty acids, consuming vegetables and fruit with antioxidants including lutein and'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='lutein and zeaxanthin, exercise, wearing sunglasses, and maintaining a healthy'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='a healthy weight. Pathophysiology Alterations in the normal transport of'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content=\"transport of metabolites, ions and water through Bruch's membrane in AMD, alter the\"),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='AMD, alter the nutrition and stability of retinal pigment epithelium (RPE) from'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='(RPE) from choriocapillaris and the transport of waste out from the neurosensory'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='neurosensory retina. Hypoxia leads to VEGF being released by the RPE, which'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='the RPE, which initiates a cascade of angiogenic responses at the level of the'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='level of the choroidal endothelium. Bruchs membrane damage is required to allow the'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='to allow the passage of abnormal neovascular vessels from the choroidal vasculature'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='vasculature through the breaks in Bruchs membrane to the retina. This impairment is'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='impairment is part of the pathological course of AMD. Classification Histologically,'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='Histologically, neovascular membranes are classified into: Type 1 (\"occult\"), when'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='when the neovascular membrane is located below the RPE. Type 1 CNV demonstrates'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='demonstrates occult leakage on fluorescein angiography. Polypoidal choroidal'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='choroidal vasculoplathy (PCV) is a subtype of Type 1 CNV that is characterized by'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='by the presence of polyp-like aneurysmal dilations of the branching vascular'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='vascular network. Type 2 (\"classic\"), passes through the RPE and is located above'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='located above the RPE in the subretinal space. This is related to the angiographic'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='angiographic classification of a classic CNV. Article initiated by: Andrea Tamine'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='Andrea Tamine Hoyos Dumar, MD, Juan.David.Arias All contributors: Leo A. Kim, MD,'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='Leo A. Kim, MD, PhD,Sun Young (Sunny) Lee, MD, PhD,Koushik Tripathy, MD'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='Tripathy, MD (AIIMS),Andrea Tamine Hoyos Dumar, MD,Diana V. Do, MD,Talisa de Carlo,'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='de Carlo, MD,Neelakshi Bhagat, MD, FACS,Jennifer I Lim MD,Aidan Lee, MD Assigned'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='MD Assigned editor: Sun Young (Sunny) Lee, MD, PhD Review: Assigned status Up to'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='status Up to Date by Sun Young (Sunny) Lee, MD, PhD on September 18, 2025. Choroidal'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='2025. Choroidal Neovascularization DiseasesDB 32400 ICD-10 H35.3 MeSH D020256 [1]'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='D020256 [1] [2][3] [4][5][6][7] [8] [9] [10] [11] [12][13] Learn more Accept'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='Type 3 CNV. An intraretinal neovascular lesion is observed. The color photo'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='The color photo identifies typical punctate hemorrhages. The OCT B-scan shows'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content=\"B-scan shows retinal edema without disruption of Bruch's membrane or RPE. OCT-A\"),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='or RPE. OCT-A depicts an anastomosis originating in the neurosensory retina. Type 3'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='retina. Type 3 is defined as Retinal Angiomatous Proliferation (RAP), which'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='(RAP), which corresponds to neovascularization that develops within the neurosensory'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='neurosensory retina an progresses posteriorly into the subretinal space. Diagnosis'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='Diagnosis Clinical findings In the presence of CNV, the patient experiences an acute'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='an acute decrease in visual acuity, relative scotoma, and/or metamorphopsia. The'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='The retinal examination shows a grayish macular lesion associated with subretinal'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='with subretinal fluid, macular edema, exudation, and/or hemorrhages. Diagnostic'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='Diagnostic Procedures OCT Angiography En face OCT angiography (OCTA) is a new'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='(OCTA) is a new technology that has the great ability to show the retinal and'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='the retinal and choroidal microcirculation in detail without invasive means. Instead'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='means. Instead of intraocular contrast, it uses motion contrast by comparing the'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='comparing the decorrelation signal between repeated B-scans obtained at a given'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='at a given retinal cross-section to detect blood flow. It utilizes the principle'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='the principle that theoretically only the circulating RBCs within the retinal'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='the retinal vasculature would be moving between the B-scans. Each en face OCT'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='en face OCT angiogram is cross-registered with the corresponding OCT B-scans, an OCT'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='B-scans, an OCT thickness map, and a structural en face OCT, which allows for'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='allows for concurrent visualization of structure and blood flow. OCTA is available'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='is available on both spectral domain and swept source OCT devices. The conventional'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='conventional CNV evaluation often consists of multimodal imaging with fluorescein'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='fluorescein angiography (FA) combined with indocyanine green angiography (ICGA) and'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='(ICGA) and OCT. These well-established modalities can guide effective CNV management'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='CNV management but have their limitations, especially when characterizing vascular'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='vascular structures at different depths. For example, FA only allows for evaluation'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='for evaluation of the superficial capillary plexus within the retina. OCTA, on the'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='OCTA, on the other hand, allows for noninvasive three-dimensional analysis of the'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='analysis of the retinal and choroidal vasculature and can be segmented to view each'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='to view each of the vascular plexuses individually. This ability to visualize'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='to visualize vascular structures at different depths/layers of the retina makes OCTA'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='makes OCTA a tool well suited to evaluate CNV. For the purpose of visualizing'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='of visualizing changes in eyes with CNV or suspected CNV, a segmentation of the'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='of the outer retina (extending from the outer plexiform layer to Bruchs membrane)'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='membrane) and a segmentation of the choriocapillaris (approximately 20um thick'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='20um thick region just below the RPE) are most useful. CNV can be seen as a seafan'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='as a seafan or coraliform neovascular complex within the outer retina, which is'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='which is ordinarily devoid of blood flow in normal eyes. Type 1 CNV is observed in'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content=\"is observed in OCTA as a neovascular complex between the RPE and Bruch's membrane,\"),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='membrane, originating in the choroid. The type 2 CNV is visualized as a neovascular'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='a neovascular network that grows from the choroid vasculature and traverses the'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content=\"traverses the RPE-Bruch's membrane complex into the subretinal space. Type 3 CNV is\"),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='Type 3 CNV is clinically seen as tiny intra- and subretinal hemorrhages that'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='that correlate on OCTA as an intraretinal anastomosis originating in the deep'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='in the deep capillary plexus of the retina. The PCV subtype of CNV can also be seen'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='also be seen as a branching neovascular network within the outer retina but with'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='retina but with concurrent aneurysmal dilations. After repeat pharmacologic'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='pharmacologic intervention the large branches of the CNV become pruned and the'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='pruned and the smaller capillaries and any polyps may no longer be visualized'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='be visualized (whether due to slow or absent flow, or complete regression). The'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='The choriocapillaris layer may demonstrate decreased flow or flow voids adjacent to'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='adjacent to the CNV complex. Additionally, choriocapillaris hypoperfusion may be'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='may be seen underlying any areas of RPE atrophy. The use of OCTA in CNV imagining is'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='imagining is not without challenges. OCTA is susceptible to several imaging'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='several imaging artifacts. Some of these, such as motion or signal attenuation, may'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='may be mitigated through patient instruction and technician training. Projection'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='Projection artifacts arise when blood flow of su perficial layers of the retina is'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='the retina is projected onto deeper structures below, which can cause false flow'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='false flow signal in deeper anatomical layers. CNV assessment suffers since proper'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='since proper visualization requires high-quality images of the outer retina, where'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='retina, where projection artifacts are especially prominent due to proximity to the'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='to the highly reflective RPE layer. Furthermore, the eruption of CNV can lead to'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='CNV can lead to segmentation artifact via the distortion of the retinal layers. This'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='layers. This may require manual adjustment of the segmentation slabs, which may be'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='which may be time consuming and lower the repeatability of the test. Tools for'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='test. Tools for automatic segmentation through deep learning and modality of OCTA'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='of OCTA such as projection-resolved OCTA (PR-OCTA) algorithm have been reported to'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='reported to improve the quality and repeatability of OCTA studies. Management'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='Management Treatment Taking into account the numerous recent studies on the'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='studies on the treatment of CNV in AMD, it has been shown that antiangiogenic'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='antiangiogenic therapy shows the best result both histologically with the regression'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='the regression of the neovascular lesion and functionally with improvement of the'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='of the visual acuity. Although the treatment is the same for all types of CNV, it is'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='of CNV, it is important to differentiate them, since they do not all respond'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='not all respond identically and some of them have a higher rate of recurrence.'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='of recurrence. References 1. Turbert, D. (2020, March 18). What are Choroidal'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='are Choroidal Neovascular membranes? Reviewed by Ninel Z Gregori, MD. American'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='MD. American Academy of Ophthalmology.'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='Ophthalmology. https://www.aao.org/eye-health/diseases/choroidal-'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='neovascular-membranes. 2. Cheung C. et al. Myopic Choroidal Neovascularization:'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='Review, Guidance, and Consensus Statement on Management. Ophthalmology. 2017'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='2017 Nov;124(11):1690-1711. doi: 10.1016/j.ophtha.2017.04.028 3. Agarwal A. et al.'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='A. et al. An update on inflammatory choroidal neovascularization: epidemiology,'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='epidemiology, multimodal imaging, and management. J Ophthalmic Inflamm Infect. Vol:'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='Infect. Vol: 8(13). doi: 10.1186/s12348-018-0155- 6 4. Kennedy CJ, Rakoczy PE,'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='CJ, Rakoczy PE, Constable IJ. Lipofuscin of the retinal pigment epithelium: a'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='epithelium: a review. Eye 1995;9:76371. 5. Rakoczy PE, Zhang D, Robertson T, et al.'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='T, et al. Progressive age-related changes similar to age-related macular'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='macular degeneration in a transgenic mouse model. Am J Pathol 2002;161:151524 6.'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='6. Hageman GS, Mullins RF. Molecular composition of drusen as related to'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='as related to substructural phenotype. Mol Vis 1999;5:28. 7. Spillsbury K. et al.'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='K. et al. Overexpression of Vascular Endothelial Growth Factor (VEGF) in the Retinal'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='in the Retinal Pigment Epithelium Leads to the Development of Choroidal'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='of Choroidal Neovascularization. Am J Pathol. 2000 Jul; 157(1): 135144. doi:'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='135144. doi: 10.1016/S0002-9440(10)64525-7 8. Klein R, Klein BE, Jensen SC, et al.'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='SC, et al. The five-year incidence and progression of age-related maculopathy: the'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='the Beaver Dam Eye Study [see comments]. Ophthalmology 1997;104:721. 9. Mullins RF,'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='9. Mullins RF, Russell SR, Anderson DH, et al. Drusen associated with aging and'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='with aging and age-related macular degeneration contain proteins common to extracel-'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='to extracel- lular deposits associated with atherosclerosis, elastosis, amyloidosis,'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='amyloidosis, and dense deposit disease. FASEB J 2000;14:83546. 10. Sarks JP, Sarks'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='Sarks JP, Sarks SH, Killingsworth MC. Evolution of soft drusen in age- related'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='in age- related macular degeneration. Eye 1994;8:26983. 11. The Age-Related Eye'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='Age-Related Eye Disease Study 2 (AREDS2) Research Group*. Lutein + Zeaxanthin and'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration: The'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='The Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial. JAMA.'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='Trial. JAMA. 2013;309(19):20052015. doi:10.1001/jama.2013.4997 12. Abdelsalam A, Del'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='A, Del Priore L, Zarbin MA. Drusen in age-related macular degeneration:'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='degeneration: pathogenesis, natural course, and laser photocoagulation- induced'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='induced regression. Surv Ophthalmol 1999;44:129. 13. Tombran-Tink J, Shivaram SM,'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='J, Shivaram SM, Chader GJ, et al. Expression, secretion, and age-related'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='and age-related downregulation of pigment epithelium-derived factor, a serpin with'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='a serpin with neurotrophic activity. J Neurosci 1995;15:49925003. 14. de Carlo TE,'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='de Carlo TE, Bonini Filho MA, Chin AT, et al. Spectral-domain optical coherence'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='coherence tomography angiography of choroidal neovascularization. Ophthalmology.'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='Ophthalmology. 2015;122(6):1228-38. [14] [15] [16] [17] [18] [19] [20] [21][22]'),\n",
       " Document(metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='[20] [21][22] Learn more'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='What Are Retinal Drusen? Written by WebMD Editorial Contributors Medically Reviewed'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='Reviewed by Timothy G. Murray,MBA,MD,FACS on August 01, 2025 4 min read Retinal'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='read Retinal drusen are yellow/white-colored spots seen under the retina of your eye'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='of your eye that are made up of proteins and a type of fat called lipids. The retina'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='The retina is the layer of cells lining the inside surface of the back of your eye'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='of your eye that sends signals to your brain and enables you to see. Small drusen'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='Small drusen may not cause problems for some people, but larger drusen can increase'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='can increase your risk of a medical condition called age-related macular'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='macular degeneration (AMD). Drusen can be a sign that you already have age-related'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='age-related macular degeneration. In age-related macular degeneration, the cells of'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='the cells of the macula, a part of the retina, start to change because of aging. Dry'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='of aging. Dry macular degeneration comes first. Wet macular degeneration is an'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='is an advanced form of the condition. A second type of advanced maculardegeneration'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='is called geographic atrophy (GA). Types of Retinal Drusen There are two types of'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='two types of retinal drusen: hard and soft. Hard drusen are small, dotted,'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='small, dotted, yellow-colored, and abnormal tissue growths. When the drusen is hard,'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='drusen is hard, there is a lower risk of losingyour vision in the future. Soft'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='future. Soft drusen look large and raised, are pale yellow or grayish-white in'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='in color, and have a dome shape. There is a higher risk of losing vision in the'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='vision in the future if you have many large or medium-sized soft drusen. Causes of'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='Causes of Retinal Drusen Retinal drusen can occur as a result of aging. It is common'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='It is common to see drusen in people over 60 years of age. 90% of drusen are caused'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='are caused by dry macular degeneration. The remaining 10% of drusen are caused by'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='are caused by wet macular degeneration. In dry macular degeneration, your central'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='your central vision becomes blurry or lessens because of the thinning of the part of'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='of the part of your retina called the macula. Dry macular degeneration can cause you'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='can cause you to lose vision slowly over time. In wet macular degeneration, your'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='your vision gets blurred or you may see a blind spot in your field of vision. This'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='of vision. This condition is caused by abnormal blood vessels that break, bleed, or'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='bleed, or leak fluid into the macula and may cause sudden and severe loss of vision.'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='loss of vision. Symptoms Sometimes you may have retinal drusen and not experience'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='not experience any symptoms. You may not find out you have them until your doctor'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='your doctor seesthem during a routine eye exam. Having a few small drusen doesnt'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='drusen doesnt mean that you have eye disease. When you have a lot of larger drusen,'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='larger drusen, it can mean that you have age-related macular degeneration. You could'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='You could then see the symptoms linked to age-related macular degeneration: Dim or'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='Dim or cloudy vision Difficulty seeing when the light changes from bright to dim'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='bright to dim light A blank or blurry spot in your central vision Risk Factors'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='Risk Factors Retinal drusen can be commonly seen in people over 60 years of age. But'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='of age. But other factors can increase your risk of getting this condition: Family'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='Family history of retinal drusen Smoking tobacco High blood pressure Excessive body'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='Excessive body fat (obesity) High blood cholesterol People of Caucasian descent have'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='descent have a higher risk of both retinal drusen and age-related macular'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='macular degeneration. When to See a Doctor You should see a doctor or eye specialist'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='eye specialist if you experience any difficulty seeing. Get urgent medical attention'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='attention if you have severe or serious loss of vision. Treatment Retinal drusen are'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='drusen are common in people over 60 years of age. Small drusen may not cause any'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='not cause any difficulties at all for some people. SubscribeEye Health Guide'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='Vitamins: You may lose vision if your age-related macular degeneration reaches an'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='reaches an advanced stage. If you have a lot of large and medium- sized drusen, your'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='drusen, your doctor may ask you to take AREDS2 formula vitamins, which can slow down'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='can slow down the growth of your condition to an advanced stage by about 25%. AREDS2'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='25%. AREDS2 formula vitamins are a combination recommended by the Age-Related Eye'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='Age-Related Eye Disease Study (AREDS), an NIH clinical trial. According to the'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='to the results of the study, when these vitamins are taken, they reduce the risk of'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='the risk of getting the disease by as much as 19 % and/or reduce the risk of vision'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='risk of vision loss by 25%. The formula has Vitamin C, Vitamin E, the antioxidants'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='antioxidants lutein and zeaxanthin, and minerals zinc and copper in specific'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='in specific amounts. Lifestyle and dietary changes: Your doctor may ask you to make'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='ask you to make lifestyle changes, such as stopping smoking. They may recommend that'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='recommend that your diet has more vegetables, fruits, and fatty fish like salmon and'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='like salmon and mackerel. You may be asked to eat less red meat in order to lower'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='order to lower your blood cholesterol. Early detection:Your doctor may ask you to'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='may ask you to monitor your vision at home if you have drusen, using a test called'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='a test called the Amsler Grid. If you candetect wet macular degeneration early on,'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='early on, your doctor may be able to help you make your vision stable or improve it'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='or improve it with injected medication. With early detection, you can slow down'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='can slow down complications and minimize loss of vision. Sources Update History'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='Update History Print View privacy policy, copyright and trust info Save NEXT ARTICLE'),\n",
       " Document(metadata={'source': 'Data/Retinal Drusen_ Everything You Need to Know.pdf'}, page_content='NEXT ARTICLE Eyelid Bump'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Figure 1: Diabetic macular edema. A: Schematic diagram of DME. Microaneurysms, or'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='or damaged capillaries, resulting from the breakdown of the bloodretina barrier leak'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='barrier leak fluid to the extracellular space, resulting in a swollen retina.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='swollen retina. Resorption of DME is dependent on the adjacent capillaries and'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='capillaries and retinal pigment epithelium. Resorption of fluid may leave behind'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='leave behind lipoprotein residues, seen here as exudates. B: OCT image of DME.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='image of DME. Published online with permission from the AAO. Diabetic Macular Edema'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Macular Edema All content on Eyewiki is protected by copyright law and the Terms of'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the Terms of Service. This content may not be reproduced, copied, or put into any'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='or put into any artificial intelligence program, including large language and'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='language and generative AI models, without permission from the Academy. Disease'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Disease Definition Diabetic macular edema (DME) is the accumulation of excess fluid'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='of excess fluid in the extracellular space within the retina in the macular area,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='macular area, typically in the inner nuclear layer, outer plexiform, Henles fiber'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Henles fiber layer, and subretinal space. Pathophysiology Chronic'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Chronic hyperglycemia-related accumulation of advanced glycated end products'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='end products disrupts the bloodretina barrier (BRB), leading to endothelial cell'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='cell junction breakdown and pericyte loss. The inner BRB is composed of endothelial'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='of endothelial cells in the retinal capillaries, while the outer BRB is composed of'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='is composed of retinal pigment epithelium cells. When the BRB is altered,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='BRB is altered, interstitial fluid is accumulated within and underneath the retina'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the retina through leakage of molecules dependent on intact cell-to-cell junctions'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='junctions (Figure 1). Evidence also shows that DME has an inflammatory component,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='component, with several chemokines and cytokines involved in its development. These'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='These include vascular endothelial growth factor (VEGF), interleukins (ILs), matrix'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='(ILs), matrix metalloproteinases, and tumor necrosis factor (TNF). Upregulation of'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Upregulation of multiple pathways leads to increased inflammation, oxidative stress,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='stress, and vascular dysfunction. Significant changes are seen in the neurovascular'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='neurovascular unit, altering the homeostasis between astrocytes, ganglion cells,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='ganglion cells, Mller cells, retinal vascular endothelial cells, and amacrine cells.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='amacrine cells. Retinal vascular permeability changes also involve the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='involve the kallikrein-kinin system, which induces vasorelaxation via bradykinin and'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='bradykinin and nitric oxide. Natural History DME can develop at any stage of'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='at any stage of diabetic retinopathy (DR), from mild nonproliferative diabetic'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='diabetic retinopathy (NPDR) to proliferative diabetic retinopathy, but is more'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='but is more frequent as the severity of DR increases. DME occurring near to or at'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='near to or at the fovea is more likely to result in blurred vision and'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='vision and metamorphopsia. When the DME involves or threatens the fovea, the risk of'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the risk of moderate visual loss (defined as a 3-line decrease in visual acuity'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='visual acuity (VA), equivalent to a doubling of the visual angle) increases; in the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='in the Early Treatment of Diabetic Retinopathy Study (ETDRS) study, visual loss'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='visual loss decreased by 24% over 3 years without treatment. The disease course is'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='course is variable, with some eyes having chronic persistent DME spanning several'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='several years, while other eyes have rapid spontaneous resolution, although the risk'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the risk of recurrence is always present. Prevalence The Wisconsin Epidemiologic'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Epidemiologic Study of Diabetic Retinopathy (WESDR) found that the 25-year incidence'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='incidence of DME in people with type 1 diabetes mellitus (T1DM) was 29%. The'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='was 29%. The Diabetes Control and Complications Trial (DCCT) reported that 27% of'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='that 27% of people with T1DM had DME within 9 years of diabetes onset. The WESDR'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='The WESDR also found that 25.4% of people with type 2 DM who used insulin and 13.9%'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='and 13.9% of those who did not use insulin had DME. Yau et al. estimated the global'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the global prevalence of DME to be 6.8% among people with DM. In the United States,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='United States, prevalence rates are between 2.7% to 3.8%, with non-Hispanic White'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='White people less likely to have DME than non-Hispanic Black people. Risk Factors'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Risk Factors Risk factors for DME and DR are similar. These include a longer DM'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='a longer DM duration, poor control of DM with elevated glycolated hemoglobin A1c'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='hemoglobin A1c (HbA ) levels, hypertension, and hyperlipidemia. Other secondary risk'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='secondary risk factors include impaired renal function and the use of'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='and the use of thiazolidinediones. Prevention Primary prevention of DME involves'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='of DME involves intensive control of DM, blood glucose and lipid levels,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='lipid levels, hypertension, and other systemic risk factors. The Diabetic'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='The Diabetic Retinopathy Clinical Research (DRCR) Protocol W investigated whether'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='whether aflibercept injections in eyes with baseline moderate-to-severe NPDR could'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='NPDR could prevent the eventual development of center-involved DME (ci-DME) with'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='(ci-DME) with vision loss. Vision loss was defined as a 10-letter decrease in VA at'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='in VA at 1 visit or a 5-to 9- letter decrease at 2 consecutive visits, with the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='with the decrease in vision attributed to the ci-DME. The 2-year cumulative'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='cumulative probability of developing ci-DME with vision loss was 4.1% in patients'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='in patients given aflibercept vs 14.8% of patients given sham injections. However,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='However, there was no significant difference in mean VA between Article initiated'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='initiated by: Cris Martin P. Jacoba, MD, Margalit G. Mitzner, Neelakshi Bhagat, MD,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Bhagat, MD, FACS, Marco Attilio Zarbin, MD, PhD, FACS, Jerry Cavallerano, OD, PhD,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='OD, PhD, Paolo A. Silva, MD, Lloyd P. Aiello, MD, PhD, Mohamed A. Elmasry, MD, PhD'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='MD, PhD All contributors: Theodore Leng, MD, MS,Koushik Tripathy, MD'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Tripathy, MD (AIIMS),Neelakshi Bhagat, MD, FACS,Jennifer I Lim MD,Cris Martin P.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Martin P. Jacoba, MD,David Kitchen,Galin J. Spicer, MD MBA Assigned editor:'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='editor: Neelakshi Bhagat, MD, FACS Review: Assigned status Update Pending by'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Pending by Neelakshi Bhagat, MD, FACS on July 6, 2025. [1][2] [3] [4] [5] [6][7][8]'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='[5] [6][7][8] [9] [10] [11] [10] [12][13][14] 1c[15][16][17] [18] Learn more Accept'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Figure 2: Circinate exudates. A: Blue arrows - Circinate exudates, defined as'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='defined as exudates arranged in a circular appearance. B: OCT b- scan across the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='scan across the fovea, confirming the presence of DME associated with an elevated'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='an elevated foveal contour. The patients best-corrected vision was 20/32. Figure 3:'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Figure 3: Dense macular exudates involving the fovea. A: Blue arrow Dense foveal'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Dense foveal exudates. B: Red arrow OCT b-scan across the fovea, confirming the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='confirming the presence of DME and the dense foveal exudate. The patients'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='The patients best-corrected vision was 20/200. Figure 4: Basic structural changes in'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='changes in DME seen on OCT. Yellow bracket Generalized retinal swelling. Blue arrow'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Blue arrow Cystoid macular edema. Red arrow Subretinal fluid. the treatment groups.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='groups. From baseline to the 2-year checkup, eyes treated with sham injections had a'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='had a mean (SD) change of 2.0 (6.1) letters, while eyes treated with aflibercept had'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='aflibercept had a mean 0.9 (5.8) letter change (adjusted mean difference 0.5'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='difference 0.5 letters; 97.5% CI, 1.0 to 1.9 letters; P = 0.47]. However, at present'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='at present the use of anti-VEGF injections for the prevention of ci-DME is not the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='is not the standard of care. Diagnosis History DME is suspected in patients with any'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='with any level of DR who present with blurred vision or metamorphopsias. A detailed'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='A detailed history including the approximate date of onset of diabetes, the use of'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the use of insulin versus oral antihyperglycemic agents, and the quality of'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the quality of metabolic control (e.g., HbA level) should be elicited. Any'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='elicited. Any associated medical problems such as hypertension,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='hypertension, hypercholesterolemia, renal disease, and thyroid disease should be'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='should be identified, along with a thorough review of medications. It should be'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='It should be noted that mild to extensive DME may be present without symptoms'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='symptoms evident to the patient. Physical Examination Patients suspected of having'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='of having DME may undergo a detailed biomicroscopic examination with a slit lamp and'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='a slit lamp and indirect ophthalmoscope. Historically, DME classifications were'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='were based on the 1980s-era ETDRS definitions of clinically significant macular'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='macular edema (CSME). The specific criteria for diagnosing CSME were: 1. Retinal'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='1. Retinal thickening at or within 500 m of the center of the fovea 2. Hard exudates'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Hard exudates at or within 500 m of the center of the fovea if adjacent to an area'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='to an area of retinal thickening 3. Retinal thickening of at least 1 disc area, any'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='disc area, any portion of which is within 1500 m (approximately 1 disc diameter)'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='disc diameter) from the center of the fovea Thus, CSME, as defined by the ETDRS, is'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the ETDRS, is a clinical diagnosis made by slit-lamp examination using a contact'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='using a contact lens. While clinical examinations remain essential for the full'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='for the full evaluation of DME, optical coherence tomography (OCT) is now routinely'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='now routinely used to complement physical examination in the diagnosis of DME. The'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='of DME. The management of DME is currently based on the central subfoveal thickness'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='thickness (CST) on the macular OCT. Signs Macular thickening with or without hard'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='or without hard exudates may be seen on stereo biomicroscopy. However, some eyes may'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='some eyes may present without apparent signs of retinal thickening on clinical'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='on clinical examination, despite significant OCT-observed DME. Thickening can occur'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='can occur in various patterns, including focal, multifocal, and diffuse areas of'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='areas of retina thickening. Despite these terms being frequently used, there are no'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='there are no well-established standard, consistently used definitions. In the ETDRS'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='In the ETDRS guidelines, focal leakage resulting from microaneurysms may be treated'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='may be treated with a fluorescein angiographyguided focal laser, while diffuse'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='while diffuse capillary leakage is from a more widespread breakdown of the BRB and'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='of the BRB and may be treated with grid laser. Hard exudates in various patterns may'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='patterns may also be seen, including circinate rings and focal aggregations of'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='aggregations of exudates (Figures 23). Hard exudates consist of lipoprotein residues'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='residues of serous leakage from damaged vessels, and can serve as biomarkers for'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='biomarkers for DME. Symptoms DME may present with decreased visual acuity (VA),'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='acuity (VA), metamorphopsia, changes in color perception, and difficulty reading,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='reading, although it may also present asymptomatically. Vision and DME Studies show'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Studies show a poor to modest correlation between VA and CST on OCT, within the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='OCT, within the range of 0.30.5. Over 2 years, only around 12%14% of the change in'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the change in VA can be attributed to the change in thickness. In a study by the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='a study by the DRCR Network, the slope of the best fit line shows an approximately'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='approximately 4.4 letter improvement (95% CI, 3.55.3) for every 100-micron decrease'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='decrease in CST at baseline. Interestingly, on follow-up after treatment with'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='treatment with macular laser photocoagulation, there were some eyes with paradoxical'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='paradoxical improvement in VA with increased CST (7-17% at different time points)'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='time points) and paradoxical worsening of VA with decreased CST (18-26% at different'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='at different time points). These findings highlight how OCT measurements cannot be'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='cannot be used as a perfect surrogate for visual acuity; however, in clinical and'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='in clinical and research settings, the technology remains an important tool. The'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='tool. The DRCR Network has recommended a 10% change in CST to indicate a real change'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='a real change that can be considered in clinical decision-making. Diagnostic'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Diagnostic Procedures Optical Coherence Tomography (OCT) Within recent years, OCT'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='years, OCT has quickly become an important ancillary procedure in diagnosing and'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='diagnosing and treating DME. Three basic structural changes can be seen on OCT:'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='be seen on OCT: retinal swelling, cystoid macular edema, and subretinal fluid'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='fluid (Figure 4). Macular scans can quickly and accurately identify even subtle'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='even subtle areas of thickening, along with quantitative metrics for different'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='for different areas. Changes in the anatomic distribution of DME can be monitored'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='be monitored over time, especially the fluids relationship to the fovea. This'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the fovea. This information has clinical and research implications for the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='for the evaluation and management of DME. The International Council of'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content=\"Council of Ophthalmology's guidelines for diabetic eye care, published in 2018,\"),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='in 2018, adopted the clinical entities of center-involved DME (ci-DME) and'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='(ci-DME) and non-centerinvolved DME (non-ciDME) for the evaluation of macular fluid'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='macular fluid (Figure 5), as follows: 1. Center-involved DME: Retinal thickening in'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='thickening in the macula that involves the central subfield zone (1 mm in diameter)'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='mm in diameter) 2. Non-centerinvolved DME: Retinal thickening in the macula that'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the macula that does not involve the central subfield zone (1 mm in diameter) [18]'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='diameter) [18] 1c [19] [20] [21][22] [22] Learn more'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Figure 5: Montage of center-involved vs non-centerinvolved DME. Top Row A:'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='DME. Top Row A: Non-centerinvolved DME. Retinal thickening does not involve the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='not involve the central 1-mm subfield zone (innermost circle) per the en-face OCT'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the en-face OCT heatmap, as seen on b-scan. Bottom Row B: Center-involved DME.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='DME. Retinal thickening involves the central 1-mm subfield zone (innermost circle)'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='circle) per the en-face OCT heatmap and b-scan. Published online with permission'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='with permission from the AAO. Figure 6: Disorganization of the retinal inner layers.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='inner layers. OCT images showing combinations of presence or absence of DRIL and'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='of DRIL and DME. The central 1-mm area is enclosed in the box. Upper images show'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='images show segmentation of inner retinal layers, with the white lines demarcating'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='demarcating the boundaries between IPL-INL and the INL-OPL. Image credit to: Barham'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='to: Barham et al., Association of Macular Nonperfusion, Leakage, and DRIL (ARVO'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='and DRIL (ARVO poster, 2016) Aside from the location of the swelling, the DRCR'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the DRCR Network has given recommendations on CST treatment thresholds based on'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='based on sex-matched standards. The thresholds were different for each OCT machine;'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='OCT machine; since thickness measurements cannot be compared between different'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='different devices, each device has its own normative database and algorithms. In'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='algorithms. In DRCR Protocol T, treatment eligibility thresholds per machine were:'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='machine were: 1. Heidelberg Spectralis: 320 m for men and 305 m for women 2. Zeiss'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='women 2. Zeiss Cirrus OCT: 305 m for men and 290 m for women 3. Zeiss Stratus'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Zeiss Stratus OCT:250 m for both men and women Moreover, OCT is a more sensitive'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='more sensitive method for objective evaluation of vitreomacular interface'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='interface abnormalities (VMIA), which include vitreomacular adhesion (VMA),'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='adhesion (VMA), vitreomacular traction (VMT), and epiretinal membrane (ERM).'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='membrane (ERM). Identifying VMIA is crucial when diagnosing the etiology of macular'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='of macular edema, whether primarily from DME, from secondary causes of VMIA, or'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content=\"of VMIA, or combined mechanism macular edema. OCT Biomarkers for DME DME's different\"),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content=\"DME's different OCT features have been associated with disparate prognostic outcomes\"),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='outcomes and treatment responses. [23] Learn more'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Figure 7: External limiting membrane and ellipsoid zone disruption. A: DME with large'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='DME with large cystic spaces (blue arrow) and exudates (green arrows). Despite'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Despite anti-VEGF treatment, DME persisted. The EZ and ELM were still intact, with'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='intact, with BCVA of 20/32. B: Five years after photo A, extensive ELM and EZ'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='ELM and EZ disruption (red bracket) developed which involved the fovea. A few'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='fovea. A few chronic parafoveal cysts can still be seen. BCVA dropped to 20/63.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='to 20/63. Figure 8: Epiretinal membrane associated with DME. Dense epiretinal'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='epiretinal membrane overlying the retinal surface, with an elevated foveal contour'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='foveal contour and significant intraretinal cystic spaces in a patient with'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='a patient with diabetes. Published online with permission from the AAO. 1.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the AAO. 1. Disorganization of the retinal inner layers (DRIL) is thought to'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='is thought to represent damaged cells within the inner retinal layers, indicating a'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='indicating a disruption in the normal visual pathway from the photoreceptors to the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='to the ganglion cells. DRIL is identified on OCT when there is disruption of the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='of the demarcating interface lines between the ganglion cell-inner plexiform'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='plexiform complex, inner nuclear layer (INL), outer plexiform layer (OPL), and outer'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='and outer nuclear layer. Eyes with DRIL have a worse baseline and final VA despite'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='VA despite antivascular endothelial growth factor (VEGF) injections and have an'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='and have an almost 8 greater risk for poor visual recovery. In contrast, the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='contrast, the resolution of DRIL results in better visual outcomes (Figure 6). DRIL'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='6). DRIL was better correlated with VA than either glycemic status and CST. 2.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='and CST. 2. External limiting membrane (ELM) and ellipsoid zone (EZ) disruption'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='(EZ) disruption strongly correlate with baseline and final BCVA. At the same time,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the same time, some studies found that restoration of the EZ was a requirement for'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='requirement for good visual recovery (Figure 7). The ELM connects a row of zonular'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='row of zonular adherents to the photoreceptor cell bodies, while the EZ represents'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='EZ represents the isthmus between the outer and inner segments of photoreceptors. 3.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='3. DME associated with VMIA, notably ERM and VMT, has poorer visual outcomes (Figure'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='(Figure 8). VMIA have been observed in 7%16% of eyes with DME, with an annual'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='with an annual incidence rate of up to 4.5%. The READ-3 trial showed that eyes with'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='that eyes with VMIA still had a good response to anti-VEGF therapy. Presence of'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Presence of posterior vitreous detachment (PVD) has been associated with improved'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='with improved visual outcomes. Nasrallah et al. reported that DME was present in 55%'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='present in 55% of eyes with an attached hyaloid, compared with only 20% of eyes with'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='of eyes with PVD. Hikishi et al. reported only a 25% rate of spontaneous resolution'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='resolution in eyes with attached posterior hyaloid, vs a 55% resolution rate in eyes'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='rate in eyes with PVD. The role of the vitreous and VMIA in DME, which may be'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='which may be related to changes in transvitreal oxygenation, hyalocyte proliferation'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='proliferation from vitreous remnants on the ILM, and the present growth factors in'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='factors in the premacular hyaloid, is still being investigated. Fluorescein'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Fluorescein Angiography Fluorescein angiography (FA) is performed to identify'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='to identify leaking microaneurysms or capillaries to help guide laser treatment, and'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='treatment, and to identify areas of retinal ischemia. Leakage seen with FA is not'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='with FA is not synonymous with retinal edema. Focal DME is characterized by focal'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='by focal leakage from microaneurysms or capillaries; in contrast, diffuse DME is'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='diffuse DME is characterized by poorly demarcated areas of capillary leakage (Figure'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='leakage (Figure 9). Recently, there has been a decreasing trend in the use of FA in'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='use of FA in the management of DME, likely due to the procedure being more invasive'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='more invasive and time-consuming than OCT. Contraindications to the use of FA'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the use of FA include pregnancy and allergy associated with the contrast dye.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='contrast dye. Laboratory Testing Primary laboratory testing for DME should involve'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='should involve checking HbA , blood pressure, and lipid levels. Secondary tests can'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='tests can include hemoglobin (anemia exacerbates diabetic retinopathy and may be'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='and may be associated with diabetic nephropathy); both fasting and postprandial'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='postprandial blood sugar; urea, creatinine, and urine microalbumin levels, and a'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='levels, and a thyroid panel. Differential Diagnosis Other causes of DME include'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='of DME include retinal vein occlusion, ruptured macroaneurysm, Irvine-Gass syndrome,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='syndrome, radiation retinopathy, hypertensive retinopathy, subfoveal choroidal'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='choroidal neovascularization, retinal vein occlusion, and VMIA. OCT and FA ancillary'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='FA ancillary diagnostics can help to identify these differential diagnoses (Figures'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='(Figures 1011). Management Management of DME includes strict control of diabetes,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='of diabetes, blood glucose, hypertension, and hypercholesterolemia. This can be'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='This can be achieved by pharmacologic methods or by nonpharmacologic methods, such'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='methods, such as diet modification, weight loss, and exercise. Pharmacotherapy At'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='At present, anti-VEGF agents are the first-line treatment for DME. The FDA approved'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='FDA approved ranibizumab for DME in 2012, aflibercept in 2014, and brolucizumab and'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='and faricimab in 2022. Since 2005, intravitreal bevacizumab has been used off-label'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='used off-label for ocular conditions. DRCR Network Anti-VEGF Treatment Algorithm The'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Algorithm The DRCR anti-VEGF treatment algorithm states that 6 monthly injections'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='injections should be given unless VA is 20/20 or better and CST is <320 m for men or'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='m for men or <305 m for women (as measured by the Heidelberg Spectralis), in which'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='in which case treatment may be withheld starting on the 4th month. At the 6th visit,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the 6th visit, if stability in vision or CST has been achieved (based on the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content=\"(based on the previous 2 visits' findings) or DME has resolved, further treatment\"),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='treatment may be withheld. Stability is defined as: 1. Lack of improvement No BCVA'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='No BCVA increase of 5 letters (approximately 1 line on a Snellen chart) No decrease'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='No decrease in OCT-measured CST 10% (per OCT imaging) 2. No worsening BCVA decreases'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='BCVA decreases by 5 letters (approximately 1 line on a Snellen chart) in the setting'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='in the setting of persistent DME OCT-measured CST increases by 10% If there is'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='10% If there is worsening on follow-up, anti-VEGF treatment is resumed. In general,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='In general, eyes showing stability may be followed up in 34 months, or sooner as'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='or sooner as needed. Withholding injections does not require 20/20 vision or a dry'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='vision or a dry macula, only evidence of stability over the previous 2 or more'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='2 or more visits. DRCR Protocol I issued the first anti-VEGF as-needed treatment'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='treatment algorithm for DME, as long-term data show that even without using a'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='without using a monthly treatment protocol, eyes with persistent [24] [25][26][27]'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='[25][26][27] [24] [28][29][30][31][32] [33] [34][35] [36][37] [38] [39] [40]'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='[38] [39] [40] [41][42][43][44] [45] 1c [46] Learn more'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Figure 9: Focal and diffuse DME. A and B: Fundus photo showing circinate exudates,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='exudates, with adjacent microaneurysms and leakage seen on FA. C and D: Fundus photo'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='D: Fundus photo with subtle signs of macular thickening, with diffuse, poorly'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='diffuse, poorly demarcated capillary leakage seen on FA. Published online with'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='online with permission from the AAO. Figure 10: Pseudophakic cystoid macular'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='cystoid macular edema/Irvine-Gass Syndrome. A: Color fundus photograph of an optic'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='of an optic nerve head and macula 3 months after complex cataract surgery. A small'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='A small incidental grayish-yellow adult vitelliform dystrophy lesion is present in'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='is present in the subfoveal region (circled). B: A mid-phase FA image demonstrates'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='demonstrates cystic hyperfluorescence, with a classic petaloid pattern. As is'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='pattern. As is typical in eyes with pseudophakic CME, there is mild'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='there is mild hyperfluorescence of the nasal portion of the optic nerve head. C: OCT'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='head. C: OCT shows cystic retinal thickening and a subfoveal vitelliform lesion. D:'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='lesion. D: Following 8 weeks of topical steroidal and nonsteroidal anti-inflammatory'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='therapy, OCT images indicate that the CME has fully resolved. Published online with'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='online with permission from the AAO. DME often maintain good BCVA over the long term'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the long term in clinical trial settings. Outside of trial settings, the 5-year'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the 5-year extension phase of Protocol T showed that CST remained stable among eyes'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='among eyes given anti- VEGF injections; however, mean BCVA worsened between the 2-'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='between the 2- and 5-year time points. On average, patients are given 68 injections'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='68 injections in the first year, 24 injections in the second year, and 01 injections'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='01 injections beginning the third year. Clinical Considerations for Treating DME'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Treating DME With Anti-VEGF Agents Observation is recommended for eyes with ci-DME'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='with ci-DME and VA of 20/25 or better. This recommendation is based on the findings'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='on the findings of DRCR Protocol V, where patients were randomized to receive'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='to receive aflibercept injections, macular laser, or no treatment (observation). At'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='At the 2-year endpoint, the mean BCVA was 20/20, and the rates of 5-letter vision'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='5-letter vision loss were similar among all 3 groups (16%19%). Given the risks of'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the risks of ocular infection and the higher costs associated with intravitreal'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='intravitreal injections, observation is a viable option in these patients if they'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='if they can reliably follow up and receive appropriate therapy when there is'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='when there is clinical deterioration. In contrast, among eyes with ci-DME presenting'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='presenting with 20/50 vision or worse, Protocol T study results showed that'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='showed that aflibercept was superior to both ranibizumab and bevacizumab, with'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='with area-under- the-curve analyses showing better visual outcomes over 1 year.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='over 1 year. However, the superiority of aflibercept over ranibizumab was not'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='was not maintained at the 2-year follow-up visit. Bevacizumab thinned the retina the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the retina the least; however, all 3 medications had similar visual outcomes among'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='outcomes among eyes with baseline VA of 20/40 or better. Not all treatments result'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='result in complete resolution of DME. In Protocol I, 40% of eyes still showed'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='still showed persistent DME (defined as never having a CST <250 m through 6 months,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='6 months, as seen on time-domain OCT) after 2 years. Eyes given bevacizumab were'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='were more likely to have persistent DME than eyes given aflibercept. The percentage'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='The percentage of eyes with complete resolution increased with each ranibizumab or'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='ranibizumab or aflibercept injection. At the 3-year follow-up visit, eyes with'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='eyes with chronic persistent DME still had a significant (7-letter) mean improvement'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='improvement in VA over baseline, though lower than the 13-letter mean improvement in'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='improvement in eyes with complete DME resolution. Importantly, only 3.4% of eyes'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='3.4% of eyes with chronic persistent DME lost 2 lines of vision over 2 years'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='over 2 years regardless of the type of anti-VEGF treatment they received. To'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='received. To summarize, in clinical trial settings, a substantial proportion of eyes'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='of eyes with persistent DME still had 2 lines of improvement in vision over the long'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='over the long term, with very few eyes developing considerable vision loss. For eyes'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='loss. For eyes that do not respond optimally to one anti-VEGF agent, switching to'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='switching to another is a treatment option. The switch is typically from bevacizumab'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='bevacizumab to either ranibizumab or aflibercept, or from ranibizumab to'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='ranibizumab to aflibercept. The rationale for switching is that aflibercept has 100'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='has 100 times more affinity for VEGF-A than bevacizumab or ranibizumab, while'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='while concurrently binding placental growth factor and VEGF-B. Aflibercept also has'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='also has a longer half-life and can negate more cytokines that promote DME'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='promote DME development. Most studies looking at switching were retrospective and'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='and showed a significant reduction in CST; however, visual outcomes varied. Some'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='varied. Some eyes may be delayed responders to anti-VEGF treatment, and need more'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='and need more than the initial 36 monthly injections to show significant'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='significant improvement, though they eventually catch up with immediate responders.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='responders. It may be viable to continue treatment with the same medication if there'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='if there is at least a trend of continued improvement, as bevacizumab and'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='bevacizumab and ranibizumab are more cost-effective options. Caution is warranted'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='is warranted for switching, as any clinical improvement may be due to continued'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='to continued treatment among delayed responders instead of due to a shift in'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='to a shift in medications. DRCR protocol AC was a randomized controlled trial'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='trial evaluating the relative efficacy of administering aflibercept monotherapy vs'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='monotherapy vs bevacizumab first with a switch to aflibercept (step therapy) in eyes'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='in eyes with suboptimal response despite treatment. A total of 312 eyes with'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='312 eyes with moderate vision loss from ci-DME were enrolled. Over a 2-year period,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='2-year period, the mean improvement in VA was 14.0 letters in the bevacizumab-first'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='group and 15.0 letters in the aflibercept-monotherapy group (adjusted difference,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='difference, 0.8 letters; 95% CI, 0.9 to 2.5; P = 0.37). At 2 years, mean changes in'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='mean changes in VA and retinal CST were similar in the two groups. Steroids'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Steroids Intravitreal steroids improve vision and decrease retinal thickness, as'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='thickness, as there is an inflammatory component to DME. Steroids have powerful'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='have powerful anti-edematous and anti-inflammatory effects, as they decrease several'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='several pro-inflammatory mediators (IL-6, IL-8, TNF- , monocyte chemotactic'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='chemotactic protein-1, intercellular adhesion molecule-1, VEGF, etc). However,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='etc). However, long-term results have not shown maintenance of initial clinical'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='clinical improvement. In DRCR Protocol I, although the group given intravitreal'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='intravitreal triamcinolone had a similar response with ranibizumab in the first 6'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='in the first 6 months, vision declined due to cataracts. Even with cataract surgery,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='surgery, the final vision did not recover to the levels seen in the group given'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the group given ranibizumab. In Protocol U, eyes with persistent DME despite at'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='DME despite at least 6 ranibizumab injections were randomized to continue [47] [48]'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='[47] [48] [49] [50] [23] [47] [51] [52] [53] [54]'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='[52] [53] [54] [55][56][57][58][59][60][61][62][63][64][65][66][67][68] [69][70]'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='[69][70] [71] [72] [47] Learn more'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Figure 11: Vitreomacular traction with secondary macular edema. A: Color fundus'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='A: Color fundus photograph of the right eye with pseudohole and epiretinal membrane'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='membrane with tractional macular edema. B: OCT image of same patient showing'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='patient showing vitreomacular traction, epiretinal membrane, and resulting macular'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='macular edema. C: OCT of the same eye after vitrectomy surgery with epiretinal'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='with epiretinal membrane peeling. Published online with permission from the AAO.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='from the AAO. ranibizumab monotherapy or shift to ranibizumab plus dexamethasone'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='dexamethasone (Ozurdex). At 6 months, the average visual gain was similar in both'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='similar in both groups, although CST improvement was greater in the combination'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the combination group. Phakic eyes given intravitreal steroids often develop'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='often develop cataracts needing surgery, and are at risk for intraocular pressure'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='pressure (IOP) elevations leading to glaucoma. Landmark Pharmacotherapy Studies'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Studies Anti-VEGF Agents Bevacizumab: Bevacizumab is a recombinant humanized'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='humanized monoclonal immunoglobulin G1 (IgG1) antibody that binds VEGF. Bevacizumab'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Bevacizumab is given off-label for the treatment of DME, and remains the most'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the most cost-effective treatment option among anti- VEGF medications. In the BOLT'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='In the BOLT study, intravitreal bevacizumab (1.25 mg), given at 6-week intervals,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='intervals, was reported to be more effective than modified ETDRS focal/grid laser in'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='laser in terms of VA improvement at 12 months. In DRCR Protocol T, a comparison'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='T, a comparison between bevacizumab, ranibizumab, and aflibercept, 1-year results'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='1-year results showed that bevacizumab thinned the retina the least. However, all 3'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='However, all 3 medications had similar visual outcomes among eyes with baseline'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='with baseline vision of 20/40 or better. A study from The Pan-American Collaborative'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Collaborative Study Group found improvements in BCVA and reduced macular thickness'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='thickness (seen on OCT) at 24 months with intravitreal bevacizumab doses of 1.25'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='doses of 1.25 mg2.5 mg. Ranibizumab: Ranibizumab is a recombinant humanized IgG1'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='humanized IgG1 monoclonal antibody fragment that binds and inhibits VEGF-A. It is'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='VEGF-A. It is FDA approved for the treatment of DME. 1. DRCR Protocol I was the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='I was the first definitive phase 3 study demonstrating the effectiveness of'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='of ranibizumab for DME treatment. Four treatment arms were compared: ranibizumab'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='ranibizumab with immediate grid/focal laser; ranibizumab with macular laser given'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='laser given only for at least 6 months of persistent DME; intravitreal triamcinolone'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='triamcinolone with immediate macular laser; and macular laser with sham injections.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='injections. Results showed that ranibizumab, given in as-needed treatment protocol,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='protocol, had efficacy superior to that of laser therapy. At the 1-year end point,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='end point, eyes treated with ranibizumab gained an average of 89 letters, vs an'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='letters, vs an average gain of only 3 letters seen with laser therapy. Protocol I'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Protocol I revolutionized the treatment protocol for DME when it was published in'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='published in 2011. Before this study, macular laser was consideredfirst-line therapy'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='therapy for DME, a treatment protocol originating from the original ETDRS papers'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='ETDRS papers first published in 1985. 2. RISE and RIDE: The 2-year results for'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='results for ranibizumab 0.3-mg monthly infections showed that 98% of patients'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='98% of patients maintained vision (lost <15 letters) and 34%45% of patients gained'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='patients gained at least 15 letters; the mean VA gain was 10.912.5 letters. Only'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='letters. Only 45%49% of patients needed macular laser, compared with 91%94% in the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='91%94% in the control group. No additional benefit was seen with ranibizumab 0.5 mg'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='0.5 mg monthly vs 0.3 mg monthly. Aflibercept: Aflibercept is a soluble decoy'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='a soluble decoy receptor that binds VEGF-A, VEGF-B, and placental growth factor with'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='factor with high affinity. It is termed a decoy receptor or a VEGF-trap, as VEGF'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='as VEGF mistakenly binds with aflibercept instead of the bodys native receptors,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='receptors, reducing VEGFs activity. It is FDA approved for the treatment of DME. In'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='of DME. In the Da Vinci study, patients with DME were randomly assigned to 1 of 5'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='to 1 of 5 treatment regimens: aflibercept 0.5 mg every 4 weeks (0.5q4), 2 mg every 4'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='2 mg every 4 weeks (2q4), 2 mg every 8 weeks after 3 initial monthly doses (2q8), or'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='doses (2q8), or 2 mg as needed after 3 initial monthly doses (2prn); or macular'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='or macular laser photocoagulation. Mean improvements in BCVA in the aflibercept'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the aflibercept groups at week 52 were 11.0, 13.1, 9.7, and 12.0 letters for the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='letters for the 0.5q4, 2q4, 2q8, and 2prn regimens, respectively, vs 1.3 letters for'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='1.3 letters for the laser group. The proportion of eyes with gains in BCVA of 15'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='in BCVA of 15 ETDRS letters at week 52 in the aflibercept groups were 40.9%, 45.5%,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='40.9%, 45.5%, 23.8%, and 42.2%, respectively, vs 11.4% for laser. Mean reductions in'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='reductions in CST in the aflibercept groups at week 52 were 165.4 m, 227.4 m, 187.8'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='227.4 m, 187.8 m, and 180.3 m, respectively, vs 58.4 m for laser. The PHOTON trial'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='PHOTON trial evaluated the use of high-dose aflibercept (8 mg) aflibercept every 12'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='every 12 weeks (8q12) or 16 weeks (8q16) vs conventional dosing of 2 mg every 8'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='of 2 mg every 8 weeks (2q8). When comparing BCVA gains and retinal thinning at 48'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='thinning at 48 weeks, the 8-mg extended interval dosage was noninferior to'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='noninferior to conventional treatment. There was an increase of 9.2, 8.8, and 7.9'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='8.8, and 7.9 letters and a mean CST reduction of 165 m, 172 m, and 148 m for the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='148 m for the 2q8, 8q12, and 8q16 groups at 48 weeks, respectively. Patients in the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Patients in the high-dose group with a 50- m increase in CST or a 10-letter loss'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='10-letter loss from week 12 onwards had their dosing schedule shortened to either 12'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='to either 12 or 8 weeks, but 93% of patients remained on dosing intervals of 12'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='intervals of 12 weeks. There was no increase in hypertension in the high-dose group.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='group. Faricimab: Faricimab is a novel combined-mechanism inhibitor that binds both'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='that binds both angiopoietin-2 and VEGF-A with high specificity and affinity. The'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='affinity. The 1-year results from the phase 2 BOULEVARD study showed that in'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='showed that in patients given faricimab 6 mg, there was a statistically significant'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='significant VA gain of 3.6 letters over that seen with ranibizumab. Moreover,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Moreover, improvement in diabetic retinopathy severity, as well as reduced CST, was'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='CST, was seen with faricimab; it also had a longer time to re-treatment than'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='than ranibizumab. There were no unexpected safety concerns. The phase 3 YOSEMITE and'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='3 YOSEMITE and RHINE noninferiority trials compared faricimab with aflibercept in'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='aflibercept in patients with DME. The noninferiority primary endpoint of BCVA was'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='of BCVA was achieved with faricimab given every 8 weeks. More than 50% of patients'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='50% of patients had good results with an every-16-weeks dosing regimen, and more'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='and more than 70% had good results with faricimab given every 12 weeks or longer.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='or longer. These results demonstrate the potential of faricimab to decrease'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content=\"to decrease patients' treatment burden by extending the intraocular durability of\"),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='durability of anti-VEGF treatment. The FDA approved the use of faricimab for DME as'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='for DME as 4 monthly loading doses followed by injections every 14 months, or as a'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='months, or as a loading dose of 6 monthly injections followed by injections every 2'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='every 2 months. Brolucizumab: Brolucizumab is a single-chain antibody fragment with'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='fragment with a high affinity for VEGF. Brolucizumabs low molecular weight of 26 kDa'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='of 26 kDa allows for more of the drug to be delivered intraocularly per injection,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='per injection, with the potential for increased durability and effective tissue'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='tissue penetration in the eye. The phase 3 KESTREL and KITE 52-week results found'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='results found that brolucizumab 6 mg was noninferior to aflibercept in mean'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='in mean improvement of BCVA. More patients taking brolucizumab had CST <280 m'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='had CST <280 m without persistent macular fluid than patients taking aflibercept,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='aflibercept, and >50% of the brolucizumab-treated patients were maintained on q12w'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='on q12w dosing after the loading dose was given. However, reports of retinal'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='of retinal vascular occlusion (RVO) and retinal vasculitis with intraocular'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='intraocular inflammation (IOI) have been reported. Risk factors for developing these'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='these adverse reactions include a prior history of IOI or RVO in the 12 months'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the 12 months before brolucizumab initiation, female sex, and same-day bilateral'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='bilateral injections. The FDA approved the use of brolucizumab for the treatment of'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='treatment of DME in June 2022, as a 6-mg injection given every 812 weeks after a'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='weeks after a loading dose of 5 injections given every 6 weeks. Aflibercept HD: FDA'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='HD: FDA granted approval for the use of 8mg Aflibercept for treating DME in 2023.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='DME in 2023. The results of PHOTON trial for CIDME after 2 years revealed mean'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='revealed mean improvement in BCVA with standard Eylea of 8.4 letters, 8.8 letters'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='8.8 letters with the 12-week Eylea HD group, and 7.5 letters with the 16-week Eylea'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='16-week Eylea HD group. Steroids Triamcinolone: In Protocol B, triamcinolone (1 or 4'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='(1 or 4 mg) preservative-free intravitreal injection was less effective and had more'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='and had more side effects than focal/grid photocoagulation at the 2-year follow-up'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='follow-up visit. Dexamethasone: In the 3-year phase 3 MEAD study, dexamethasone 0.7'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='0.7 mg biodegradable implant improved vision by at least 15 letters in 22% of'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='in 22% of patients. At this dose, 41.5% of patients needed antiglaucoma medications,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='medications, with 0.6% needing glaucoma surgery. Around 60% of eyes in the 0.7-mg'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='in the 0.7-mg [73] [74] [75] [23] [53] [76] [77] [47] [78] [79] [79] [80] [79] [81]'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='[80] [79] [81] [82] [83] [84] [85][86] [87][88] [89] [90] Learn more'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Figure 12: Focal laser for focal CSME. A: Planning of focal laser for focal CSME.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='for focal CSME. Note the identified treatment areas, specifically the leaking'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the leaking microaneurysms that would be highlighted on FA. B: Focal laser-treated'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='laser-treated areas with parameters. Published online with permission from the AAO.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='from the AAO. Figure 13: Grid laser for diffuse CSME. A: Planning of grid laser for'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='grid laser for diffuse CSME. Note the identified treatment area, specifically the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the outlined region with diffuse edema that would be highlighted on FA. B: Grid'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='on FA. B: Grid lasertreated area with parameters. Published online with permission'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='with permission from the AAO. implant group had cataract surgery. The 0.7-mg implant'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='0.7-mg implant has been approved by the FDA for DME, and is effective for'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='effective for approximately 36 months. Fluocinolone acetonide: The fluocinolone'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='fluocinolone acetonide (Iluvien) 0.19-mg non-biodegradable implant is a'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='implant is a sustained-release device that is effective for up to 3 years when'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='to 3 years when administered intraocularly. It is FDA approved to treat DME in'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='to treat DME in patients who have been previously treated with a course of'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='a course of corticosteroids and did not have a clinically significant rise in IOP.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='rise in IOP. At the 0.2- g/day dosage, BCVA improvement of at least 15 letters was'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='15 letters was found in 28.7% of patients, with 38.4% needing anti-glaucoma'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='anti-glaucoma medications and 4.8% needing glaucoma surgery. The latter figure was'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='figure was reduced to 0% among eyes that did not have a history of IOP elevation'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='IOP elevation with a prior steroid challenge. Complications associate with both the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='with both the fluocinolone and the dexamethasone implants include cataracts and'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='cataracts and implant migration. Laser Photocoagulation Before anti-VEGF treatments'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='treatments for DME were approved, the standard treatment for CSME was macular laser'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='macular laser photocoagulation. In focal CSME, a focal laser pattern is used to'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='is used to treat leaking microaneurysms identified on the FA that contribute to the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='to the retinal edema (Figure 12). In diffuse CSME, intraretinal leakage is noted on'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='is noted on the FA from dilated retinal capillary beds or intraretinal microvascular'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='microvascular abnormalities without isolated, discrete foci of leakage. A macular'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='A macular grid is done in cases of diffuse macular edema (Figure 13). Laser'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='13). Laser photocoagulation has been shown to decrease the risk of moderate visual'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='moderate visual loss (loss of 15 ETDRS letters) from 24% to 12% after 3 years. After'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='3 years. After the laser treatment is administered, the patient will come back in 3'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='come back in 3 months for a follow-up examination. If residual CSME is noted, OCT'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='is noted, OCT and FA may be performed to evaluate the benefit and location of repeat'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='of repeat laser treatment. With the FDA approval of anti-VEGF agents for DME,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='agents for DME, focal/grid laser is only indicated in patients with non-ciDME.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='with non-ciDME. Macular laser remains a viable treatment option for patients with'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='patients with DME, especially in resource-limited countries with decreased access to'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='access to anti- VEGF agents. Combined Therapy Intravitreal ranibizumab with laser:'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='with laser: In Protocol I, intravitreal ranibizumab with prompt (within 1 week) or'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='1 week) or deferred (after 24 weeks) laser was more effective than focal/grid laser'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='laser alone for the treatment of ci-DME. Ranibizumab is injected intravitreally at'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='at baseline, followed by monthly injections for 4 months followed by the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='followed by the continuation of injections at 16 weeks if the OCT central subfield'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='subfield thickness is 250 um with VA worse than 20/20. Steroid with laser: Protocol'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='laser: Protocol B found that intravitreal triamcinolone (IVT) 4 mg plus focal/grid'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='plus focal/grid laser (given within a week of injection) was more effective than'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='effective than laser alone at 4 months. However, long- term benefit with this'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='with this combined therapy was not seen, with mean BCVA better in the laser'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='in the laser monotherapy group than the combined therapy group from the 16-month'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the 16-month time point until the 2-year end point. Complications of steroid therapy'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='steroid therapy included cataracts, ocular hypertension, and glaucoma. The'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='glaucoma. The difference in BCVA could not be attributed fully to the development of'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='development of cataracts. In Protocol I, 6-month VA improvement in eyes given IVT'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='eyes given IVT with prompt laser was comparable to that seen in eyes given'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='in eyes given ranibizumab, but vision declined afterward until the 2-year time'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the 2-year time point. A subgroup analysis in pseudophakic eyes given IVT showed'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='IVT showed that visual improvement was significantly better than in phakic eyes,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='in phakic eyes, with 1- and 2-year results comparable to pseudophakic eyes given'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='eyes given ranibizumab. Intravitreal ranibizumab with peripheral targeted retinal'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='retinal photocoagulation (TRP): The DAVE study was a phase 1/2 clinical trial that'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='trial that compared ranibizumab plus peripheral TRP and ranibizumab monotherapy for'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='monotherapy for reduce the number of required anti-VEGF injections. Peripheral TRP'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Peripheral TRP was defined as retinal photocoagulation administered outside the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='outside the macula to areas of retinal capillary nonperfusion identified on'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='identified on widefield FA. The nonperfused hypoxic retina is thought to upregulate'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='to upregulate hypoxia-inducible factors and cytokines, including VEGF and'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='VEGF and erythropoietin, with small studies suggesting that TRP can decrease the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='decrease the anti-VEGF treatment burden. At the 3-year endpoint, there was no'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='there was no evidence that combined ranibizumab plus TRP reduced treatment burden or'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='burden or improved vision outcomes compared with ranibizumab alone. Surgery No'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Surgery No well-constructed studies show a definitive benefit of pars plana'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='of pars plana vitrectomy (PPV) for managing DME. The theoretical basis for PPV as a'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='for PPV as a treatment option comes from reports that it increases vitreous'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='vitreous oxygenation in ischemia, leading to decreased VEGF production, and from the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='and from the observation that DME is less common among eyes with PVD. Vitreous'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='PVD. Vitreous viscosity also significantly decreases after PPV, which may bring'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='which may bring about a greater diffusion of pro-inflammatory cytokines away from'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='away from the macula. Other studies suggest that PPV plus internal limiting membrane'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='membrane (ILM) peeling brings better resolution of the tractional forces at the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='forces at the vitreoretinal interface known to worsen DME. This procedure also'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='procedure also prevents proliferating astrocytes from using the ILM as a scaffold,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='as a scaffold, which may lead to ERM. In a systematic review looking at PPV for DME,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='at PPV for DME, CST was significantly decreased by 102 m, and a nonsignificant VA'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='VA increase of 2 letters was observed. However, the anatomic benefit was not'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='benefit was not maintained by the 12-month time point. A similar meta-analysis'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='meta-analysis looking at PPV plus ILM peeling vs PPV alone showed no significant'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='no significant difference in postoperative vision and macular thickness between the'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='between the treatments. DRCR Protocol D, a prospective study of eyes with DME and'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='with DME and VMT, found that at 6 months after surgery, 43% of eyes had a reduction'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='had a reduction in CST to <250 m. However, the median VA did not change at 6 months.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='at 6 months. In 38% of eyes, the median visual acuity improved by 10 letters, and in'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='letters, and in 22% the median VA decreased by 10 letters. A post hoc analysis of'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='hoc analysis of Protocol I showed that previously vitrectomized eyes with ci-DME'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='with ci-DME given anti-VEGF treatments had no improved clinical outcomes compared'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='compared with non-vitrectomized eyes. Treatment Complications The complications'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='complications listed below may arise from the various treatment modalities. The'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='modalities. The per-injection risk of developing complications is also listed below,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='listed below, when available. Intravitreal Injections Endophthalmitis (0.019%0.05%)'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='(0.019%0.05%) Intraocular inflammation (0.09%0.4%) Retinal tears/detachment'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='(0.01%0.08%) Increase in IOP (for intravitreal steroids, IOP 21 mmHg in 45% at 1'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='in 45% at 1 month, 20% at 3 months, and 13% of eyes at 6 months post-injection.)'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Cataract (common after intravitreal steroid injections. By year 3, 83% of patients'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='83% of patients given IVT needed cataract surgery.) Subconjunctival hemorrhage (10%)'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='(10%) [91][92] [9] [47] [47][93] [94] [95][96][97][98][99]'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='[100][101][102][103][104][105] [106] [107] [108] [109] [110] [111] [112][113][114]'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='[112][113][114] [115] [116][117][118] [119] [120] [121] Learn more'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Vitreous hemorrhage Laser Photocoagulation Subretinal fibrosis Extension of the laser'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='of the laser scar into the fovea Choroidal neovascular membrane Paracentral scotoma'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='scotoma Decreased visual acuity Pars Plana Vitrectomy Retinal tears and retinal'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='and retinal detachment Vitreous hemorrhage Elevated intraocular pressure'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='pressure Endophthalmitis Cataract Prognosis Clinical factors associated with better'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='with better visual outcomes with anti-VEGF treatment include lower HbA1c, younger'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='HbA1c, younger age, less severe diabetic retinopathy, absence of ERM, quick and'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='ERM, quick and consistent CST decreases, and absence of prior panretinal'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='panretinal photocoagulation. In terms of anatomic outcomes, eyes with hard exudates'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='hard exudates within the 6-mm foveal center had a larger CST decrease at the end of'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='at the end of 1 year. The presence of exudates may be a marker of BRB abnormalities'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='abnormalities typical of DME responsive to anti-VEGF therapy. Eyes that lack'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Eyes that lack exudates may have other underlying mechanisms of retinal thickening,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='thickening, including cystoid degeneration, traction, or ischemia. In contrast, eyes'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='contrast, eyes with high baseline CST ( 570 m) had a significantly higher chance of'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='chance of developing persistent DME despite monthly ranibizumab therapy. In terms of'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='In terms of response to macular laser therapy, the ETDRS reported that worse'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='that worse clinical outcomes were associated with higher blood lipid levels,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='lipid levels, presence of hard exudates, and diffuse edema. Matsunaga et al. looked'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='et al. looked at eyes with DME treated with at least 1 dose of anti-VEGF agents that'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='agents that were then awere lost to follow-up (LTFU) for at least 6 months before'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='6 months before returning to the clinic. Vison worsened significantly at the initial'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='at the initial return visit, to ~20/69 from ~20/52; however, at the 3-, 6-, and'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the 3-, 6-, and 12-month follow-up visits and the final checkup, vision recovered'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='recovered with no significant differences from baseline. OCT CST also showed similar'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='showed similar trends. Gao et al. found that 25% of patients with NPDR and DME had'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='and DME had no follow-up visits for at least 1 year after receiving 1 anti-VEGF'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='1 anti-VEGF injection. Factors associated with being LTFU included Hispanic'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Hispanic ethnicity (OR 1.7) and American Indian/Pacific Islander/multiple'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='ethnicities (OR 2.6). Lower adjusted gross income and decreasing baseline vision'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='baseline vision were also factors significantly associated with LTFU. Some studies'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Some studies have shown increased risks of end-stage renal disease in patients with'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='patients with concurrent DME. Assessment of renal function should be strongly'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='be strongly encouraged in patients with chronic DME. Future Directions Numerous'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Numerous pharmacotherapy trials for DME treatment are underway. The development of a'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='of a long-acting anti-VEGF agent that could remain effective in the vitreous for'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='vitreous for multiple months or years would significantly decrease the treatment'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='the treatment burden for patients needing monthly injections. Novel'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Novel pharmacotherapies based on different mechanisms of action include anti-VEGF'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='anti-VEGF designed ankyrin repeat proteins, growth factor inhibitors,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='inhibitors, anti-inflammatory medications, hormone modulators, acetylcholine'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='acetylcholine receptor blockers, insulin-like growth factor 1 receptor blockers, and'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='blockers, and neuroprotective/antiapoptotic agents. Port delivery systems that are'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='that are FDA approved for wet AMD are in development to treat diabetic retinopathy'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='retinopathy and DME. These experimental therapies have the potential to'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='potential to significantly decrease the burden of treatment while restoring vision'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='vision to patients with DME in the coming years ahead. An ophthalmic suspension,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='suspension, OCS-01, a topical dexamethasone that is formulated with nanoparticle'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='nanoparticle technology, in a completed Phase 2 trial has shown a higher reduction'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='reduction in CMT with OCS-01 compared to control. Further phase 3 studies are'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='3 studies are pending yet. Artificial intelligence (AI) plus tele-ophthalmology'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='models are being used to develop screening tools for diabetic retinopathy and DME.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='and DME. These models can detect the retinal complications of diabetes remotely, and'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='remotely, and if this technology is placed in the offices of internists and'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='internists and endocrinologists, it may allow for early detection and timely'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='and timely intervention. Further reading 1. Bhagat N, Grigorian RA, Tutela A, Zarbin'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Ophthalmol. 2009;54(1):1-32 2. Diabetic Retinopathy Clinical Research Network'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Network Randomized trial evaluating ranibizumab plus prompt or deferred laser or'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Ophthalmology. 2010; 117(6):1064-1077. 3. Early Treatment Diabetic Retinopathy'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Retinopathy Study: Photocoagulation for diabetic macular edema. Early Treatment'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103(12):1796-1806.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='4. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='trial of intravitreal bevacizumab or laser therapy in the management of diabetic'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='of diabetic macular edema (BOLT study) 12 month data: report 2. Ophthalmology. 2010;'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='2010; 117(6):1078-1086.e2. 5. Schachat AP. A new approach to the management of'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='management of diabetic macular edema. Ophthalmology. 2010;117(6):1059-1060.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='References 1. Otani T, Kishi S, Maruyama Y. Patterns of diabetic macular edema with'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='edema with optical coherence tomography. Am J Ophthalmol. 1999;127(6):688-693. 2.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='2. Yanoff M, Fine BS, Brucker AJ, et al. Pathology of human cystoid macular edema.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='macular edema. Surv Ophthalmol. 1984;28(suppl):505-511. 3. Xu H-Z, Le Y-Z.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='Xu H-Z, Le Y-Z. Significance of outer bloodretina barrier breakdown in diabetes and'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='in diabetes and ischemia. Invest Ophthalmol Vis Sci. 2011;52(5):2160-2164. 4.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='4. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='mechanism. Diabetes. 2005;54(6):1615-1625. 5. Del Zoppo G. The neurovascular unit in'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='unit in the setting of stroke. J Intern Med. 2010;267(2):156-171. 6. Gao B-B,'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='6. Gao B-B, Clermont A, Rook S, et al. Extracellular carbonic anhydrase mediates'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='mediates hemorrhagic retinal and cerebral vascular permeability through'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='through prekallikrein activation. Nat Med. 2007;13(2):181-188. 7. Jeppesen P, Aalkjr'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='P, Aalkjr C, Bek T. Bradykinin relaxation in small porcine retinal arterioles.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='arterioles. Invest Ophthalmol Vis Sci. 2002;43(6):1891-1896. 8. Parpura V, Basarsky'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='V, Basarsky TA, Liu F, et al. Glutamate-mediated astrocyte neuron signalling.'),\n",
       " Document(metadata={'source': 'Data/Diabetic Macular Edema - EyeWiki.pdf'}, page_content='signalling. Nature. 1994;369(6483):744-747. 9. Early Treatment Diabetic Retinopathy'),\n",
       " ...]"
      ]
     },
     "execution_count": 43,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "text_chunks"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "397eaa43",
   "metadata": {},
   "source": [
    "Embeddings\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f2922a93",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.embeddings import HuggingFaceEmbeddings\n",
    "def text_embedding():\n",
    "    \"\"\"\n",
    "    Download and Return HuggingFace Embeddings model.\n",
    "    \"\"\"\n",
    "    Model_name = \"sentence-transformers/all-MiniLM-L6-v2\"\n",
    "    embeddings = HuggingFaceEmbeddings(\n",
    "        model_name=Model_name\n",
    "\n",
    "        )\n",
    "    return embeddings\n",
    "\n",
    "embeddings = text_embedding()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "89be5990",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 45,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from dotenv import load_dotenv\n",
    "import os\n",
    "load_dotenv()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "62d7c775",
   "metadata": {},
   "outputs": [],
   "source": [
    "PINECONE_API_KEY = os.getenv(\"PINECONE_API_KEY\")\n",
    "GOOGLE_API_KEY = os.getenv(\"GOOGLE_API_KEY\")\n",
    "\n",
    "os.environ[\"PINECONE_API_KEY\"] = PINECONE_API_KEY\n",
    "os.environ[\"GOOGLE_API_KEY\"] = GOOGLE_API_KEY"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "71726a59",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<pinecone.pinecone.Pinecone at 0x7c23544d7c50>"
      ]
     },
     "execution_count": 47,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from pinecone import Pinecone\n",
    "pinecone_api_key = PINECONE_API_KEY\n",
    "pc = Pinecone(api_key=pinecone_api_key) #for connecting to pinecone database, pc is picone connect\n",
    "\n",
    "pc"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a8099cb3",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[\n",
       "    {\n",
       "        \"name\": \"eye-disease-chatbot\",\n",
       "        \"metric\": \"cosine\",\n",
       "        \"host\": \"eye-disease-chatbot-kuovyk1.svc.aped-4627-b74a.pinecone.io\",\n",
       "        \"spec\": {\n",
       "            \"serverless\": {\n",
       "                \"cloud\": \"aws\",\n",
       "                \"region\": \"us-east-1\"\n",
       "            }\n",
       "        },\n",
       "        \"status\": {\n",
       "            \"ready\": true,\n",
       "            \"state\": \"Ready\"\n",
       "        },\n",
       "        \"vector_type\": \"dense\",\n",
       "        \"dimension\": 384,\n",
       "        \"deletion_protection\": \"disabled\",\n",
       "        \"tags\": null\n",
       "    }\n",
       "]"
      ]
     },
     "execution_count": 48,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pc.list_indexes()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "e6e06fb9",
   "metadata": {},
   "outputs": [],
   "source": [
    "# from pinecone import ServerlessSpec\n",
    "# index_name = \"eye-disease-chatbot\"\n",
    "# if not pc.has_index(index_name):\n",
    "#     pc.create_index(\n",
    "#         name=index_name,\n",
    "#         dimension=384, #Dimenstion of embedings , if you know Dimension you can directly pass it\n",
    "#         metric=\"cosine\", #for similarity search\n",
    "#         spec=ServerlessSpec(\n",
    "#             cloud = \"aws\",\n",
    "#             region = \"us-east-1\"\n",
    "#         )\n",
    "#     )\n",
    "\n",
    "# index = pc.Index(index_name)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "41d3ed0d",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_pinecone import PineconeVectorStore\n",
    "docsearch = PineconeVectorStore.from_documents(\n",
    "    documents = text_chunks,\n",
    "    embedding=embeddings,\n",
    "    index_name=\"eye-disease-chatbot\"\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "e739870c",
   "metadata": {},
   "outputs": [],
   "source": [
    "restriver = docsearch.as_retriever(search_type=\"similarity\", search_kwargs={\"k\":5})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "7b9e607e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(id='432895d2-836d-481c-8601-1510057daac8', metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='pharmacologic intervention the large branches of the CNV become pruned and the'),\n",
       " Document(id='ac61d1bc-a7d1-479f-8130-ba05b41520f3', metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='pharmacologic intervention the large branches of the CNV become pruned and the'),\n",
       " Document(id='60cf260c-d874-4271-bfaf-394bf0f6d88a', metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='pharmacologic intervention the large branches of the CNV become pruned and the'),\n",
       " Document(id='c1d25b92-24e9-4f0c-80fa-2fb03566921d', metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='(ICGA) and OCT. These well-established modalities can guide effective CNV management'),\n",
       " Document(id='8d38b0c1-4cc0-4121-bb8e-d685665e7131', metadata={'source': 'Data/(CNV)Choroidal Neovascularization_ OCT Angiography Findings - EyeWiki.pdf'}, page_content='(ICGA) and OCT. These well-established modalities can guide effective CNV management')]"
      ]
     },
     "execution_count": 52,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "restriver.invoke(\"what is CNV\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "3b723f5a",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_google_genai import ChatGoogleGenerativeAI\n",
    "ChatModel = ChatGoogleGenerativeAI(model=\"gemini-2.5-flash\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "3bafac23",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.chains import create_retrieval_chain\n",
    "from langchain.chains.combine_documents import create_stuff_documents_chain\n",
    "from langchain_core.prompts import ChatPromptTemplate"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f666b304",
   "metadata": {},
   "outputs": [],
   "source": [
    "system_prompt = (\n",
    "    \"You are a helpful medical assistant specializing in eye diseases. \"\n",
    "    \"Answer questions based on the provided context from reliable medical sources. \"\n",
    "    \"If the context doesn't fully cover the query, use your general knowledge to provide accurate, concise information. \"\n",
    "    \"Be clear, concise, and empathetic. Always advise consulting a qualified eye care professional for diagnosis or treatment. if they ask for medical advaice. \"\n",
    "    \"By the given context answer the questions carefully without menstioning that you are an AI language model. \"\n",
    "    \"when they ask you about the any disease provide the all the information that you in the context and also include the general infromation form realbel medical sources. to extend the answer in clear way.\"\n",
    "    \"Do not provide medical advice or diagnoses. \"\n",
    "    \"\\n\\n\"\n",
    "    \"{context}\"\n",
    ")\n",
    "\n",
    "prompt = ChatPromptTemplate.from_messages([\n",
    "    (\"system\", system_prompt),\n",
    "    (\"user\", \"{input}\")\n",
    "])\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "e6c882dc",
   "metadata": {},
   "outputs": [],
   "source": [
    "question_answer_chain = create_stuff_documents_chain(\n",
    "    llm=ChatModel,\n",
    "    prompt=prompt \n",
    ")\n",
    "rag_chain = create_retrieval_chain(restriver, question_answer_chain)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "74356d3f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "CNV stands for Choroidal Neovascularization. It is a condition characterized by the growth of new, abnormal blood vessels originating from the choroid (a layer of blood vessels behind the retina) into the subretinal space or under the retinal pigment epithelium.\n",
      "\n",
      "In the presence of CNV, a patient may experience acute symptoms, often involving sudden changes in vision. These new blood vessels are fragile and prone to leaking fluid or blood, which can lead to:\n",
      "*   Blurred or distorted vision\n",
      "*   The appearance of a blind spot (scotoma) in the central vision\n",
      "*   Rapid vision loss\n",
      "\n",
      "CNV is a significant cause of vision loss, particularly in conditions like wet age-related macular degeneration (AMD), but it can also occur due to other eye conditions. Pharmacologic interventions are available that can help to prune or regress the large branches of these abnormal vessels, aiming to preserve vision.\n",
      "\n",
      "If you are experiencing any changes in your vision, it is crucial to consult a qualified eye care professional for an accurate diagnosis and appropriate treatment.\n"
     ]
    }
   ],
   "source": [
    "response = rag_chain.invoke({'input': \"What is cnv?\"})\n",
    "print(response[\"answer\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "507b862d",
   "metadata": {},
   "outputs": [],
   "source": [
    "import tensorflow as tf\n",
    "import numpy as np\n",
    "import os"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "b18f5be9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'/home/user/Desktop/medical_bot/Eye_Disease_Chatbot'"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import os\n",
    "os.chdir(\"../\")\n",
    "\n",
    "%pwd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "049db353",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "File exists: True\n",
      "Current working directory: /home/user/Desktop/medical_bot/Eye_Disease_Chatbot\n",
      "File path: eye_dieases_model.h5\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "MODEL_PATH = \"eye_dieases_model.h5\"\n",
    "print(\"File exists:\", os.path.exists(MODEL_PATH))\n",
    "print(\"Current working directory:\", os.getcwd())\n",
    "print(\"File path:\", MODEL_PATH)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "b4c52320",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:absl:Compiled the loaded model, but the compiled metrics have yet to be built. `model.compile_metrics` will be empty until you train or evaluate the model.\n"
     ]
    }
   ],
   "source": [
    "MODEL_PATH = \"/home/user/Desktop/medical_bot/Eye_Disease_Chatbot/eye_dieases_model.h5\"\n",
    "model = tf.keras.models.load_model(MODEL_PATH)\n",
    "\n",
    "CLASS_NAMES = ['CNV', 'DME', 'DRUSEN', 'NORMAL']\n",
    "IMG_SIZE = (224, 224)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "59f87f64",
   "metadata": {},
   "outputs": [],
   "source": [
    "def preprocess_image(image_path):\n",
    "    img = tf.keras.preprocessing.image.load_img(\n",
    "        image_path,\n",
    "        target_size=IMG_SIZE\n",
    "    )\n",
    "    img_array = tf.keras.preprocessing.image.img_to_array(img)\n",
    "    img_array = np.expand_dims(img_array, axis=0)\n",
    "    img_array = tf.keras.applications.efficientnet.preprocess_input(img_array)\n",
    "    return img_array\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "91929e24",
   "metadata": {},
   "outputs": [],
   "source": [
    "# def predict_eye_disease(image_path):\n",
    "#     img = preprocess_image(image_path)\n",
    "\n",
    "#     probs = model.predict(img)[0]\n",
    "#     pred_idx = np.argmax(probs)\n",
    "\n",
    "#     result = {\n",
    "#         \"disease\": CLASS_NAMES[pred_idx],\n",
    "#         \"confidence\": float(probs[pred_idx]),\n",
    "#         \"all_probabilities\": {\n",
    "#             CLASS_NAMES[i]: float(probs[i]) for i in range(len(CLASS_NAMES))\n",
    "#         }\n",
    "#     }\n",
    "\n",
    "#     return result\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "62e1d3bd",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1m1/1\u001b[0m \u001b[32m━━━━━━━━━━━━━━━━━━━━\u001b[0m\u001b[37m\u001b[0m \u001b[1m3s\u001b[0m 3s/step\n",
      "{'disease': 'CNV', 'confidence': 0.9503692388534546, 'all_probabilities': {'CNV': 0.9503692388534546, 'DME': 0.049628857523202896, 'DRUSEN': 1.2482005331548862e-06, 'NORMAL': 6.577961926268472e-07}}\n"
     ]
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a31708d8",
   "metadata": {},
   "outputs": [],
   "source": [
    "import tensorflow as tf\n",
    "import numpy as np\n",
    "\n",
    "IMG_SIZE = (224, 224)\n",
    "CLASS_NAMES = ['CNV', 'DME', 'DRUSEN', 'NORMAL']\n",
    "\n",
    "def build_model():\n",
    "    base_model = tf.keras.applications.EfficientNetB0(\n",
    "        include_top=False,\n",
    "        weights=None,   # IMPORTANT\n",
    "        input_shape=(224, 224, 3)\n",
    "    )\n",
    "    base_model.trainable = False\n",
    "\n",
    "    inputs = tf.keras.Input(shape=(224, 224, 3))\n",
    "    x = tf.keras.applications.efficientnet.preprocess_input(inputs)\n",
    "    x = base_model(x)\n",
    "    x = tf.keras.layers.GlobalAveragePooling2D()(x)\n",
    "    x = tf.keras.layers.Dense(128, activation=\"relu\")(x)\n",
    "    outputs = tf.keras.layers.Dense(4, activation=\"softmax\")(x)\n",
    "\n",
    "    return tf.keras.Model(inputs, outputs)\n",
    "\n",
    "model = build_model()\n",
    "model.load_weights(\"eye_diseases_weights.weights.h5\")\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "25740ff5",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "CLASS_NAMES = ['CNV', 'DME', 'DRUSEN', 'NORMAL']\n",
    "IMG_SIZE = (224, 224)\n",
    "\n",
    "def preprocess_image(image_path):\n",
    "    img = tf.keras.preprocessing.image.load_img(\n",
    "        image_path,\n",
    "        target_size=IMG_SIZE\n",
    "    )\n",
    "    img_array = tf.keras.preprocessing.image.img_to_array(img)\n",
    "    img_array = np.expand_dims(img_array, axis=0)\n",
    "    img_array = tf.keras.applications.efficientnet.preprocess_input(img_array)\n",
    "    return img_array\n",
    "\n",
    "def predict_eye_disease(image_path):\n",
    "    img = preprocess_image(image_path)\n",
    "\n",
    "    probs = model.predict(img)[0]\n",
    "    pred_idx = np.argmax(probs)\n",
    "\n",
    "    result = {\n",
    "        \"disease\": CLASS_NAMES[pred_idx],\n",
    "        \"confidence\": float(probs[pred_idx]),\n",
    "        \"all_probabilities\": {\n",
    "            CLASS_NAMES[i]: float(probs[i]) for i in range(len(CLASS_NAMES))\n",
    "        }\n",
    "    }\n",
    "\n",
    "    return result\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "3eb769c7",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1m1/1\u001b[0m \u001b[32m━━━━━━━━━━━━━━━━━━━━\u001b[0m\u001b[37m\u001b[0m \u001b[1m2s\u001b[0m 2s/step\n",
      "{'disease': 'CNV', 'confidence': 0.7266435027122498, 'all_probabilities': {'CNV': 0.7266435027122498, 'DME': 0.05322744697332382, 'DRUSEN': 0.20679524540901184, 'NORMAL': 0.013333828188478947}}\n"
     ]
    }
   ],
   "source": [
    "image_path = \"/home/user/Desktop/medical_bot/Eye_Disease_Chatbot/CNV-1016042-3.jpeg\"\n",
    "prediction = predict_eye_disease(image_path)\n",
    "print(prediction)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "af6bc6e3",
   "metadata": {},
   "source": [
    "##### adding Voice to the chat \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "c6d42968",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING: All log messages before absl::InitializeLog() is called are written to STDERR\n",
      "I0000 00:00:1771841519.888792    4163 fork_posix.cc:71] Other threads are currently calling into gRPC, skipping fork() handlers\n",
      "huggingface/tokenizers: The current process just got forked, after parallelism has already been used. Disabling parallelism to avoid deadlocks...\n",
      "To disable this warning, you can either:\n",
      "\t- Avoid using `tokenizers` before the fork if possible\n",
      "\t- Explicitly set the environment variable TOKENIZERS_PARALLELISM=(true | false)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already satisfied: sounddevice in ./medchatenv/lib/python3.12/site-packages (0.5.5)\n",
      "Requirement already satisfied: scipy in ./medchatenv/lib/python3.12/site-packages (1.16.3)\n",
      "Requirement already satisfied: cffi in ./medchatenv/lib/python3.12/site-packages (from sounddevice) (2.0.0)\n",
      "Requirement already satisfied: numpy<2.6,>=1.25.2 in ./medchatenv/lib/python3.12/site-packages (from scipy) (1.26.4)\n",
      "Requirement already satisfied: pycparser in ./medchatenv/lib/python3.12/site-packages (from cffi->sounddevice) (2.23)\n"
     ]
    }
   ],
   "source": [
    "!pip install sounddevice scipy"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "df4fa0b6",
   "metadata": {},
   "outputs": [],
   "source": [
    "# input_audio.py\n",
    "import sounddevice as sd\n",
    "from scipy.io.wavfile import write\n",
    "\n",
    "def record_audio(filename=\"input.wav\", duration=5):\n",
    "    sample_rate = 16000  # standard for speech models\n",
    "\n",
    "    print(\"🎙️ Speak now...\")\n",
    "    audio = sd.rec(\n",
    "        int(duration * sample_rate),\n",
    "        samplerate=sample_rate,\n",
    "        channels=1,\n",
    "        dtype=\"int16\"\n",
    "    )\n",
    "    sd.wait()\n",
    "\n",
    "    write(filename, sample_rate, audio)\n",
    "    print(\"✅ Audio recorded\")\n",
    "\n",
    "    return filename"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "787c85d3",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "I0000 00:00:1771841563.254344    4163 fork_posix.cc:71] Other threads are currently calling into gRPC, skipping fork() handlers\n",
      "huggingface/tokenizers: The current process just got forked, after parallelism has already been used. Disabling parallelism to avoid deadlocks...\n",
      "To disable this warning, you can either:\n",
      "\t- Avoid using `tokenizers` before the fork if possible\n",
      "\t- Explicitly set the environment variable TOKENIZERS_PARALLELISM=(true | false)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already satisfied: openai-whisper in ./medchatenv/lib/python3.12/site-packages (20250625)\n",
      "Requirement already satisfied: more-itertools in ./medchatenv/lib/python3.12/site-packages (from openai-whisper) (10.8.0)\n",
      "Requirement already satisfied: numba in ./medchatenv/lib/python3.12/site-packages (from openai-whisper) (0.64.0)\n",
      "Requirement already satisfied: numpy in ./medchatenv/lib/python3.12/site-packages (from openai-whisper) (1.26.4)\n",
      "Requirement already satisfied: tiktoken in ./medchatenv/lib/python3.12/site-packages (from openai-whisper) (0.12.0)\n",
      "Requirement already satisfied: torch in ./medchatenv/lib/python3.12/site-packages (from openai-whisper) (2.10.0)\n",
      "Requirement already satisfied: tqdm in ./medchatenv/lib/python3.12/site-packages (from openai-whisper) (4.67.1)\n",
      "Requirement already satisfied: triton>=2 in ./medchatenv/lib/python3.12/site-packages (from openai-whisper) (3.6.0)\n",
      "Requirement already satisfied: llvmlite<0.47,>=0.46.0dev0 in ./medchatenv/lib/python3.12/site-packages (from numba->openai-whisper) (0.46.0)\n",
      "Requirement already satisfied: regex>=2022.1.18 in ./medchatenv/lib/python3.12/site-packages (from tiktoken->openai-whisper) (2025.11.3)\n",
      "Requirement already satisfied: requests>=2.26.0 in ./medchatenv/lib/python3.12/site-packages (from tiktoken->openai-whisper) (2.32.5)\n",
      "Requirement already satisfied: filelock in ./medchatenv/lib/python3.12/site-packages (from torch->openai-whisper) (3.20.0)\n",
      "Requirement already satisfied: typing-extensions>=4.10.0 in ./medchatenv/lib/python3.12/site-packages (from torch->openai-whisper) (4.15.0)\n",
      "Requirement already satisfied: setuptools in ./medchatenv/lib/python3.12/site-packages (from torch->openai-whisper) (80.9.0)\n",
      "Requirement already satisfied: sympy>=1.13.3 in ./medchatenv/lib/python3.12/site-packages (from torch->openai-whisper) (1.14.0)\n",
      "Requirement already satisfied: networkx>=2.5.1 in ./medchatenv/lib/python3.12/site-packages (from torch->openai-whisper) (3.6.1)\n",
      "Requirement already satisfied: jinja2 in ./medchatenv/lib/python3.12/site-packages (from torch->openai-whisper) (3.1.6)\n",
      "Requirement already satisfied: fsspec>=0.8.5 in ./medchatenv/lib/python3.12/site-packages (from torch->openai-whisper) (2025.12.0)\n",
      "Requirement already satisfied: cuda-bindings==12.9.4 in ./medchatenv/lib/python3.12/site-packages (from torch->openai-whisper) (12.9.4)\n",
      "Requirement already satisfied: nvidia-cuda-nvrtc-cu12==12.8.93 in ./medchatenv/lib/python3.12/site-packages (from torch->openai-whisper) (12.8.93)\n",
      "Requirement already satisfied: nvidia-cuda-runtime-cu12==12.8.90 in ./medchatenv/lib/python3.12/site-packages (from torch->openai-whisper) (12.8.90)\n",
      "Requirement already satisfied: nvidia-cuda-cupti-cu12==12.8.90 in ./medchatenv/lib/python3.12/site-packages (from torch->openai-whisper) (12.8.90)\n",
      "Requirement already satisfied: nvidia-cudnn-cu12==9.10.2.21 in ./medchatenv/lib/python3.12/site-packages (from torch->openai-whisper) (9.10.2.21)\n",
      "Requirement already satisfied: nvidia-cublas-cu12==12.8.4.1 in ./medchatenv/lib/python3.12/site-packages (from torch->openai-whisper) (12.8.4.1)\n",
      "Requirement already satisfied: nvidia-cufft-cu12==11.3.3.83 in ./medchatenv/lib/python3.12/site-packages (from torch->openai-whisper) (11.3.3.83)\n",
      "Requirement already satisfied: nvidia-curand-cu12==10.3.9.90 in ./medchatenv/lib/python3.12/site-packages (from torch->openai-whisper) (10.3.9.90)\n",
      "Requirement already satisfied: nvidia-cusolver-cu12==11.7.3.90 in ./medchatenv/lib/python3.12/site-packages (from torch->openai-whisper) (11.7.3.90)\n",
      "Requirement already satisfied: nvidia-cusparse-cu12==12.5.8.93 in ./medchatenv/lib/python3.12/site-packages (from torch->openai-whisper) (12.5.8.93)\n",
      "Requirement already satisfied: nvidia-cusparselt-cu12==0.7.1 in ./medchatenv/lib/python3.12/site-packages (from torch->openai-whisper) (0.7.1)\n",
      "Requirement already satisfied: nvidia-nccl-cu12==2.27.5 in ./medchatenv/lib/python3.12/site-packages (from torch->openai-whisper) (2.27.5)\n",
      "Requirement already satisfied: nvidia-nvshmem-cu12==3.4.5 in ./medchatenv/lib/python3.12/site-packages (from torch->openai-whisper) (3.4.5)\n",
      "Requirement already satisfied: nvidia-nvtx-cu12==12.8.90 in ./medchatenv/lib/python3.12/site-packages (from torch->openai-whisper) (12.8.90)\n",
      "Requirement already satisfied: nvidia-nvjitlink-cu12==12.8.93 in ./medchatenv/lib/python3.12/site-packages (from torch->openai-whisper) (12.8.93)\n",
      "Requirement already satisfied: nvidia-cufile-cu12==1.13.1.3 in ./medchatenv/lib/python3.12/site-packages (from torch->openai-whisper) (1.13.1.3)\n",
      "Requirement already satisfied: cuda-pathfinder~=1.1 in ./medchatenv/lib/python3.12/site-packages (from cuda-bindings==12.9.4->torch->openai-whisper) (1.3.4)\n",
      "Requirement already satisfied: charset_normalizer<4,>=2 in ./medchatenv/lib/python3.12/site-packages (from requests>=2.26.0->tiktoken->openai-whisper) (3.4.4)\n",
      "Requirement already satisfied: idna<4,>=2.5 in ./medchatenv/lib/python3.12/site-packages (from requests>=2.26.0->tiktoken->openai-whisper) (3.11)\n",
      "Requirement already satisfied: urllib3<3,>=1.21.1 in ./medchatenv/lib/python3.12/site-packages (from requests>=2.26.0->tiktoken->openai-whisper) (2.6.1)\n",
      "Requirement already satisfied: certifi>=2017.4.17 in ./medchatenv/lib/python3.12/site-packages (from requests>=2.26.0->tiktoken->openai-whisper) (2025.11.12)\n",
      "Requirement already satisfied: mpmath<1.4,>=1.1.0 in ./medchatenv/lib/python3.12/site-packages (from sympy>=1.13.3->torch->openai-whisper) (1.3.0)\n",
      "Requirement already satisfied: MarkupSafe>=2.0 in ./medchatenv/lib/python3.12/site-packages (from jinja2->torch->openai-whisper) (3.0.3)\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "I0000 00:00:1771841567.550114    4163 fork_posix.cc:71] Other threads are currently calling into gRPC, skipping fork() handlers\n",
      "huggingface/tokenizers: The current process just got forked, after parallelism has already been used. Disabling parallelism to avoid deadlocks...\n",
      "To disable this warning, you can either:\n",
      "\t- Avoid using `tokenizers` before the fork if possible\n",
      "\t- Explicitly set the environment variable TOKENIZERS_PARALLELISM=(true | false)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already satisfied: ffmpeg-python in ./medchatenv/lib/python3.12/site-packages (0.2.0)\n",
      "Requirement already satisfied: future in ./medchatenv/lib/python3.12/site-packages (from ffmpeg-python) (1.0.0)\n"
     ]
    }
   ],
   "source": [
    "!pip install openai-whisper\n",
    "!pip install ffmpeg-python"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "2a0f681d",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Collecting ffmpeg\n",
      "  Downloading ffmpeg-1.4.tar.gz (5.1 kB)\n",
      "  Preparing metadata (setup.py) ... \u001b[?25ldone\n",
      "\u001b[?25hBuilding wheels for collected packages: ffmpeg\n",
      "  Building wheel for ffmpeg (setup.py) ... \u001b[?25ldone\n",
      "\u001b[?25h  Created wheel for ffmpeg: filename=ffmpeg-1.4-py3-none-any.whl size=6127 sha256=d24bfa6da90e64101d0527e3414058493354bab962c5bb7aad578a5de85bcee0\n",
      "  Stored in directory: /home/user/.cache/pip/wheels/26/21/0c/c26e09dff860a9071683e279445262346e008a9a1d2142c4ad\n",
      "Successfully built ffmpeg\n",
      "Installing collected packages: ffmpeg\n",
      "Successfully installed ffmpeg-1.4\n"
     ]
    }
   ],
   "source": [
    "!pip  install  ffmpeg"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 98,
   "id": "498f340d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'/home/user/snap/code/225/.local/share/Trash/files/LuxTTS.3'"
      ]
     },
     "execution_count": 98,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "%pwd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 102,
   "id": "f7664417",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "/home/user/Desktop/medical_bot/Eye_Disease_Chatbot/research\n"
     ]
    }
   ],
   "source": [
    "cd /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/research"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 103,
   "id": "5da1750e",
   "metadata": {},
   "outputs": [],
   "source": [
    "# stt_whisper.py\n",
    "import whisper\n",
    "\n",
    "model = whisper.load_model(\"base\")\n",
    "\n",
    "def speech_to_text(audio_file):\n",
    "    result = model.transcribe(audio_file)\n",
    "    return result[\"text\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 104,
   "id": "16bd35d9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'/home/user/Desktop/medical_bot/Eye_Disease_Chatbot/research'"
      ]
     },
     "execution_count": 104,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# !wget https://github.com/rhasspy/piper/releases/download/v1.2.0/piper_linux_x86_64.tar.gz\n",
    "\n",
    "%pwd\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 105,
   "id": "7a74c692",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "I0000 00:00:1771848291.973200    4109 fork_posix.cc:71] Other threads are currently calling into gRPC, skipping fork() handlers\n",
      "huggingface/tokenizers: The current process just got forked, after parallelism has already been used. Disabling parallelism to avoid deadlocks...\n",
      "To disable this warning, you can either:\n",
      "\t- Avoid using `tokenizers` before the fork if possible\n",
      "\t- Explicitly set the environment variable TOKENIZERS_PARALLELISM=(true | false)\n",
      "5118.99s - pydevd: Sending message related to process being replaced timed-out after 5 seconds\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "piper/\n",
      "piper/espeak-ng\n",
      "piper/libpiper_phonemize.so.1.2.0\n",
      "piper/piper_phonemize\n",
      "piper/libespeak-ng.so.1.52.0.1\n",
      "piper/libtashkeel_model.ort\n",
      "piper/pkgconfig/\n",
      "piper/libpiper_phonemize.so\n",
      "piper/libpiper_phonemize.so.1\n",
      "piper/piper\n",
      "piper/espeak-ng-data/\n",
      "piper/espeak-ng-data/ms_dict\n",
      "piper/espeak-ng-data/vi_dict\n",
      "piper/espeak-ng-data/haw_dict\n",
      "piper/espeak-ng-data/be_dict\n",
      "piper/espeak-ng-data/ur_dict\n",
      "piper/espeak-ng-data/am_dict\n",
      "piper/espeak-ng-data/as_dict\n",
      "piper/espeak-ng-data/ne_dict\n",
      "piper/espeak-ng-data/jbo_dict\n",
      "piper/espeak-ng-data/ja_dict\n",
      "piper/espeak-ng-data/phonindex\n",
      "piper/espeak-ng-data/qu_dict\n",
      "piper/espeak-ng-data/cs_dict\n",
      "piper/espeak-ng-data/bpy_dict\n",
      "piper/espeak-ng-data/ko_dict\n",
      "piper/espeak-ng-data/lv_dict\n",
      "piper/espeak-ng-data/sd_dict\n",
      "piper/espeak-ng-data/voices/\n",
      "piper/espeak-ng-data/voices/!v/\n",
      "piper/espeak-ng-data/voices/!v/robosoft2\n",
      "piper/espeak-ng-data/voices/!v/Andrea\n",
      "piper/espeak-ng-data/voices/!v/robosoft4\n",
      "piper/espeak-ng-data/voices/!v/linda\n",
      "piper/espeak-ng-data/voices/!v/robosoft8\n",
      "piper/espeak-ng-data/voices/!v/Tweaky\n",
      "piper/espeak-ng-data/voices/!v/rob\n",
      "piper/espeak-ng-data/voices/!v/m2\n",
      "piper/espeak-ng-data/voices/!v/robosoft6\n",
      "piper/espeak-ng-data/voices/!v/aunty\n",
      "piper/espeak-ng-data/voices/!v/m1\n",
      "piper/espeak-ng-data/voices/!v/iven\n",
      "piper/espeak-ng-data/voices/!v/Alicia\n",
      "piper/espeak-ng-data/voices/!v/robert\n",
      "piper/espeak-ng-data/voices/!v/Michael\n",
      "piper/espeak-ng-data/voices/!v/Mike\n",
      "piper/espeak-ng-data/voices/!v/klatt2\n",
      "piper/espeak-ng-data/voices/!v/fast\n",
      "piper/espeak-ng-data/voices/!v/shelby\n",
      "piper/espeak-ng-data/voices/!v/gustave\n",
      "piper/espeak-ng-data/voices/!v/pedro\n",
      "piper/espeak-ng-data/voices/!v/m5\n",
      "piper/espeak-ng-data/voices/!v/travis\n",
      "piper/espeak-ng-data/voices/!v/marcelo\n",
      "piper/espeak-ng-data/voices/!v/croak\n",
      "piper/espeak-ng-data/voices/!v/kaukovalta\n",
      "piper/espeak-ng-data/voices/!v/f4\n",
      "piper/espeak-ng-data/voices/!v/iven2\n",
      "piper/espeak-ng-data/voices/!v/grandpa\n",
      "piper/espeak-ng-data/voices/!v/steph3\n",
      "piper/espeak-ng-data/voices/!v/iven3\n",
      "piper/espeak-ng-data/voices/!v/Gene\n",
      "piper/espeak-ng-data/voices/!v/Reed\n",
      "piper/espeak-ng-data/voices/!v/klatt4\n",
      "piper/espeak-ng-data/voices/!v/Alex\n",
      "piper/espeak-ng-data/voices/!v/paul\n",
      "piper/espeak-ng-data/voices/!v/pablo\n",
      "piper/espeak-ng-data/voices/!v/robosoft5\n",
      "piper/espeak-ng-data/voices/!v/Denis\n",
      "piper/espeak-ng-data/voices/!v/m3\n",
      "piper/espeak-ng-data/voices/!v/robosoft\n",
      "piper/espeak-ng-data/voices/!v/belinda\n",
      "piper/espeak-ng-data/voices/!v/f1\n",
      "piper/espeak-ng-data/voices/!v/quincy\n",
      "piper/espeak-ng-data/voices/!v/Jacky\n",
      "piper/espeak-ng-data/voices/!v/edward\n",
      "piper/espeak-ng-data/voices/!v/sandro\n",
      "piper/espeak-ng-data/voices/!v/m4\n",
      "piper/espeak-ng-data/voices/!v/grandma\n",
      "piper/espeak-ng-data/voices/!v/miguel\n",
      "piper/espeak-ng-data/voices/!v/Storm\n",
      "piper/espeak-ng-data/voices/!v/klatt\n",
      "piper/espeak-ng-data/voices/!v/Mario\n",
      "piper/espeak-ng-data/voices/!v/Henrique\n",
      "piper/espeak-ng-data/voices/!v/anika\n",
      "piper/espeak-ng-data/voices/!v/f5\n",
      "piper/espeak-ng-data/voices/!v/Annie\n",
      "piper/espeak-ng-data/voices/!v/klatt3\n",
      "piper/espeak-ng-data/voices/!v/Andy\n",
      "piper/espeak-ng-data/voices/!v/whisperf\n",
      "piper/espeak-ng-data/voices/!v/Nguyen\n",
      "piper/espeak-ng-data/voices/!v/whisper\n",
      "piper/espeak-ng-data/voices/!v/benjamin\n",
      "piper/espeak-ng-data/voices/!v/anikaRobot\n",
      "piper/espeak-ng-data/voices/!v/Diogo\n",
      "piper/espeak-ng-data/voices/!v/steph2\n",
      "piper/espeak-ng-data/voices/!v/caleb\n",
      "piper/espeak-ng-data/voices/!v/adam\n",
      "piper/espeak-ng-data/voices/!v/ian\n",
      "piper/espeak-ng-data/voices/!v/steph\n",
      "piper/espeak-ng-data/voices/!v/antonio\n",
      "piper/espeak-ng-data/voices/!v/zac\n",
      "piper/espeak-ng-data/voices/!v/Mr serious\n",
      "piper/espeak-ng-data/voices/!v/david\n",
      "piper/espeak-ng-data/voices/!v/john\n",
      "piper/espeak-ng-data/voices/!v/AnxiousAndy\n",
      "piper/espeak-ng-data/voices/!v/mike2\n",
      "piper/espeak-ng-data/voices/!v/Demonic\n",
      "piper/espeak-ng-data/voices/!v/m6\n",
      "piper/espeak-ng-data/voices/!v/Marco\n",
      "piper/espeak-ng-data/voices/!v/victor\n",
      "piper/espeak-ng-data/voices/!v/Gene2\n",
      "piper/espeak-ng-data/voices/!v/robosoft3\n",
      "piper/espeak-ng-data/voices/!v/edward2\n",
      "piper/espeak-ng-data/voices/!v/m7\n",
      "piper/espeak-ng-data/voices/!v/klatt5\n",
      "piper/espeak-ng-data/voices/!v/max\n",
      "piper/espeak-ng-data/voices/!v/ed\n",
      "piper/espeak-ng-data/voices/!v/f2\n",
      "piper/espeak-ng-data/voices/!v/Hugo\n",
      "piper/espeak-ng-data/voices/!v/norbert\n",
      "piper/espeak-ng-data/voices/!v/michel\n",
      "piper/espeak-ng-data/voices/!v/boris\n",
      "piper/espeak-ng-data/voices/!v/RicishayMax\n",
      "piper/espeak-ng-data/voices/!v/klatt6\n",
      "piper/espeak-ng-data/voices/!v/announcer\n",
      "piper/espeak-ng-data/voices/!v/RicishayMax2\n",
      "piper/espeak-ng-data/voices/!v/robosoft7\n",
      "piper/espeak-ng-data/voices/!v/Lee\n",
      "piper/espeak-ng-data/voices/!v/UniRobot\n",
      "piper/espeak-ng-data/voices/!v/m8\n",
      "piper/espeak-ng-data/voices/!v/iven4\n",
      "piper/espeak-ng-data/voices/!v/RicishayMax3\n",
      "piper/espeak-ng-data/voices/!v/f3\n",
      "piper/espeak-ng-data/phontab\n",
      "piper/espeak-ng-data/gu_dict\n",
      "piper/espeak-ng-data/cy_dict\n",
      "piper/espeak-ng-data/nog_dict\n",
      "piper/espeak-ng-data/de_dict\n",
      "piper/espeak-ng-data/sv_dict\n",
      "piper/espeak-ng-data/qdb_dict\n",
      "piper/espeak-ng-data/py_dict\n",
      "piper/espeak-ng-data/kn_dict\n",
      "piper/espeak-ng-data/grc_dict\n",
      "piper/espeak-ng-data/om_dict\n",
      "piper/espeak-ng-data/bs_dict\n",
      "piper/espeak-ng-data/si_dict\n",
      "piper/espeak-ng-data/eu_dict\n",
      "piper/espeak-ng-data/nl_dict\n",
      "piper/espeak-ng-data/ta_dict\n",
      "piper/espeak-ng-data/sr_dict\n",
      "piper/espeak-ng-data/phondata-manifest\n",
      "piper/espeak-ng-data/af_dict\n",
      "piper/espeak-ng-data/ku_dict\n",
      "piper/espeak-ng-data/mto_dict\n",
      "piper/espeak-ng-data/ia_dict\n",
      "piper/espeak-ng-data/cv_dict\n",
      "piper/espeak-ng-data/io_dict\n",
      "piper/espeak-ng-data/fr_dict\n",
      "piper/espeak-ng-data/kk_dict\n",
      "piper/espeak-ng-data/tt_dict\n",
      "piper/espeak-ng-data/tk_dict\n",
      "piper/espeak-ng-data/da_dict\n",
      "piper/espeak-ng-data/or_dict\n",
      "piper/espeak-ng-data/is_dict\n",
      "piper/espeak-ng-data/uz_dict\n",
      "piper/espeak-ng-data/pl_dict\n",
      "piper/espeak-ng-data/sk_dict\n",
      "piper/espeak-ng-data/ky_dict\n",
      "piper/espeak-ng-data/intonations\n",
      "piper/espeak-ng-data/quc_dict\n",
      "piper/espeak-ng-data/nci_dict\n",
      "piper/espeak-ng-data/bn_dict\n",
      "piper/espeak-ng-data/hy_dict\n",
      "piper/espeak-ng-data/mk_dict\n",
      "piper/espeak-ng-data/ro_dict\n",
      "piper/espeak-ng-data/pa_dict\n",
      "piper/espeak-ng-data/sq_dict\n",
      "piper/espeak-ng-data/yue_dict\n",
      "piper/espeak-ng-data/piqd_dict\n",
      "piper/espeak-ng-data/qya_dict\n",
      "piper/espeak-ng-data/eo_dict\n",
      "piper/espeak-ng-data/gn_dict\n",
      "piper/espeak-ng-data/ht_dict\n",
      "piper/espeak-ng-data/hu_dict\n",
      "piper/espeak-ng-data/shn_dict\n",
      "piper/espeak-ng-data/mi_dict\n",
      "piper/espeak-ng-data/fi_dict\n",
      "piper/espeak-ng-data/el_dict\n",
      "piper/espeak-ng-data/hr_dict\n",
      "piper/espeak-ng-data/et_dict\n",
      "piper/espeak-ng-data/tr_dict\n",
      "piper/espeak-ng-data/id_dict\n",
      "piper/espeak-ng-data/gd_dict\n",
      "piper/espeak-ng-data/lb_dict\n",
      "piper/espeak-ng-data/chr_dict\n",
      "piper/espeak-ng-data/kl_dict\n",
      "piper/espeak-ng-data/ka_dict\n",
      "piper/espeak-ng-data/an_dict\n",
      "piper/espeak-ng-data/hi_dict\n",
      "piper/espeak-ng-data/mt_dict\n",
      "piper/espeak-ng-data/pt_dict\n",
      "piper/espeak-ng-data/sw_dict\n",
      "piper/espeak-ng-data/ca_dict\n",
      "piper/espeak-ng-data/th_dict\n",
      "piper/espeak-ng-data/ga_dict\n",
      "piper/espeak-ng-data/lt_dict\n",
      "piper/espeak-ng-data/ml_dict\n",
      "piper/espeak-ng-data/he_dict\n",
      "piper/espeak-ng-data/uk_dict\n",
      "piper/espeak-ng-data/ru_dict\n",
      "piper/espeak-ng-data/sl_dict\n",
      "piper/espeak-ng-data/es_dict\n",
      "piper/espeak-ng-data/ba_dict\n",
      "piper/espeak-ng-data/bg_dict\n",
      "piper/espeak-ng-data/az_dict\n",
      "piper/espeak-ng-data/pap_dict\n",
      "piper/espeak-ng-data/mr_dict\n",
      "piper/espeak-ng-data/te_dict\n",
      "piper/espeak-ng-data/my_dict\n",
      "piper/espeak-ng-data/la_dict\n",
      "piper/espeak-ng-data/fa_dict\n",
      "piper/espeak-ng-data/kok_dict\n",
      "piper/espeak-ng-data/sjn_dict\n",
      "piper/espeak-ng-data/no_dict\n",
      "piper/espeak-ng-data/smj_dict\n",
      "piper/espeak-ng-data/lang/\n",
      "piper/espeak-ng-data/lang/miz/\n",
      "piper/espeak-ng-data/lang/miz/mto\n",
      "piper/espeak-ng-data/lang/sai/\n",
      "piper/espeak-ng-data/lang/sai/gn\n",
      "piper/espeak-ng-data/lang/qu\n",
      "piper/espeak-ng-data/lang/zls/\n",
      "piper/espeak-ng-data/lang/zls/bg\n",
      "piper/espeak-ng-data/lang/zls/sr\n",
      "piper/espeak-ng-data/lang/zls/sl\n",
      "piper/espeak-ng-data/lang/zls/mk\n",
      "piper/espeak-ng-data/lang/zls/bs\n",
      "piper/espeak-ng-data/lang/zls/hr\n",
      "piper/espeak-ng-data/lang/bat/\n",
      "piper/espeak-ng-data/lang/bat/lt\n",
      "piper/espeak-ng-data/lang/bat/lv\n",
      "piper/espeak-ng-data/lang/bat/ltg\n",
      "piper/espeak-ng-data/lang/sit/\n",
      "piper/espeak-ng-data/lang/sit/yue\n",
      "piper/espeak-ng-data/lang/sit/cmn\n",
      "piper/espeak-ng-data/lang/sit/yue-Latn-jyutping\n",
      "piper/espeak-ng-data/lang/sit/my\n",
      "piper/espeak-ng-data/lang/sit/hak\n",
      "piper/espeak-ng-data/lang/sit/cmn-Latn-pinyin\n",
      "piper/espeak-ng-data/lang/itc/\n",
      "piper/espeak-ng-data/lang/itc/la\n",
      "piper/espeak-ng-data/lang/eu\n",
      "piper/espeak-ng-data/lang/urj/\n",
      "piper/espeak-ng-data/lang/urj/et\n",
      "piper/espeak-ng-data/lang/urj/hu\n",
      "piper/espeak-ng-data/lang/urj/smj\n",
      "piper/espeak-ng-data/lang/urj/fi\n",
      "piper/espeak-ng-data/lang/ine/\n",
      "piper/espeak-ng-data/lang/ine/hyw\n",
      "piper/espeak-ng-data/lang/ine/hy\n",
      "piper/espeak-ng-data/lang/ine/sq\n",
      "piper/espeak-ng-data/lang/map/\n",
      "piper/espeak-ng-data/lang/map/haw\n",
      "piper/espeak-ng-data/lang/azc/\n",
      "piper/espeak-ng-data/lang/azc/nci\n",
      "piper/espeak-ng-data/lang/ccs/\n",
      "piper/espeak-ng-data/lang/ccs/ka\n",
      "piper/espeak-ng-data/lang/iro/\n",
      "piper/espeak-ng-data/lang/iro/chr\n",
      "piper/espeak-ng-data/lang/zlw/\n",
      "piper/espeak-ng-data/lang/zlw/pl\n",
      "piper/espeak-ng-data/lang/zlw/cs\n",
      "piper/espeak-ng-data/lang/zlw/sk\n",
      "piper/espeak-ng-data/lang/gmq/\n",
      "piper/espeak-ng-data/lang/gmq/is\n",
      "piper/espeak-ng-data/lang/gmq/nb\n",
      "piper/espeak-ng-data/lang/gmq/sv\n",
      "piper/espeak-ng-data/lang/gmq/da\n",
      "piper/espeak-ng-data/lang/bnt/\n",
      "piper/espeak-ng-data/lang/bnt/tn\n",
      "piper/espeak-ng-data/lang/bnt/sw\n",
      "piper/espeak-ng-data/lang/art/\n",
      "piper/espeak-ng-data/lang/art/eo\n",
      "piper/espeak-ng-data/lang/art/qya\n",
      "piper/espeak-ng-data/lang/art/jbo\n",
      "piper/espeak-ng-data/lang/art/sjn\n",
      "piper/espeak-ng-data/lang/art/qdb\n",
      "piper/espeak-ng-data/lang/art/ia\n",
      "piper/espeak-ng-data/lang/art/piqd\n",
      "piper/espeak-ng-data/lang/art/io\n",
      "piper/espeak-ng-data/lang/art/py\n",
      "piper/espeak-ng-data/lang/art/lfn\n",
      "piper/espeak-ng-data/lang/trk/\n",
      "piper/espeak-ng-data/lang/trk/tt\n",
      "piper/espeak-ng-data/lang/trk/tk\n",
      "piper/espeak-ng-data/lang/trk/ky\n",
      "piper/espeak-ng-data/lang/trk/az\n",
      "piper/espeak-ng-data/lang/trk/tr\n",
      "piper/espeak-ng-data/lang/trk/uz\n",
      "piper/espeak-ng-data/lang/trk/nog\n",
      "piper/espeak-ng-data/lang/trk/ug\n",
      "piper/espeak-ng-data/lang/trk/kk\n",
      "piper/espeak-ng-data/lang/trk/ba\n",
      "piper/espeak-ng-data/lang/trk/cv\n",
      "piper/espeak-ng-data/lang/dra/\n",
      "piper/espeak-ng-data/lang/dra/kn\n",
      "piper/espeak-ng-data/lang/dra/ml\n",
      "piper/espeak-ng-data/lang/dra/ta\n",
      "piper/espeak-ng-data/lang/dra/te\n",
      "piper/espeak-ng-data/lang/jpx/\n",
      "piper/espeak-ng-data/lang/jpx/ja\n",
      "piper/espeak-ng-data/lang/aav/\n",
      "piper/espeak-ng-data/lang/aav/vi\n",
      "piper/espeak-ng-data/lang/aav/vi-VN-x-central\n",
      "piper/espeak-ng-data/lang/aav/vi-VN-x-south\n",
      "piper/espeak-ng-data/lang/zle/\n",
      "piper/espeak-ng-data/lang/zle/ru-LV\n",
      "piper/espeak-ng-data/lang/zle/be\n",
      "piper/espeak-ng-data/lang/zle/ru-cl\n",
      "piper/espeak-ng-data/lang/zle/uk\n",
      "piper/espeak-ng-data/lang/zle/ru\n",
      "piper/espeak-ng-data/lang/roa/\n",
      "piper/espeak-ng-data/lang/roa/es-419\n",
      "piper/espeak-ng-data/lang/roa/ca\n",
      "piper/espeak-ng-data/lang/roa/fr\n",
      "piper/espeak-ng-data/lang/roa/pt-BR\n",
      "piper/espeak-ng-data/lang/roa/fr-BE\n",
      "piper/espeak-ng-data/lang/roa/ht\n",
      "piper/espeak-ng-data/lang/roa/it\n",
      "piper/espeak-ng-data/lang/roa/fr-CH\n",
      "piper/espeak-ng-data/lang/roa/es\n",
      "piper/espeak-ng-data/lang/roa/pap\n",
      "piper/espeak-ng-data/lang/roa/an\n",
      "piper/espeak-ng-data/lang/roa/pt\n",
      "piper/espeak-ng-data/lang/roa/ro\n",
      "piper/espeak-ng-data/lang/cel/\n",
      "piper/espeak-ng-data/lang/cel/gd\n",
      "piper/espeak-ng-data/lang/cel/cy\n",
      "piper/espeak-ng-data/lang/cel/ga\n",
      "piper/espeak-ng-data/lang/poz/\n",
      "piper/espeak-ng-data/lang/poz/id\n",
      "piper/espeak-ng-data/lang/poz/mi\n",
      "piper/espeak-ng-data/lang/poz/ms\n",
      "piper/espeak-ng-data/lang/esx/\n",
      "piper/espeak-ng-data/lang/esx/kl\n",
      "piper/espeak-ng-data/lang/grk/\n",
      "piper/espeak-ng-data/lang/grk/el\n",
      "piper/espeak-ng-data/lang/grk/grc\n",
      "piper/espeak-ng-data/lang/cus/\n",
      "piper/espeak-ng-data/lang/cus/om\n",
      "piper/espeak-ng-data/lang/inc/\n",
      "piper/espeak-ng-data/lang/inc/gu\n",
      "piper/espeak-ng-data/lang/inc/or\n",
      "piper/espeak-ng-data/lang/inc/ur\n",
      "piper/espeak-ng-data/lang/inc/bpy\n",
      "piper/espeak-ng-data/lang/inc/as\n",
      "piper/espeak-ng-data/lang/inc/mr\n",
      "piper/espeak-ng-data/lang/inc/bn\n",
      "piper/espeak-ng-data/lang/inc/si\n",
      "piper/espeak-ng-data/lang/inc/hi\n",
      "piper/espeak-ng-data/lang/inc/ne\n",
      "piper/espeak-ng-data/lang/inc/pa\n",
      "piper/espeak-ng-data/lang/inc/sd\n",
      "piper/espeak-ng-data/lang/inc/kok\n",
      "piper/espeak-ng-data/lang/ira/\n",
      "piper/espeak-ng-data/lang/ira/fa-Latn\n",
      "piper/espeak-ng-data/lang/ira/fa\n",
      "piper/espeak-ng-data/lang/ira/ku\n",
      "piper/espeak-ng-data/lang/sem/\n",
      "piper/espeak-ng-data/lang/sem/he\n",
      "piper/espeak-ng-data/lang/sem/ar\n",
      "piper/espeak-ng-data/lang/sem/am\n",
      "piper/espeak-ng-data/lang/sem/mt\n",
      "piper/espeak-ng-data/lang/ko\n",
      "piper/espeak-ng-data/lang/myn/\n",
      "piper/espeak-ng-data/lang/myn/quc\n",
      "piper/espeak-ng-data/lang/tai/\n",
      "piper/espeak-ng-data/lang/tai/th\n",
      "piper/espeak-ng-data/lang/tai/shn\n",
      "piper/espeak-ng-data/lang/gmw/\n",
      "piper/espeak-ng-data/lang/gmw/en-GB-x-gbcwmd\n",
      "piper/espeak-ng-data/lang/gmw/en-US\n",
      "piper/espeak-ng-data/lang/gmw/de\n",
      "piper/espeak-ng-data/lang/gmw/en-GB-scotland\n",
      "piper/espeak-ng-data/lang/gmw/en-GB-x-rp\n",
      "piper/espeak-ng-data/lang/gmw/en-GB-x-gbclan\n",
      "piper/espeak-ng-data/lang/gmw/en\n",
      "piper/espeak-ng-data/lang/gmw/lb\n",
      "piper/espeak-ng-data/lang/gmw/nl\n",
      "piper/espeak-ng-data/lang/gmw/af\n",
      "piper/espeak-ng-data/lang/gmw/en-US-nyc\n",
      "piper/espeak-ng-data/lang/gmw/en-029\n",
      "piper/espeak-ng-data/phondata\n",
      "piper/espeak-ng-data/cmn_dict\n",
      "piper/espeak-ng-data/ug_dict\n",
      "piper/espeak-ng-data/it_dict\n",
      "piper/espeak-ng-data/lfn_dict\n",
      "piper/espeak-ng-data/tn_dict\n",
      "piper/espeak-ng-data/hak_dict\n",
      "piper/espeak-ng-data/en_dict\n",
      "piper/espeak-ng-data/ar_dict\n",
      "piper/libonnxruntime.so.1.14.1\n",
      "piper/libespeak-ng.so\n",
      "piper/libespeak-ng.so.1\n",
      "piper/libonnxruntime.so\n"
     ]
    }
   ],
   "source": [
    "!tar -xvf piper_linux_x86_64.tar.gz"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 106,
   "id": "d658e86c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "/home/user/Desktop/medical_bot/Eye_Disease_Chatbot/research/piper\n"
     ]
    }
   ],
   "source": [
    "cd piper"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 109,
   "id": "ea17ebca",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "I0000 00:00:1771848490.299427    4109 fork_posix.cc:71] Other threads are currently calling into gRPC, skipping fork() handlers\n",
      "huggingface/tokenizers: The current process just got forked, after parallelism has already been used. Disabling parallelism to avoid deadlocks...\n",
      "To disable this warning, you can either:\n",
      "\t- Avoid using `tokenizers` before the fork if possible\n",
      "\t- Explicitly set the environment variable TOKENIZERS_PARALLELISM=(true | false)\n",
      "5317.34s - pydevd: Sending message related to process being replaced timed-out after 5 seconds\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "--2026-02-23 17:38:15--  https://huggingface.co/rhasspy/piper-voices/resolve/main/en/en_US/amy/medium/en_US-amy-medium.onnx\n",
      "Resolving huggingface.co (huggingface.co)... 2600:9000:2634:2000:17:b174:6d00:93a1, 2600:9000:2634:1600:17:b174:6d00:93a1, 2600:9000:2634:ee00:17:b174:6d00:93a1, ...\n",
      "Connecting to huggingface.co (huggingface.co)|2600:9000:2634:2000:17:b174:6d00:93a1|:443... connected.\n",
      "HTTP request sent, awaiting response... 302 Found\n",
      "Location: https://cas-bridge.xethub.hf.co/xet-bridge-us/64949e47c841c90374a1fb82/2b0a534800d3208ad2735ea1feda9d3b36947554f24816bf0e922bf8c09a9255?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Credential=cas%2F20260223%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Date=20260223T120816Z&X-Amz-Expires=3600&X-Amz-Signature=bc3bcfc56f9a2fd0cc6ab40b8c17f7b9a538a47bd617d509d728e05935e6fd44&X-Amz-SignedHeaders=host&X-Xet-Cas-Uid=public&response-content-disposition=inline%3B+filename*%3DUTF-8%27%27en_US-amy-medium.onnx%3B+filename%3D%22en_US-amy-medium.onnx%22%3B&x-id=GetObject&Expires=1771852096&Policy=eyJTdGF0ZW1lbnQiOlt7IkNvbmRpdGlvbiI6eyJEYXRlTGVzc1RoYW4iOnsiQVdTOkVwb2NoVGltZSI6MTc3MTg1MjA5Nn19LCJSZXNvdXJjZSI6Imh0dHBzOi8vY2FzLWJyaWRnZS54ZXRodWIuaGYuY28veGV0LWJyaWRnZS11cy82NDk0OWU0N2M4NDFjOTAzNzRhMWZiODIvMmIwYTUzNDgwMGQzMjA4YWQyNzM1ZWExZmVkYTlkM2IzNjk0NzU1NGYyNDgxNmJmMGU5MjJiZjhjMDlhOTI1NSoifV19&Signature=b3YO-6FJ4usGzcFjYEoilFyKRKm%7E%7EXNQpfUsVEcsIXuApC9HzStqrjH4BgMg5Z5Hr-by0JYi-%7EaB-fqN%7EFhMGgjgI6XRWxemY99S414yLqqfNv1B%7EC5j5DtAXdq3u-rcSP-KZ4mcUmPN%7EU0BQ0FmExwdzoogDMlKppIFUf%7ERfU5sBXlpgN3wtJ%7Es7JTLF05Yq-bKfvuIbRMkTini7MHqyVIFRLFzZBaLw7eBlVjs6z1UIfo4p4wBkJOTmKRXGBbftrOOTjdTvscrRkbFAFF3-hwTLD6X%7E%7EfO3HUSVOvtDsYsnBsrJ7RiLxKTINdkKHBwKxkBXWxT8oCdwGfnp14Y4w__&Key-Pair-Id=K2L8F4GPSG1IFC [following]\n",
      "--2026-02-23 17:38:16--  https://cas-bridge.xethub.hf.co/xet-bridge-us/64949e47c841c90374a1fb82/2b0a534800d3208ad2735ea1feda9d3b36947554f24816bf0e922bf8c09a9255?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Credential=cas%2F20260223%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Date=20260223T120816Z&X-Amz-Expires=3600&X-Amz-Signature=bc3bcfc56f9a2fd0cc6ab40b8c17f7b9a538a47bd617d509d728e05935e6fd44&X-Amz-SignedHeaders=host&X-Xet-Cas-Uid=public&response-content-disposition=inline%3B+filename*%3DUTF-8%27%27en_US-amy-medium.onnx%3B+filename%3D%22en_US-amy-medium.onnx%22%3B&x-id=GetObject&Expires=1771852096&Policy=eyJTdGF0ZW1lbnQiOlt7IkNvbmRpdGlvbiI6eyJEYXRlTGVzc1RoYW4iOnsiQVdTOkVwb2NoVGltZSI6MTc3MTg1MjA5Nn19LCJSZXNvdXJjZSI6Imh0dHBzOi8vY2FzLWJyaWRnZS54ZXRodWIuaGYuY28veGV0LWJyaWRnZS11cy82NDk0OWU0N2M4NDFjOTAzNzRhMWZiODIvMmIwYTUzNDgwMGQzMjA4YWQyNzM1ZWExZmVkYTlkM2IzNjk0NzU1NGYyNDgxNmJmMGU5MjJiZjhjMDlhOTI1NSoifV19&Signature=b3YO-6FJ4usGzcFjYEoilFyKRKm%7E%7EXNQpfUsVEcsIXuApC9HzStqrjH4BgMg5Z5Hr-by0JYi-%7EaB-fqN%7EFhMGgjgI6XRWxemY99S414yLqqfNv1B%7EC5j5DtAXdq3u-rcSP-KZ4mcUmPN%7EU0BQ0FmExwdzoogDMlKppIFUf%7ERfU5sBXlpgN3wtJ%7Es7JTLF05Yq-bKfvuIbRMkTini7MHqyVIFRLFzZBaLw7eBlVjs6z1UIfo4p4wBkJOTmKRXGBbftrOOTjdTvscrRkbFAFF3-hwTLD6X%7E%7EfO3HUSVOvtDsYsnBsrJ7RiLxKTINdkKHBwKxkBXWxT8oCdwGfnp14Y4w__&Key-Pair-Id=K2L8F4GPSG1IFC\n",
      "Resolving cas-bridge.xethub.hf.co (cas-bridge.xethub.hf.co)... 64:ff9b::129b:3117, 64:ff9b::129b:312a, 64:ff9b::129b:3160, ...\n",
      "Connecting to cas-bridge.xethub.hf.co (cas-bridge.xethub.hf.co)|64:ff9b::129b:3117|:443... connected.\n",
      "HTTP request sent, awaiting response... 200 OK\n",
      "Length: 63201294 (60M)\n",
      "Saving to: ‘en_US-amy-medium.onnx’\n",
      "\n",
      "en_US-amy-medium.on 100%[===================>]  60.27M  5.47MB/s    in 11s     \n",
      "\n",
      "2026-02-23 17:38:28 (5.63 MB/s) - ‘en_US-amy-medium.onnx’ saved [63201294/63201294]\n",
      "\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "I0000 00:00:1771848508.495430    4109 fork_posix.cc:71] Other threads are currently calling into gRPC, skipping fork() handlers\n",
      "huggingface/tokenizers: The current process just got forked, after parallelism has already been used. Disabling parallelism to avoid deadlocks...\n",
      "To disable this warning, you can either:\n",
      "\t- Avoid using `tokenizers` before the fork if possible\n",
      "\t- Explicitly set the environment variable TOKENIZERS_PARALLELISM=(true | false)\n",
      "5335.53s - pydevd: Sending message related to process being replaced timed-out after 5 seconds\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "--2026-02-23 17:38:33--  https://huggingface.co/rhasspy/piper-voices/resolve/main/en/en_US/amy/medium/en_US-amy-medium.onnx.json\n",
      "Resolving huggingface.co (huggingface.co)... 2600:9000:2634:2000:17:b174:6d00:93a1, 2600:9000:2634:8600:17:b174:6d00:93a1, 2600:9000:2634:a800:17:b174:6d00:93a1, ...\n",
      "Connecting to huggingface.co (huggingface.co)|2600:9000:2634:2000:17:b174:6d00:93a1|:443... connected.\n",
      "HTTP request sent, awaiting response... 307 Temporary Redirect\n",
      "Location: /api/resolve-cache/models/rhasspy/piper-voices/9b2a7bdd829bc1bf446ccbef7fe6e57358de9b7d/en%2Fen_US%2Famy%2Fmedium%2Fen_US-amy-medium.onnx.json?%2Frhasspy%2Fpiper-voices%2Fresolve%2Fmain%2Fen%2Fen_US%2Famy%2Fmedium%2Fen_US-amy-medium.onnx.json=&etag=%225a1e0a2d94d3719de29a4771aa0e6c116552445f%22 [following]\n",
      "--2026-02-23 17:38:36--  https://huggingface.co/api/resolve-cache/models/rhasspy/piper-voices/9b2a7bdd829bc1bf446ccbef7fe6e57358de9b7d/en%2Fen_US%2Famy%2Fmedium%2Fen_US-amy-medium.onnx.json?%2Frhasspy%2Fpiper-voices%2Fresolve%2Fmain%2Fen%2Fen_US%2Famy%2Fmedium%2Fen_US-amy-medium.onnx.json=&etag=%225a1e0a2d94d3719de29a4771aa0e6c116552445f%22\n",
      "Reusing existing connection to [huggingface.co]:443.\n",
      "HTTP request sent, awaiting response... 200 OK\n",
      "Length: 4882 (4.8K) [text/plain]\n",
      "Saving to: ‘en_US-amy-medium.onnx.json’\n",
      "\n",
      "en_US-amy-medium.on 100%[===================>]   4.77K  --.-KB/s    in 0s      \n",
      "\n",
      "2026-02-23 17:38:36 (129 MB/s) - ‘en_US-amy-medium.onnx.json’ saved [4882/4882]\n",
      "\n"
     ]
    }
   ],
   "source": [
    "!wget https://huggingface.co/rhasspy/piper-voices/resolve/main/en/en_US/amy/medium/en_US-amy-medium.onnx\n",
    "!wget https://huggingface.co/rhasspy/piper-voices/resolve/main/en/en_US/amy/medium/en_US-amy-medium.onnx.json"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 110,
   "id": "e48726c3",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "I0000 00:00:1771848537.111852    4109 fork_posix.cc:71] Other threads are currently calling into gRPC, skipping fork() handlers\n",
      "huggingface/tokenizers: The current process just got forked, after parallelism has already been used. Disabling parallelism to avoid deadlocks...\n",
      "To disable this warning, you can either:\n",
      "\t- Avoid using `tokenizers` before the fork if possible\n",
      "\t- Explicitly set the environment variable TOKENIZERS_PARALLELISM=(true | false)\n",
      "5364.14s - pydevd: Sending message related to process being replaced timed-out after 5 seconds\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[2026-02-23 17:39:02.664] [piper] [\u001b[32minfo\u001b[m] Loaded voice in 0.388678738 second(s)\n",
      "[2026-02-23 17:39:02.665] [piper] [\u001b[32minfo\u001b[m] Initialized piper\n",
      "test.wav\n",
      "[2026-02-23 17:39:04.034] [piper] [\u001b[32minfo\u001b[m] Real-time factor: 0.24985874583305387 (infer=1.351798138 sec, audio=5.410249433106577 sec)\n",
      "[2026-02-23 17:39:04.035] [piper] [\u001b[32minfo\u001b[m] Terminated piper\n"
     ]
    }
   ],
   "source": [
    "!echo \"Hello. I am your health assistant. I will explain things calmly and clearly.\" \\\n",
    "| ./piper \\\n",
    "  --model en_US-amy-medium.onnx \\\n",
    "  --output_file test.wav"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 114,
   "id": "d52e14d0",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "I0000 00:00:1771848710.257711    4109 fork_posix.cc:71] Other threads are currently calling into gRPC, skipping fork() handlers\n",
      "huggingface/tokenizers: The current process just got forked, after parallelism has already been used. Disabling parallelism to avoid deadlocks...\n",
      "To disable this warning, you can either:\n",
      "\t- Avoid using `tokenizers` before the fork if possible\n",
      "\t- Explicitly set the environment variable TOKENIZERS_PARALLELISM=(true | false)\n",
      "5537.28s - pydevd: Sending message related to process being replaced timed-out after 5 seconds\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Playing WAVE 'test.wav' : Signed 16 bit Little Endian, Rate 22050 Hz, Mono\n"
     ]
    }
   ],
   "source": [
    "!aplay test.wav"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 122,
   "id": "fd8da7c6",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'/home/user/Desktop/medical_bot/Eye_Disease_Chatbot/research/piper'"
      ]
     },
     "execution_count": 122,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "%pwd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 129,
   "id": "5e1f0eb8",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "/home/user/Desktop/medical_bot/Eye_Disease_Chatbot/research\n"
     ]
    }
   ],
   "source": [
    "cd .."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 139,
   "id": "2a78bd03",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "I0000 00:00:1771849309.126405    4109 fork_posix.cc:71] Other threads are currently calling into gRPC, skipping fork() handlers\n",
      "huggingface/tokenizers: The current process just got forked, after parallelism has already been used. Disabling parallelism to avoid deadlocks...\n",
      "To disable this warning, you can either:\n",
      "\t- Avoid using `tokenizers` before the fork if possible\n",
      "\t- Explicitly set the environment variable TOKENIZERS_PARALLELISM=(true | false)\n",
      "6136.15s - pydevd: Sending message related to process being replaced timed-out after 5 seconds\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "'arctic_a0250 copy.wav'   input.wav              piper_linux_x86_64.tar.gz\n",
      " arctic_a0250.wav        'IPL (2008-2025).csv'   recording.wav\n",
      " DSP.ipynb                output.csv             trial.ipynb\n",
      " DSP.txt                  \u001b[0m\u001b[01;34mpiper\u001b[0m/\n"
     ]
    }
   ],
   "source": [
    "ls"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "c5adbe6b",
   "metadata": {},
   "outputs": [],
   "source": [
    "# tts_piper.py\n",
    "import subprocess\n",
    "\n",
    "PIPER_BIN = \"piper/piper\"          # adjust if needed\n",
    "MODEL = \"piper/en_US-amy-medium.onnx\"\n",
    "\n",
    "def speak(text, output=\"reply.wav\"):\n",
    "# Generate speech\n",
    "    out_file = output\n",
    "    p = subprocess.Popen(\n",
    "        [PIPER_BIN, \"--model\", MODEL, \"--output_file\", out_file],\n",
    "        stdin=subprocess.PIPE\n",
    "    )\n",
    "    p.stdin.write(text.encode(\"utf-8\"))\n",
    "    p.stdin.close()\n",
    "    p.wait()\n",
    "\n",
    "    # 🔊 PLAY THE AUDIO (Ubuntu)\n",
    "    subprocess.run([\"aplay\", out_file])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 149,
   "id": "d849421e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "🤖 Health Assistant (Text + Voice)\n",
      "Type: text / voice / exit\n",
      "\n",
      "🎙️ Speak now...\n",
      "✅ Audio recorded\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages/whisper/transcribe.py:132: UserWarning: FP16 is not supported on CPU; using FP32 instead\n",
      "  warnings.warn(\"FP16 is not supported on CPU; using FP32 instead\")\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "🧑 You said:  What is this? It's obviously a bit...\n",
      "\n",
      "🤖 Bot: It seems like your message might be incomplete, as you asked \"What is this? It's obviously a bit...\" without specifying what \"this\" refers to.\n",
      "\n",
      "However, based on the context snippets you provided, there are a few important terms related to eye health that I can explain:\n",
      "\n",
      "*   **OCT (Optical Coherence Tomography)**: This is an advanced imaging test used to take detailed cross-sectional pictures of the retina, the light-sensitive tissue at the back of the eye. It's very helpful for detecting even subtle areas of thickening and provides quantitative measurements, which can indicate conditions like swelling or fluid accumulation.\n",
      "*   **CME (Cystoid Macular Edema)**: This is a condition where fluid collects in the macula, the central part of the retina responsible for sharp, detailed vision. This fluid collection often leads to swelling or \"thickening\" of the macula, which can distort vision.\n",
      "*   **Therapy and Resolution**: The context mentions that with therapy, OCT images can indicate that CME has fully resolved, meaning the swelling has gone down and the condition has improved or cleared.\n",
      "\n",
      "If you were referring to something else, please provide more details, and I'll do my best to assist you.\n",
      "\n",
      "Always remember, for any concerns about your eye health, it is essential to consult a qualified eye care professional for proper diagnosis and treatment.\n",
      "\n"
     ]
    },
    {
     "ename": "NameError",
     "evalue": "name 'out_file' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mNameError\u001b[39m                                 Traceback (most recent call last)",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[149]\u001b[39m\u001b[32m, line 34\u001b[39m\n\u001b[32m     32\u001b[39m \u001b[38;5;66;03m# -------- OUTPUT --------\u001b[39;00m\n\u001b[32m     33\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m mode == \u001b[33m\"\u001b[39m\u001b[33mvoice\u001b[39m\u001b[33m\"\u001b[39m:\n\u001b[32m---> \u001b[39m\u001b[32m34\u001b[39m     \u001b[43mspeak\u001b[49m\u001b[43m(\u001b[49m\u001b[43mresponse\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[148]\u001b[39m\u001b[32m, line 10\u001b[39m, in \u001b[36mspeak\u001b[39m\u001b[34m(text, output)\u001b[39m\n\u001b[32m      7\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mspeak\u001b[39m(text, output=\u001b[33m\"\u001b[39m\u001b[33mreply.wav\u001b[39m\u001b[33m\"\u001b[39m):\n\u001b[32m      8\u001b[39m \u001b[38;5;66;03m# Generate speech\u001b[39;00m\n\u001b[32m      9\u001b[39m     p = subprocess.Popen(\n\u001b[32m---> \u001b[39m\u001b[32m10\u001b[39m         [PIPER_BIN, \u001b[33m\"\u001b[39m\u001b[33m--model\u001b[39m\u001b[33m\"\u001b[39m, MODEL, \u001b[33m\"\u001b[39m\u001b[33m--output_file\u001b[39m\u001b[33m\"\u001b[39m, \u001b[43mout_file\u001b[49m],\n\u001b[32m     11\u001b[39m         stdin=subprocess.PIPE\n\u001b[32m     12\u001b[39m     )\n\u001b[32m     13\u001b[39m     p.stdin.write(text.encode(\u001b[33m\"\u001b[39m\u001b[33mutf-8\u001b[39m\u001b[33m\"\u001b[39m))\n\u001b[32m     14\u001b[39m     p.stdin.close()\n",
      "\u001b[31mNameError\u001b[39m: name 'out_file' is not defined"
     ]
    }
   ],
   "source": [
    "print(\"\\n🤖 Health Assistant (Text + Voice)\")\n",
    "print(\"Type: text / voice / exit\\n\")\n",
    "\n",
    "while True:\n",
    "    mode = input(\"Choose mode (text/voice): \").strip().lower()\n",
    "\n",
    "    if mode == \"exit\":\n",
    "        print(\"👋 Goodbye\")\n",
    "        break\n",
    "\n",
    "    # -------- INPUT --------\n",
    "    if mode == \"text\":\n",
    "        user_text = input(\"You: \")\n",
    "\n",
    "    elif mode == \"voice\":\n",
    "        audio_file = record_audio()\n",
    "        user_text = speech_to_text(audio_file)\n",
    "        print(f\"🧑 You said: {user_text}\")\n",
    "\n",
    "    else:\n",
    "        print(\"❌ Invalid mode\")\n",
    "        continue\n",
    "\n",
    "    if not user_text.strip():\n",
    "        print(\"⚠️ Empty input\")\n",
    "        continue\n",
    "\n",
    "    # -------- AI BRAIN --------\n",
    "    response = rag_chain.invoke({'input': user_text})[\"answer\"]\n",
    "    print(f\"\\n🤖 Bot: {response}\\n\")\n",
    "\n",
    "    # -------- OUTPUT --------\n",
    "    if mode == \"voice\":\n",
    "        speak(response)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "2a57b4d1",
   "metadata": {},
   "outputs": [],
   "source": [
    "# from tts_piper import speak\n",
    "\n",
    "# speak(\"Please relax. I will explain this step by step.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "68c2c969",
   "metadata": {},
   "outputs": [],
   "source": [
    "# # tts_pyttsx3.py\n",
    "# import pyttsx3\n",
    "\n",
    "# engine = pyttsx3.init()\n",
    "\n",
    "# # ---------- SELECT FEMALE VOICE ----------\n",
    "# voices = engine.getProperty(\"voices\")\n",
    "\n",
    "# selected_voice = None\n",
    "# for voice in voices:\n",
    "#     if \"female\" in voice.name.lower() or \"zira\" in voice.name.lower():\n",
    "#         selected_voice = voice.id\n",
    "#         break\n",
    "\n",
    "# if selected_voice:\n",
    "#     engine.setProperty(\"voice\", selected_voice)\n",
    "\n",
    "# # ---------- HEALTH BOT VOICE TUNING ----------\n",
    "# engine.setProperty(\"rate\", 145)     # slow, calm\n",
    "# engine.setProperty(\"volume\", 0.9)   # gentle volume\n",
    "\n",
    "# def speak(text: str):\n",
    "#     \"\"\"\n",
    "#     Speak text in a calm, pleasant female voice\n",
    "#     \"\"\"\n",
    "#     print(f\"🤖 Speaking...\")\n",
    "#     engine.say(text)\n",
    "#     engine.runAndWait()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "029ed4d7",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "I0000 00:00:1771828209.969222    5489 fork_posix.cc:71] Other threads are currently calling into gRPC, skipping fork() handlers\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already satisfied: openai in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (1.109.1)\n",
      "Requirement already satisfied: anyio<5,>=3.5.0 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from openai) (4.12.0)\n",
      "Requirement already satisfied: distro<2,>=1.7.0 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from openai) (1.9.0)\n",
      "Requirement already satisfied: httpx<1,>=0.23.0 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from openai) (0.28.1)\n",
      "Requirement already satisfied: jiter<1,>=0.4.0 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from openai) (0.12.0)\n",
      "Requirement already satisfied: pydantic<3,>=1.9.0 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from openai) (2.12.5)\n",
      "Requirement already satisfied: sniffio in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from openai) (1.3.1)\n",
      "Requirement already satisfied: tqdm>4 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from openai) (4.67.1)\n",
      "Requirement already satisfied: typing-extensions<5,>=4.11 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from openai) (4.15.0)\n",
      "Requirement already satisfied: idna>=2.8 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from anyio<5,>=3.5.0->openai) (3.11)\n",
      "Requirement already satisfied: certifi in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from httpx<1,>=0.23.0->openai) (2025.11.12)\n",
      "Requirement already satisfied: httpcore==1.* in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from httpx<1,>=0.23.0->openai) (1.0.9)\n",
      "Requirement already satisfied: h11>=0.16 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from httpcore==1.*->httpx<1,>=0.23.0->openai) (0.16.0)\n",
      "Requirement already satisfied: annotated-types>=0.6.0 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from pydantic<3,>=1.9.0->openai) (0.7.0)\n",
      "Requirement already satisfied: pydantic-core==2.41.5 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from pydantic<3,>=1.9.0->openai) (2.41.5)\n",
      "Requirement already satisfied: typing-inspection>=0.4.2 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from pydantic<3,>=1.9.0->openai) (0.4.2)\n"
     ]
    }
   ],
   "source": [
    "# !pip install openai\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "829a4f32",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "2ee70ea6",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Exception ignored on calling ctypes callback function: <bound method EspeakDriver._onSynth of <pyttsx3.drivers.espeak.EspeakDriver object at 0x75ab7e42fc50>>\n",
      "Traceback (most recent call last):\n",
      "  File \"/home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages/pyttsx3/drivers/espeak.py\", line 245, in _onSynth\n",
      "    self._proxy.notify(\"finished-utterance\", completed=True)\n",
      "    ^^^^^^^^^^^^^^^^^^\n",
      "ReferenceError: weakly-referenced object no longer exists\n"
     ]
    }
   ],
   "source": [
    "# import pyttsx3\n",
    "\n",
    "# def speak(text):\n",
    "#     engine = pyttsx3.init()\n",
    "#     engine.setProperty(\"rate\", 160)\n",
    "#     engine.say(text)\n",
    "#     engine.runAndWait()\n",
    "\n",
    "# speak(\"Hello, how can I assist you today?\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "id": "a950c0d5",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "🤖 Health Assistant (Text + Voice)\n",
      "Type: text / voice / exit\n",
      "\n",
      "❌ Invalid mode\n",
      "❌ Invalid mode\n",
      "❌ Invalid mode\n",
      "❌ Invalid mode\n",
      "❌ Invalid mode\n",
      "❌ Invalid mode\n",
      "⚠️ Empty input\n"
     ]
    },
    {
     "ename": "KeyboardInterrupt",
     "evalue": "Interrupted by user",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mKeyboardInterrupt\u001b[39m                         Traceback (most recent call last)",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[75]\u001b[39m\u001b[32m, line 11\u001b[39m\n\u001b[32m      8\u001b[39m \u001b[38;5;28mprint\u001b[39m(\u001b[33m\"\u001b[39m\u001b[33mType: text / voice / exit\u001b[39m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[33m\"\u001b[39m)\n\u001b[32m     10\u001b[39m \u001b[38;5;28;01mwhile\u001b[39;00m \u001b[38;5;28;01mTrue\u001b[39;00m:\n\u001b[32m---> \u001b[39m\u001b[32m11\u001b[39m     mode = \u001b[38;5;28;43minput\u001b[39;49m\u001b[43m(\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mChoose mode (text/voice): \u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m)\u001b[49m.strip().lower()\n\u001b[32m     13\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m mode == \u001b[33m\"\u001b[39m\u001b[33mexit\u001b[39m\u001b[33m\"\u001b[39m:\n\u001b[32m     14\u001b[39m         \u001b[38;5;28mprint\u001b[39m(\u001b[33m\"\u001b[39m\u001b[33m👋 Goodbye\u001b[39m\u001b[33m\"\u001b[39m)\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages/ipykernel/kernelbase.py:1282\u001b[39m, in \u001b[36mKernel.raw_input\u001b[39m\u001b[34m(self, prompt)\u001b[39m\n\u001b[32m   1280\u001b[39m     msg = \u001b[33m\"\u001b[39m\u001b[33mraw_input was called, but this frontend does not support input requests.\u001b[39m\u001b[33m\"\u001b[39m\n\u001b[32m   1281\u001b[39m     \u001b[38;5;28;01mraise\u001b[39;00m StdinNotImplementedError(msg)\n\u001b[32m-> \u001b[39m\u001b[32m1282\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_input_request\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   1283\u001b[39m \u001b[43m    \u001b[49m\u001b[38;5;28;43mstr\u001b[39;49m\u001b[43m(\u001b[49m\u001b[43mprompt\u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1284\u001b[39m \u001b[43m    \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_parent_ident\u001b[49m\u001b[43m[\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mshell\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1285\u001b[39m \u001b[43m    \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mget_parent\u001b[49m\u001b[43m(\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mshell\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1286\u001b[39m \u001b[43m    \u001b[49m\u001b[43mpassword\u001b[49m\u001b[43m=\u001b[49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[32m   1287\u001b[39m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages/ipykernel/kernelbase.py:1325\u001b[39m, in \u001b[36mKernel._input_request\u001b[39m\u001b[34m(self, prompt, ident, parent, password)\u001b[39m\n\u001b[32m   1322\u001b[39m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mKeyboardInterrupt\u001b[39;00m:\n\u001b[32m   1323\u001b[39m     \u001b[38;5;66;03m# re-raise KeyboardInterrupt, to truncate traceback\u001b[39;00m\n\u001b[32m   1324\u001b[39m     msg = \u001b[33m\"\u001b[39m\u001b[33mInterrupted by user\u001b[39m\u001b[33m\"\u001b[39m\n\u001b[32m-> \u001b[39m\u001b[32m1325\u001b[39m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mKeyboardInterrupt\u001b[39;00m(msg) \u001b[38;5;28;01mfrom\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[32m   1326\u001b[39m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mException\u001b[39;00m:\n\u001b[32m   1327\u001b[39m     \u001b[38;5;28mself\u001b[39m.log.warning(\u001b[33m\"\u001b[39m\u001b[33mInvalid Message:\u001b[39m\u001b[33m\"\u001b[39m, exc_info=\u001b[38;5;28;01mTrue\u001b[39;00m)\n",
      "\u001b[31mKeyboardInterrupt\u001b[39m: Interrupted by user"
     ]
    }
   ],
   "source": [
    "# # conversation.py\n",
    "# from input_audio import record_audio\n",
    "# from stt_whisper import speech_to_text\n",
    "# from brain_gemini import ask_brain\n",
    "# from tts_pyttsx3 import speak\n",
    "\n",
    "# print(\"\\n🤖 Health Assistant (Text + Voice)\")\n",
    "# print(\"Type: text / voice / exit\\n\")\n",
    "\n",
    "# # while True:\n",
    "#     mode = input(\"Choose mode (text/voice): \").strip().lower()\n",
    "\n",
    "#     if mode == \"exit\":\n",
    "#         print(\"👋 Goodbye\")\n",
    "#         break\n",
    "\n",
    "#     # -------- INPUT --------\n",
    "#     if mode == \"text\":\n",
    "#         user_text = input(\"You: \")\n",
    "\n",
    "#     elif mode == \"voice\":\n",
    "#         audio_file = record_audio()\n",
    "#         user_text = speech_to_text(audio_file)\n",
    "#         print(f\"🧑 You said: {user_text}\")\n",
    "\n",
    "#     else:\n",
    "#         print(\"❌ Invalid mode\")\n",
    "#         continue\n",
    "\n",
    "#     if not user_text.strip():\n",
    "#         print(\"⚠️ Empty input\")\n",
    "#         continue\n",
    "\n",
    "#     # -------- AI BRAIN --------\n",
    "#     response = rag_chain.invoke({'input': user_text})[\"answer\"]\n",
    "#     print(f\"\\n🤖 Bot: {response}\\n\")\n",
    "\n",
    "#     # -------- OUTPUT --------\n",
    "#     if mode == \"voice\":\n",
    "#         speak(response)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "id": "34c7f75a",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "I0000 00:00:1771845000.303143    4109 fork_posix.cc:71] Other threads are currently calling into gRPC, skipping fork() handlers\n",
      "huggingface/tokenizers: The current process just got forked, after parallelism has already been used. Disabling parallelism to avoid deadlocks...\n",
      "To disable this warning, you can either:\n",
      "\t- Avoid using `tokenizers` before the fork if possible\n",
      "\t- Explicitly set the environment variable TOKENIZERS_PARALLELISM=(true | false)\n",
      "1827.33s - pydevd: Sending message related to process being replaced timed-out after 5 seconds\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already satisfied: par-cli-tts in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (0.2.2)\n",
      "Requirement already satisfied: elevenlabs>=1.0.0 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from par-cli-tts) (2.36.1)\n",
      "Requirement already satisfied: kokoro-onnx>=0.4.9 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from par-cli-tts) (0.5.0)\n",
      "Requirement already satisfied: openai>=1.100.1 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from par-cli-tts) (1.109.1)\n",
      "Requirement already satisfied: platformdirs>=4.3.0 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from par-cli-tts) (4.5.1)\n",
      "Requirement already satisfied: python-dotenv>=1.0.0 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from par-cli-tts) (1.1.0)\n",
      "Requirement already satisfied: pyyaml>=6.0.0 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from par-cli-tts) (6.0.3)\n",
      "Requirement already satisfied: rich>=13.0.0 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from par-cli-tts) (14.2.0)\n",
      "Requirement already satisfied: soundfile>=0.13.1 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from par-cli-tts) (0.13.1)\n",
      "Requirement already satisfied: typer>=0.12.0 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from par-cli-tts) (0.24.1)\n",
      "Requirement already satisfied: httpx>=0.21.2 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from elevenlabs>=1.0.0->par-cli-tts) (0.28.1)\n",
      "Requirement already satisfied: pydantic>=1.9.2 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from elevenlabs>=1.0.0->par-cli-tts) (2.12.5)\n",
      "Requirement already satisfied: pydantic-core>=2.18.2 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from elevenlabs>=1.0.0->par-cli-tts) (2.41.5)\n",
      "Requirement already satisfied: requests>=2.20 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from elevenlabs>=1.0.0->par-cli-tts) (2.32.5)\n",
      "Requirement already satisfied: typing_extensions>=4.0.0 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from elevenlabs>=1.0.0->par-cli-tts) (4.15.0)\n",
      "Requirement already satisfied: websockets>=11.0 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from elevenlabs>=1.0.0->par-cli-tts) (16.0)\n",
      "Requirement already satisfied: espeakng-loader>=0.2.4 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from kokoro-onnx>=0.4.9->par-cli-tts) (0.2.4)\n",
      "Requirement already satisfied: numpy>=2.0.2 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from kokoro-onnx>=0.4.9->par-cli-tts) (2.4.2)\n",
      "Requirement already satisfied: onnxruntime>=1.20.1 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from kokoro-onnx>=0.4.9->par-cli-tts) (1.24.2)\n",
      "Requirement already satisfied: phonemizer-fork>=3.3.2 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from kokoro-onnx>=0.4.9->par-cli-tts) (3.3.2)\n",
      "Requirement already satisfied: anyio<5,>=3.5.0 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from openai>=1.100.1->par-cli-tts) (4.12.0)\n",
      "Requirement already satisfied: distro<2,>=1.7.0 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from openai>=1.100.1->par-cli-tts) (1.9.0)\n",
      "Requirement already satisfied: jiter<1,>=0.4.0 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from openai>=1.100.1->par-cli-tts) (0.12.0)\n",
      "Requirement already satisfied: sniffio in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from openai>=1.100.1->par-cli-tts) (1.3.1)\n",
      "Requirement already satisfied: tqdm>4 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from openai>=1.100.1->par-cli-tts) (4.67.1)\n",
      "Requirement already satisfied: markdown-it-py>=2.2.0 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from rich>=13.0.0->par-cli-tts) (4.0.0)\n",
      "Requirement already satisfied: pygments<3.0.0,>=2.13.0 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from rich>=13.0.0->par-cli-tts) (2.19.2)\n",
      "Requirement already satisfied: cffi>=1.0 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from soundfile>=0.13.1->par-cli-tts) (2.0.0)\n",
      "Requirement already satisfied: click>=8.2.1 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from typer>=0.12.0->par-cli-tts) (8.3.1)\n",
      "Requirement already satisfied: shellingham>=1.3.0 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from typer>=0.12.0->par-cli-tts) (1.5.4)\n",
      "Requirement already satisfied: annotated-doc>=0.0.2 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from typer>=0.12.0->par-cli-tts) (0.0.4)\n",
      "Requirement already satisfied: idna>=2.8 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from anyio<5,>=3.5.0->openai>=1.100.1->par-cli-tts) (3.11)\n",
      "Requirement already satisfied: pycparser in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from cffi>=1.0->soundfile>=0.13.1->par-cli-tts) (2.23)\n",
      "Requirement already satisfied: certifi in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from httpx>=0.21.2->elevenlabs>=1.0.0->par-cli-tts) (2025.11.12)\n",
      "Requirement already satisfied: httpcore==1.* in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from httpx>=0.21.2->elevenlabs>=1.0.0->par-cli-tts) (1.0.9)\n",
      "Requirement already satisfied: h11>=0.16 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from httpcore==1.*->httpx>=0.21.2->elevenlabs>=1.0.0->par-cli-tts) (0.16.0)\n",
      "Requirement already satisfied: mdurl~=0.1 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from markdown-it-py>=2.2.0->rich>=13.0.0->par-cli-tts) (0.1.2)\n",
      "Requirement already satisfied: flatbuffers in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from onnxruntime>=1.20.1->kokoro-onnx>=0.4.9->par-cli-tts) (25.9.23)\n",
      "Requirement already satisfied: packaging in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from onnxruntime>=1.20.1->kokoro-onnx>=0.4.9->par-cli-tts) (24.2)\n",
      "Requirement already satisfied: protobuf in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from onnxruntime>=1.20.1->kokoro-onnx>=0.4.9->par-cli-tts) (6.33.2)\n",
      "Requirement already satisfied: sympy in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from onnxruntime>=1.20.1->kokoro-onnx>=0.4.9->par-cli-tts) (1.14.0)\n",
      "Requirement already satisfied: attrs>=18.1 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from phonemizer-fork>=3.3.2->kokoro-onnx>=0.4.9->par-cli-tts) (25.4.0)\n",
      "Requirement already satisfied: dlinfo in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from phonemizer-fork>=3.3.2->kokoro-onnx>=0.4.9->par-cli-tts) (2.0.0)\n",
      "Requirement already satisfied: joblib in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from phonemizer-fork>=3.3.2->kokoro-onnx>=0.4.9->par-cli-tts) (1.5.2)\n",
      "Requirement already satisfied: segments in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from phonemizer-fork>=3.3.2->kokoro-onnx>=0.4.9->par-cli-tts) (2.3.0)\n",
      "Requirement already satisfied: annotated-types>=0.6.0 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from pydantic>=1.9.2->elevenlabs>=1.0.0->par-cli-tts) (0.7.0)\n",
      "Requirement already satisfied: typing-inspection>=0.4.2 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from pydantic>=1.9.2->elevenlabs>=1.0.0->par-cli-tts) (0.4.2)\n",
      "Requirement already satisfied: charset_normalizer<4,>=2 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from requests>=2.20->elevenlabs>=1.0.0->par-cli-tts) (3.4.4)\n",
      "Requirement already satisfied: urllib3<3,>=1.21.1 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from requests>=2.20->elevenlabs>=1.0.0->par-cli-tts) (2.6.1)\n",
      "Requirement already satisfied: regex in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from segments->phonemizer-fork>=3.3.2->kokoro-onnx>=0.4.9->par-cli-tts) (2025.11.3)\n",
      "Requirement already satisfied: csvw>=1.5.6 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from segments->phonemizer-fork>=3.3.2->kokoro-onnx>=0.4.9->par-cli-tts) (3.7.0)\n",
      "Requirement already satisfied: mpmath<1.4,>=1.1.0 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from sympy->onnxruntime>=1.20.1->kokoro-onnx>=0.4.9->par-cli-tts) (1.3.0)\n",
      "Requirement already satisfied: isodate in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from csvw>=1.5.6->segments->phonemizer-fork>=3.3.2->kokoro-onnx>=0.4.9->par-cli-tts) (0.7.2)\n",
      "Requirement already satisfied: python-dateutil in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from csvw>=1.5.6->segments->phonemizer-fork>=3.3.2->kokoro-onnx>=0.4.9->par-cli-tts) (2.9.0.post0)\n",
      "Requirement already satisfied: rfc3986<2 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from csvw>=1.5.6->segments->phonemizer-fork>=3.3.2->kokoro-onnx>=0.4.9->par-cli-tts) (1.5.0)\n",
      "Requirement already satisfied: uritemplate>=3.0.0 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from csvw>=1.5.6->segments->phonemizer-fork>=3.3.2->kokoro-onnx>=0.4.9->par-cli-tts) (4.2.0)\n",
      "Requirement already satisfied: babel in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from csvw>=1.5.6->segments->phonemizer-fork>=3.3.2->kokoro-onnx>=0.4.9->par-cli-tts) (2.18.0)\n",
      "Requirement already satisfied: language-tags in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from csvw>=1.5.6->segments->phonemizer-fork>=3.3.2->kokoro-onnx>=0.4.9->par-cli-tts) (1.2.0)\n",
      "Requirement already satisfied: rdflib in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from csvw>=1.5.6->segments->phonemizer-fork>=3.3.2->kokoro-onnx>=0.4.9->par-cli-tts) (7.6.0)\n",
      "Requirement already satisfied: termcolor in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from csvw>=1.5.6->segments->phonemizer-fork>=3.3.2->kokoro-onnx>=0.4.9->par-cli-tts) (3.2.0)\n",
      "Requirement already satisfied: jsonschema in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from csvw>=1.5.6->segments->phonemizer-fork>=3.3.2->kokoro-onnx>=0.4.9->par-cli-tts) (4.26.0)\n",
      "Requirement already satisfied: jsonschema-specifications>=2023.03.6 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from jsonschema->csvw>=1.5.6->segments->phonemizer-fork>=3.3.2->kokoro-onnx>=0.4.9->par-cli-tts) (2025.9.1)\n",
      "Requirement already satisfied: referencing>=0.28.4 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from jsonschema->csvw>=1.5.6->segments->phonemizer-fork>=3.3.2->kokoro-onnx>=0.4.9->par-cli-tts) (0.37.0)\n",
      "Requirement already satisfied: rpds-py>=0.25.0 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from jsonschema->csvw>=1.5.6->segments->phonemizer-fork>=3.3.2->kokoro-onnx>=0.4.9->par-cli-tts) (0.30.0)\n",
      "Requirement already satisfied: six>=1.5 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from python-dateutil->csvw>=1.5.6->segments->phonemizer-fork>=3.3.2->kokoro-onnx>=0.4.9->par-cli-tts) (1.17.0)\n",
      "Requirement already satisfied: pyparsing<4,>=2.1.0 in /home/user/Desktop/medical_bot/Eye_Disease_Chatbot/medchatenv/lib/python3.12/site-packages (from rdflib->csvw>=1.5.6->segments->phonemizer-fork>=3.3.2->kokoro-onnx>=0.4.9->par-cli-tts) (3.2.5)\n"
     ]
    }
   ],
   "source": [
    "!pip install par-cli-tts"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "id": "a851fea8",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "I0000 00:00:1771845014.743342    4109 fork_posix.cc:71] Other threads are currently calling into gRPC, skipping fork() handlers\n",
      "huggingface/tokenizers: The current process just got forked, after parallelism has already been used. Disabling parallelism to avoid deadlocks...\n",
      "To disable this warning, you can either:\n",
      "\t- Avoid using `tokenizers` before the fork if possible\n",
      "\t- Explicitly set the environment variable TOKENIZERS_PARALLELISM=(true | false)\n",
      "1841.76s - pydevd: Sending message related to process being replaced timed-out after 5 seconds\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[32m✓ Models are already downloaded\u001b[0m\n",
      "Model: \u001b[35m/home/user/snap/code/225/.local/share/par-tts-kokoro/\u001b[0m\u001b[95mkokoro-v1.0.onnx\u001b[0m\n",
      "Voices: \u001b[35m/home/user/snap/code/225/.local/share/par-tts-kokoro/\u001b[0m\u001b[95mvoices-v1.0.bin\u001b[0m\n"
     ]
    }
   ],
   "source": [
    "\n",
    "!par-tts-kokoro download"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "id": "8abc4aff",
   "metadata": {},
   "outputs": [
    {
     "ename": "ModuleNotFoundError",
     "evalue": "No module named 'par_tts_tts'",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mModuleNotFoundError\u001b[39m                       Traceback (most recent call last)",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[82]\u001b[39m\u001b[32m, line 1\u001b[39m\n\u001b[32m----> \u001b[39m\u001b[32m1\u001b[39m \u001b[38;5;28;01mfrom\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34;01mpar_tts_tts\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;28;01mimport\u001b[39;00m TTS\n\u001b[32m      3\u001b[39m tts = TTS(provider=\u001b[33m\"\u001b[39m\u001b[33mkokoro\u001b[39m\u001b[33m\"\u001b[39m)\n\u001b[32m      4\u001b[39m tts.save(text=\u001b[33m\"\u001b[39m\u001b[33mHello world\u001b[39m\u001b[33m\"\u001b[39m, file=\u001b[33m\"\u001b[39m\u001b[33mreply.wav\u001b[39m\u001b[33m\"\u001b[39m)\n",
      "\u001b[31mModuleNotFoundError\u001b[39m: No module named 'par_tts_tts'"
     ]
    }
   ],
   "source": [
    "from par_tts_tts import TTS\n",
    "\n",
    "tts = TTS(provider=\"kokoro\")\n",
    "tts.save(text=\"Hello world\", file=\"reply.wav\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "2abfffec",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "medchatenv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
